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1. Summary 
 
The short-chain dehydrogenase/reductase (SDRs) family represents one of the largest enzyme 
superfamilies, with over 80 members in the human genome. Even though the human genome project 
has sequenced and mapped the entire human genome, the physiological functions of more than 70% 
of all SDRs are currently unexplored or insufficiently characterized. To start to fill this gap, the present 
thesis aimed to employ a combination of molecular modeling approaches and biological assessments 
for the identification and characterization of novel inhibitors and/or potential substrates of different 
SDRs. 
Due to their involvement in steroid biosynthesis and metabolism, SDRs are potential targets of 
endocrine disrupting chemicals (EDCs). To test the use of pharmacophore-based virtual screening (VS) 
applications and subsequent in vitro evaluation of virtual hits for the identification and characterization 
of potential inhibitors, 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2) was selected as an example. 
11β-HSD2 has an important role in the placenta by inactivating cortisol and protecting the fetus from 
high maternal glucocorticoid levels. An impaired placental 11β-HSD2 function has been associated with 
altered fetal growth and angiogenesis as well as a higher risk for cardio-metabolic diseases in later life. 
Despite this vital function, 11β-HSD2 is not covered in common off-target screening approaches. 
Several azole fungicides were identified as 11β-HSD inhibitors amongst approved drugs by testing 
selected virtually retrieved hits for inhibition of cortisol to cortisone conversion in cell lysates 
expressing recombinant human 11β-HSD2. Moreover, a significant structure-activity relationship 
between azole scaffold size, 11β-HSD enzyme selectivity and potency was observed. The most potent 
11β-HSD2 inhibition was obtained for itraconazole (IC50 139 ± 14 nM), for its active metabolite 
hydroxyitraconazole (IC50 223 ± 31 nM), and for posaconazole (IC50 460 ± 98 nM). Interestingly, 
substantially lower inhibitory 11β-HSD2 activity of these compounds was detected using mouse and 
rat kidney homogenate preparations, indicating species-specific differences. Impaired placental 11β-
HSD2 function exerted by these compounds might, in addition to the known inhibition of P-
glycoprotein efflux transport and cytochrome P450 enzymes, lead to locally elevated cortisol levels 
and thereby could affect fetal programming. 
Successful employment of pharmacophore-based VS applications requires suitable and reliable in vitro 
validation strategies. Therefore, the following study addressed the re-evaluation of a potential EDC, 
the widely used flame retardant tetrabromobisphenol A (TBBPA), on glucocorticoid receptor (GR) and 
androgen receptor (AR) function. TBBPA was reported earlier in yeast-based reporter assays to 
potently interfere with GR and moderately with AR function. Human HEK-293 cell-based reporter 
assays and cell-free receptor binding assays did not show any activity of TBBPA on GR function, which 
was supported by molecular docking calculations. The antiandrogenic effect, however, could be 
confirmed, although less pronounced than in the HEK-293 cell system. Nevertheless, the evaluation of 
the relevant concentrations of an EDC found in the human body is crucial for an appropriate safety 
assessment. Considering the rapid metabolism of TBBPA and the low concentrations observed in the 
human body, it is questionable whether relevant concentrations can be reached to cause harmful 
effects. Thus, it is vital to take the limitations of each testing system including the distinct sensitivities 
and specificities into account to avoid false positive or false negative results. 
To extend the applications of in silico tools with demonstrated proof-of-concept, they were further 
employed to investigate novel substrate specificities for three different SDR members: the two multi-
functional enzymes, 11β-HSD1 and carbonyl reductase (CBR) 1 as well as the orphan enzyme DHRS7.  
A role for 11β-HSD1 in oxysterol metabolism by metabolizing 7-ketocholesterol (7kC) has already been 
described. However, in contrast to the known receptors for 7α,25-dihydroxycholesterol (7α25OHC), 
i.e. Epstein-Barr virus-induced gene 2 (EBI2), or 7β,27-dihydroxycholesterol (7β27OHC), i.e. retinoic 
acid related orphan receptor (ROR)γ, no endogenous receptor has been identified so far for 7kC or its 
metabolite 7β-hydroxycholesterol. To explore the underlying biosynthetic pathways of such 
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dihydroxylated oxysterols, the role of 11β-HSD1 in the generation of dihydroxylated oxysterols was 
investigated. For the first time, the stereospecific and seemingly irreversible oxoreduction of 7-
keto,25-hydroxycholesterol (7k25OHC) and 7-keto,27-hydroxycholesterol (7k27OHC) to their 
corresponding 7β-hydroxylated metabolites 7β25OHC and 7β27OHC by recombinant human 11β-
HSD1 could be demonstrated in vitro in intact HEK-293 cells. Furthermore, 7k25OHC and 7k27OHC 
were found to be potently inhibited the 11β-HSD1-dependent oxoreduction of cortisone to cortisol. 
Molecular modeling experiments confirmed these results and suggested competition of 7k25OHC and 
7k27OHC with cortisone in the enzyme binding pocket.  
For a more detailed enzyme characterization, 11β-HSD1 pharmacophore models were generated and 
employed for VS of the human metabolome database and the lipidmaps structure database. The VS 
yielded several hundred virtual hits, including the successful filtering of known substrates such as 
endogenous 11-ketoglucocorticoids, synthetic glucocorticoids, 7kC, and several bile acids known to 
inhibit the enzyme. Further hits comprised several eicosanoids including prostaglandins, leukotrienes, 
cyclopentenone isoprostanes, levuglandins or hydroxyeicosatetraenoic acids (HETEs) and compounds 
of the kynurenine pathway. The important role of these compounds as well as 11β-HSD1 in 
inflammation emphasizes a potential association. However, further biological validation is of utmost 
necessity to explore a potential link.  
The closest relative of 11β-HSD1 is the orphan enzyme DHRS7, which has been suggested to act as 
tumor suppressor. Among others, cortisone and 5α-dihydrotestosterone have been identified as 
substrates of DHRS7, although effects in functional assays could only be observed at high 
concentrations that may not be of physiological relevance. Hence, the existence of other yet 
unexplored substrates of DHRS7 can be assumed, and the generation of homology models to study the 
structural features of the substrate binding site of DHRS7 was employed. The predictivity of the 
constructed models is currently limited, due to a highly variable region comprising a part of the ligand 
binding site but particularly the entry of the binding pocket, and requires further optimizations. 
Nevertheless, the models generally displayed a cone-shaped binding site with a rather hydrophobic 
core. This may suggest larger metabolites to be converted by DHRS7. Moreover, the flexible loops 
surrounding the binding pocket may lead to the induction of an induced fit upon ligand binding. 
However, further studies are crucial to confirm these findings.  
CBR1 is well-known for its role in phase I metabolism of a variety of carbonyl containing xenobiotic 
compounds. Several endogenous substrates of CBR1 have been reported such as prostaglandins, S-
nitrosoglutathione or lipid aldehydes. The physiological relevance of these endogenous substrates, 
however, is not fully understood. Thus, the physiological roles of CBR1 was further explored by 
identifying a novel function for CBR1 in the metabolism glucocorticoids. CBR1 was found to catalyze 
the conversion of cortisol into 20β-dihydrocortisol (20β-DHF), which was in turn detected as the major 
route of cortisol metabolism in horses and elevated in adipose tissue derived from obese horses, 
humans and mice. Additionally, 20β-DHF was demonstrated as weak endogenous agonist of the GR, 
suggesting a novel pathway to modulate GR activation by CBR1-depenent protection against excessive 
GR activation in obesity. 
In conclusion, this thesis emphasized the employment of molecular modeling approaches as an initial 
filter to identify toxicological relevant compound classes for the identification of potential EDCs and, 
moreover, as valuable tools to identify novel substrates of multifunctional SDRs and to unravel novel 
functions for the large majority of yet unexplored orphan SDR members, while carefully considering 
the limitations of this strategy.    
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2. Short-chain dehydrogenase/reductase superfamily 
 
The family of short-chain dehydrogenases/reductases (SDRs) comprise more than 47,000 members, 
thus, representing one of the largest enzyme superfamilies [1]. SDRs are present in almost all domains 
of life, from archaea to bacteria, and eukaryota, with over 80 members described in the human 
genome [2, 3], emphasizing their significant and versatile role in distinct metabolic processes, such as 
the metabolism of steroid hormones, oxysterols, bile acids, fatty acid derivatives, prostaglandins, 
retinoids, amino acids, carbohydrates, and xenobiotics or redox sensor mechanisms [4].  
SDRs generally share a low primary sequence identity of about 15-25% but they have common 
structural features. The basic three-dimensional core element conserved in all SDRs is the so-called 
Rossmann-fold, a common α/β-folding pattern composed of a central stranded parallel β-sheet with 
6-7 strands flanked by 3-4 α-helices on each side. This structural feature displays the required scaffold 
for cofactor binding and includes a Tyr-(Xaa)3-Lys motif crucial for the catalytic activity. The general 
topology of SDRs is illustrated in Figure 1, exemplified on 17β-hydroxysteroid dehydrogenase type 1 
(17β-HSD1). The arrangement of the β-sheets has the following order: 3-2-1-4-5-6-7 with a long loop 
between strands 3 and 4, creating the binding site of the adenine ring of NAD(P)(H) [5]. This cavity 
includes a highly variable Gly-rich sequence (between the first strand the following helix), enabling the 
binding of the pyrophosphate group of the cofactor. The cofactor preference is dictated by the 
presence of either an acidic residue at the C-terminus after the second β-strand for NAD(H) or a basic 
residue for NADP(H) that interacts with the additional phosphate group [6, 7]. The majority of SDRs 
contain a catalytic triad/tetrad including a Tyr, Lys, Ser (and Asn) residue. The Tyr residue functions as 
catalytic base/acid donating or withdrawing a proton to or from the substrate, whereas the Lys residue 
forms a hydrogen bond (H-bond) with the nicotinamide ribose and thereby enhances the catalytic 
activity by lowering the pKa from the tyrosine hydroxyl. Additionally, the conserved Ser acts as 
stabilizing residue for the carbonyl substrate group. Although the Tyr residue in the catalytic center is 
found among the majority of SDRs, it is not rigidly conserved, indicated by divergent SDRs using a 
different mechanism [4]. This further gives rise to the strikingly broad mechanistic diversity of SDRs 
including the catalysis of carbonyl-alcohol oxidoreductions, isomerizations, decarboxylations, 
epimerizations, C=N reductions, enoyl-CoA reductions, dehydrations, and dehalogenation reactions. 
Interestingly, active site superimposition of SDRs and members of the family of aldo-keto reductases 
(AKRs) showed conserved Tyr and Lys residues in similar positions, even though AKRs structurally 
belong to the (α/β)8 or TIM barrel protein superfamily. This suggests convergent evolution of a 
common catalytic reaction mechanism [8].  
Although, more than 15 years ago, the human genome project has achieved the accessibility of the 
entire human genome, the physiological roles of more than 70% of all SDRs are currently unknown or 
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inadequately characterized. To bridge this gap, in silico approaches could adopt a significant role, in 
the identification of substrates and modulators of such enzymes, even though many challenges 
remain, not only from the limited availability of structural information of many SDR members. 
Additionally, computational tools can also support and facilitate the identification of inhibitors, 
including potential therapeutic compounds but also toxic industrial chemicals and environmentally 
relevant hazardous compounds. Furthermore, due to the involvement of SDRs in steroid biosynthesis 
and metabolism, they represent potential sites for molecular initiating events of endocrine disrupting 
chemicals (EDCs). Therefore, the present thesis aimed to apply a combination of molecular modeling 
(including pharmacophore-based virtual screening and molecular docking) and biological assessment 
for the identification and characterization of novel inhibitors and/or potential substrates of different 
SDRs. A detailed overview of the efforts attempted in the field of virtual screening supported 
identification of bioactive molecules in SDR research and the accompanying limitations can be gained 
in the following two published review articles [9, 10]. 
 
 
Figure 1. General 2D and 3D representation of SDR enzymes based on 17β-HSD1 as an example. 
(Figure adapted from Kaserer T and Beck KR et al., Molecules 2015 [10]). (A) 2D illustration of 17β-
HSD1 (Protein database (PDB) entry 1EQU). Yellow squares depict β-sheets and barrels represent α-
helices. Further structurally conserved regions (variable Gly-rich sequence and catalytic site) are 
highlighted in orange. The + illustrates in this case of 17β-HSD1 a positive charged residue at the C-
terminus following the second β-strand essential for NADP(H) binding (an acidic residue would favor 
NAD(H) binding. (B) 3D depiction of 17β-HSD1 (PDB entry 1EQU) showing the same color code as the 
2D representation. Several parallel stranded β-sheets (yellow), ﬂanked by α-helices on both sides 
(green) build the Rossmann-fold. The Tyr-(Xaa)3-Lys motif and the conserved Ser are highlighted in 
orange.  
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2.1. Published review articles: 
2.1.1. Pharmacophore Models and Pharmacophore-Based Virtual Screening: Concepts 
and Applications Exemplified on Hydroxysteroid Dehydrogenases 
 
Teresa Kaserer1,*, Katharina R. Beck2,*, Muhammad Akram1, Alex Odermatt2, Daniela 
Schuster1, Molecules. 2015 Dec 19;20(12):22799-832 
* These authors contributed equally to this work. 
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Abstract: Computational methods are well-established tools in the drug discovery process and
can be employed for a variety of tasks. Common applications include lead identification and
scaffold hopping, as well as lead optimization by structure-activity relationship analysis and
selectivity profiling. In addition, compound-target interactions associated with potentially harmful
effects can be identified and investigated. This review focuses on pharmacophore-based virtual
screening campaigns specifically addressing the target class of hydroxysteroid dehydrogenases.
Many members of this enzyme family are associated with specific pathological conditions, and
pharmacological modulation of their activity may represent promising therapeutic strategies.
On the other hand, unintended interference with their biological functions, e.g., upon inhibition by
xenobiotics, can disrupt steroid hormone-mediated effects, thereby contributing to the development
and progression of major diseases. Besides a general introduction to pharmacophore modeling
and pharmacophore-based virtual screening, exemplary case studies from the field of short-chain
dehydrogenase/reductase (SDR) research are presented. These success stories highlight the suitability
of pharmacophore modeling for the various application fields and suggest its application also in
futures studies.
Keywords: pharmacophore; virtual screening; ligand protein interactions; hydroxysteroid
dehydrogenase; oxidoreductase
1. Introduction
Pharmacophore Modeling
The concept of “pharmacophores” dates back to the late 19th century, when Paul Ehrlich
suggested that specific groups within a molecule are responsible for its biological activity [1,2].
The pharmacophore definition, as currently used, was developed over time, with many researchers
actively participating in the process (for a detailed history of pharmacophores, please refer to
Güner and Bowen [2]). However, Schueler provided the basis for our modern understanding of
a pharmacophore [2,3], which is defined by the International Union of Pure and Applied Chemistry
Molecules 2015, 20, 22799–22832; doi:10.3390/molecules201219880 www.mdpi.com/journal/molecules
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(IUPAC) as “the ensemble of steric and electronic features that is necessary to ensure the optimal
supra-molecular interactions with a specific biological target structure and to trigger (or to block) its
biological response” [4]. According to this definition, the interaction patterns of bioactive molecules
with their targets are represented via a three-dimensional (3D) arrangement of abstract features that
define interaction types rather than specific functional groups. These interaction types can, for example,
include the formation of hydrogen bonds, charged interactions, metal interactions, or hydrophobic
(H) and aromatic (AR) contacts (Figure 1). Besides that, many pharmacophore modeling programs
allow for the addition of steric constraints. These so-called exclusion volumes (XVols) mimic the
geometry of the binding pocket and prevent the mapping of compounds that would be inactive in the
experimental assessment due to clashes with the protein surface. In its entirety, a pharmacophore model
represents one binding mode of ligands with a specific target, as exemplified on 17β-hydroxysteroid
dehydrogenase (HSD) type 1 (Figure 1).
Figure 1. Pharmacophore models based on the estrogen equilin co-crystallized with 17β-hydroxysteroid
dehydrogenase type 1 (PDB entry 1EQU [5]) and generated with LigandScout [6] (*), Discovery
Studio [7] (#), and Molecular Operating Environment (MOE) [8] (§). H, hydrophobic feature; HBD,
hydrogen bond donor; HBA, hydrogen bond acceptor; XVols, exclusion volume.
Pharmacophore models can be generated using two different approaches (Figure 2) depending
on the input data employed for model construction. In the structure-based approach, the interaction
pattern of a molecule and its targets are directly extracted from experimentally determined
ligand-target complexes (Figure 2A). An important source for these complexes, e.g., derived from
NMR-spectroscopy or X-ray crystallography, represents the Protein Data Bank (PDB, www.pdb.org) [9].
To date (access date 2 November 2015), more than 113,000 macromolecular structures are stored in
this online repository. However, not all of these structures were solved in a complex with a bound
ligand, and in the case of induced fit, the binding of different ligands to an enzyme or receptor can
lead to different interactions that are not covered by a single structure. To address this limitation, some
pharmacophore modeling programs, e.g., Discovery Studio [7] and LigandScout [6], also provide tools
to create pharmacophore models based exclusively on the topology of the binding site and in the
absence of a ligand [10]. In Discovery Studio, for example, the binding site can be defined manually by
selecting residues within the desired cavity or by applying implemented binding site identification
tools. Once the binding site is defined, the program automatically calculates pharmacophore features
based on the residues lining the active site. This initial ensemble of pharmacophore features can then be
adapted to construct the final hypothesis [10]. In addition, structure-based pharmacophore models can
also be generated with computationally derived ligand-target complexes. In the course of a docking
run, known active compounds are fitted into the empty binding pocket of the target [11]. These docked
binding poses can then directly be employed to extract the interaction patterns. For further refinement
of the initial docking poses, molecular dynamics (MD) simulations can be conducted [12] prior to
model generation.
In the course of ligand-based modeling, three-dimensional (3D) structures of two or more known
active molecules are aligned and common pharmacophore features shared among these training set
molecules are identified (Figure 2B). In a ligand-based approach, all of the common chemical features from
the pharmacophore have to be presumed as essential, whereas in a structure-based approach, it can be
considered whether a chemical feature of a molecule is directly involved in the ligand binding or not.
22800
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Figure 2. (A) Structure- and (B) ligand-based pharmacophore model generation with LigandScout.
(A) Based on the complex of equilin bound to 17β-HSD1 (PDB entry 1EQU [5]), an initial
pharmacophore model is created automatically; (B) Conformational models of known 17β-HSD1
ligands [13,14] are used to align the compounds and extract pharmacophore features they share.
Usually, datasets containing known active and inactive molecules are employed to assess the
quality of the developed models. These datasets need to be designed carefully, because they largely
influence the quality of the model and, accordingly, the success of the study. Only active molecules
should be included, for which the direct interaction has been experimentally proven [15,16], e.g., by
receptor binding or enzyme activity assays on isolated or recombinant proteins. Cell-based assays
should be avoided in this context, because many factors other than interaction with the target can
influence the results: Active compounds may potentially exert their effect via other mechanisms
than the intended one, whereas on the other hand, inactive compounds may actually interact
with the target, but due to poor pharmacokinetic properties, this cannot be detected. In addition,
appropriate activity cut-offs need to be defined to avoid the inclusion of compounds with a low binding
affinity and high EC50/IC50 values (which may even be classified as “inactive”). Finally, the dataset
should contain structurally diverse molecules [17] whenever possible. Preferably, experimentally
confirmed inactive compounds should be included in the “inactives” dataset used for the theoretical
validation [17,18]. Besides the original literature, several public compound repositories such as
ChEMBL [19], Drugbank [20], or OpenPHACTS [21] can be explored for target-based activity data of
compounds. In addition, several high-throughput screening (HTS) initiatives such as ToxCast [22],
Tox21 [23], and PubChem Bioassay [24] provide a valuable resource for both active and inactive
molecules. Whenever no or only a limited number of known inactive molecules are available, so-called
decoys (compounds with unknown biological activity but assumed to be inactive) might be employed.
These decoy-datasets need to be adapted for every target and should contain compounds with similar
one-dimensional (1D) properties [25–27] but different topologies compared to the known active
molecules. These properties can include the number of hydrogen bond donors (HBDs), the number
of hydrogen bond acceptors (HBAs), the number of non-polar atoms [25], molecular weight, logP,
and the number of rotatable bonds [27]. The Directory of Useful Decoys, Enhanced (DUD-E) [28]
provides a free service (http://dude.docking.org), where optimized decoys are generated based on
the smiles codes of the uploaded active molecules. In general, a ratio of about 1:50 for the number
of active molecules and decoys is recommended [28]. This should reflect the prospective screening
22801
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database, where usually only a few active molecules are also distributed among a vast amount of
inactive molecules (Figure 3).
Figure 3. Enrichment of active molecules in the virtual hit list. Usually, the majority of compounds in
a screening database are inactive molecules, while a small pool of bioactive molecules is contained.
Pharmacophore-based virtual screening can help to enrich active molecules in the hit list compared to
a random selection of test compounds.
The preliminary models generated with both approaches need further improvement in the
majority of cases [16,29] to facilitate the recovery of the active molecules and concomitantly exclude
the inactive compounds in the dataset from the hit list. Basic model refinement steps include the
deletion or addition of pharmacophore features and adaptations concerning the feature weight and
size. Selected features can also be defined as optional and, therefore, can but do not have to be mapped
by a molecule. In addition, a user-defined number of omitted features can be specified in many
pharmacophore modeling programs. More sophisticated modifications comprise the modification of
feature definitions, i.e., the functional groups covered by a pharmacophore feature.
The aim of pharmacophore-based virtual screening (VS) is to enrich active molecules in a screening
database in the virtual hit list (Figure 3). Multiple quality metrics are available that help to evaluate
the quality of the developed pharmacophore model, for example the enrichment factor [30] (the
enrichment of active molecules compared to random selection), yield of actives (the percentage of
active compounds in the virtual hit list), specificity (the ability to exclude inactive compounds) and
sensitivity (the ability to identify active molecules), and the area under the curve of the Receiver
Operating Characteristic plot (ROC-AUC) [31]. For detailed descriptions of commonly applied quality
parameters we refer to earlier work [15,16,26,32]. The ultimate proof of a model’s quality and value, i.e.,
whether it is indeed capable of proposing novel active molecules, can, however, only be determined in
a prospective experiment, as will be explained in more detail below. A workflow summarizing the
individual steps of pharmacophore model generation and application is depicted in Figure 4.
As outlined below, refined, high quality pharmacophore models can then be employed for
multiple tasks.
22802
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Figure 4. The different consecutive steps in pharmacophore model generation, refinement, and
prospective application.
2. Applications of Pharmacophore-Based VS
In the course of a VS run, a pharmacophore model is screened against large chemical libraries,
and molecules mapping the model are collected in a virtual hit list. These molecules fulfill the
requirements of the model and therefore have a high likelihood to be active in the experimental testing.
Accordingly, VS can be used to filter promising compounds out of large compound collections and
enrich active molecules in chemical databases selected for experimental investigations. VS is considered
a valuable support for classical HTS campaigns [33,34], because true positive hit rates are usually
much higher than in those “random” testing strategies [35–37]. Reported hit rates from prospective
pharmacophore-based virtual screening vary between individual studies, but are typically in the range
of 5% to 40% (an excellent collection of prospective studies has been presented earlier [16]). On the other
side, the hit rates of identifying active molecules upon random selection of test compounds are typically
below 1% and have been described, for example, as 0.55% for glycogen synthase kinase-3β [36],
0.075% for peroxisome proliferator-activated receptor (PPAR) γ [38], and 0.021% for protein tyrosine
phosphatase-1B [37].
2.1. Drug Discovery
Pharmacophore-based VS is widely applied in different steps of the drug discovery process and
facilitates the initial selection of compound classes as well as the optimization of compound properties
as outlined below.
2.1.1. Lead Identification
The most common application of pharmacophore-based virtual screening concerns lead
identification, the so-called cherry-picking approach. Virtual screening is often deployed in these
22803
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projects to prioritize molecules for testing and minimizing the number of compounds to be investigated
in biological screens. The ultimate aim is the identification of novel lead compounds for a specific
disease-related target, which can be developed into drug candidates for the treatment of the intended
disease, with numerous studies during the last years describing such applications [39–44]. For example,
Ha et al. reported the discovery of novel ligands for the chemokine receptor CXCR2 by using a
ligand-based pharmacophore modeling approach [45]. In the course of a pharmacophore-based virtual
screening for novel histamine H3 receptor antagonists, Lepailleur et al. identified novel compounds
additionally binding to the 5HT4 receptor [46]. Both activities were considered beneficial for the
treatment of Alzheimer’s disease and the authors were the first to report compounds with this dual
mechanism of action [46].
2.1.2. Structure-Activity Relationships
As mentioned in the introduction, a pharmacophore model represents the putative binding mode
of active molecules to their target. It therefore describes the crucial functionalities required for a
compound’s activity. A pharmacophore model is trained to discriminate between active and inactive
molecules (in the best case even between members of the same chemical series), which makes it highly
valuable for establishing structure-activity relationships (SARs). Differences in the experimentally
observed biological activities of a set of compounds can be rationalized based on the presence/absence
of chemical groups, represented by pharmacophore features, in the respective molecules. SARs
can be established during model building, thereby elucidating the underlying mechanisms for the
(absent) biological activity. For example, Ferreira et al. employed pharmacophore models to elucidate
important features responsible for the interaction of compounds with the P-glycoprotein drug binding
site [47]. Previous studies suggested a crucial role for a nitrogen atom in the modulators; however,
active constituents from Euphorbia species isolated in-house did not contain such a moiety. The
authors generated multiple refined pharmacophore models and evaluated them against a dataset of
literature-derived modulators, the in-house collection, and inactive molecules. Their final model
highlighted the important role of hydrophobic contacts and the presence of a HBA feature for
P-glycoprotein modulators and showed that mapping of the most active compounds was also
preserved when a further HBA/HBD feature was added [47]. In addition, pharmacophore models can
be employed to reflect previously elucidated SARs for the identification of novel bioactive molecules. In
2002, Flohr et al. used the endogenous peptide urotensin II and synthetic analogues to experimentally
identify interactions that are crucial for binding to the urotensin II receptor [48]. Based on the
established SAR, pharmacophore models were built and employed to screen a chemical library
containing small drug-like compounds. Subsequent experimental testing of the virtual hits led to the
identification of six novel scaffold classes, which, importantly, contained non-peptic molecules [48].
2.1.3. Scaffold Hopping
A pharmacophore feature describes abstract chemical functionalities rather than specific functional
groups. Additionally, pharmacophore models only demand local functional similarity of active
compounds and virtual hits at 3D locations essential for biological activity. Therefore, there are
no specifications concerning the actual two-dimensional (2D) structures of mapping compounds.
Although the composition of a pharmacophore model is influenced by the 2D structure of the molecules
employed for model generation and refinement, it still allows for mapping of structurally distinct
hits. This makes pharmacophore modeling broadly applicable for the investigation of molecules
originating from a diverse chemical space such as natural products and synthetic compounds.
Importantly, it also allows for the identification of novel scaffolds that have not been associated with
the target of interest before, a strategy that is called scaffold hopping. An earlier review extensively
discussed pharmacophore modeling in the context of scaffold hopping [49]. A recent study employed
pharmacophore modeling for the discovery of novel transient receptor potential vanilloid type 1
channel ligands [50]. Although the initial hits only weakly interacted with the target, they represent an
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interesting starting point for further chemical optimization. Such studies mostly emphasized novel
chemical scaffolds and retrieved low similarity scores compared to the highly active compounds in the
theoretical validation dataset [50].
Scaffold hopping is certainly relevant for the pharmaceutical industry that needs to explore
compounds which are not yet covered by intellectual property issues. Of relevance for the general
public, scaffold hopping facilitates the identification of chemicals with only limited available data.
This is often the case for environmental pollutants and chemicals from consumer products that are
often not drug-like by their nature.
2.1.4. Selectivity Profiling
For some projects, it may be of the utmost importance to identify compounds that selectively
modulate the activity of one or more isoforms of an enzyme (family) to trigger the desired biological
effect. For example, steroidal core structures are frequently found in endogenous and exogenous
bioactive compounds; however, these compounds often lack selectivity. To identify selective
compounds, specific chemical substitutions leading to additional hydrophobic or ionic interactions
and hydrogen bonds have to be implemented. It has to be emphasized that these specific chemical
modifications allow for distinguishing between the enzyme of interest and its related enzymes.
For example, 17β-HSD1 inhibitors are promising drug candidates for the treatment of
hormone-sensitive breast cancer as well as endometriosis because they block the activation of estrone
to the highly potent endogenous estrogen receptor (ER) agonist estradiol [51–53]. On the other side,
the converse reaction, (i.e., inactivation of estradiol) mediated via 17β-HSD2, should not be blocked
by these molecules. Ideally, bioassays of all relevant members within a given protein family would
be employed to assess a compound’s selectivity. Additionally, proteins sharing structural similarity
in the domain that contains the ligand binding pocket rather than sequence similarity should be
considered in the selectivity assessment of compounds [54,55]. Thus, a huge number of proteins
need to be covered in this resource- and time-consuming approach. In a first step, parallel screening
using a large collection of pharmacophores, covering the most relevant proteins, allows for an initial
characterization of a compound’s activity profile and facilitates the prioritization of the bioassays to be
chosen for further biological analyses.
However, selectivity may not be limited to different isoforms. As exemplified by a study from
Guasch et al., it can even address the biological effect exerted via the same target [56]. The authors
focused on the exclusive discovery of novel PPARγ partial agonists. The retrieval of full agonists
was avoided to prevent the side effects accompanying full receptor activation. For this purpose, a
pharmacophore model for full agonists (called the anti-pharmacophore) was generated and used to
remove all potential full agonists from the screening database. In the second step, a partial agonist
pharmacophore model was applied to identify potential partial agonists in the compound library.
After several additional filtering steps, eight compounds were finally subjected to biological testing
and five of them could be confirmed as novel PPARγ ligands displaying partial agonistic effects [56].
2.1.5. Combination with Other Techniques
Pharmacophore models are also often used together with other methods to further increase
the number of active molecules in the hit list via the application of a consensus approach.
Commonly employed combinations comprise docking, shape-based modeling, and MD simulation.
In addition, a number of filters are available that help to limit the virtual hits to those with the
desired properties and eliminate unwanted actions or molecules. Probably the most prominent filter
represents the Lipinski’s, describing properties that are shared by approved and orally administered
drugs [57]. In particular, these comprise a number ofď5 HBDs,ď10 HBAs, a molecular weight ofď500,
and a cLogP ď5. Since all descriptors are either five or a multiple of five, Lipinski et al. referred to it as
the “rule of five”. Although the rule of five was initially developed to predict the oral bioavailability
of molecules, it is also widely applied as a general drug-like filter. Veber et al. suggested two other
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criteria for the oral bioavailability of compounds: First, compounds should have a number of ď10
rotatable bonds and, second, either a polar surface area of ď140 Å2 or ď12 HBAs and HBDs [58].
In analogy to Lipinski’s rule of five, Congreve et al. introduced the “rule of three” for the
identification of promising hit compounds in fragment-based drug discovery [59]. Their analysis
revealed that most of the small compounds that were successfully optimized to potent lead-like
candidates had a molecular weight of ď300, a number of HBDs ď3, a number of HBAs ď3, and a
cLogP ď3 [59].
More recently, a substructure filter was developed to identify highly problematic compounds that
notoriously produce false positive assay read-outs [60]. Baell and Holloway analyzed high-throughput
testing results and observed that a group of molecules were prone to unspecifically interfere with some
experimental test systems. The subsequently developed substructure filter can help to detect these
pan-assay-interference compounds (PAINS) [60] prior to spending time and resources in investigating
and optimizing such molecules [61].
Multiple of these methods and filters can be included as well. As an example, Noha et al. employed
a variety of computational techniques in a sequential manner to identify novel inhibitors of microsomal
prostaglandin E2 synthase-1 [62]. The workflow included multiple prefilters, among them also the
Lipinski filter, a pharmacophore-based virtual screening procedure, and molecular docking. Out of the
17 molecules finally selected for testing, two showed good activity in the experimental assay, and two
further had moderate effects. Temml et al. used a combination of pharmacophore- and shape-based
virtual screening to identify novel liver X receptor agonists [44]. In their study mentioned above [56],
Guasch et al. not only applied pharmacophore models, but also a multistep protocol comprised of
electrostatic and shape similarity and molecular docking to identify novel PPARγ partial agonists.
2.2. The Short-Chain Dehydrogenase/Reductase Superfamily
The short-chain dehydrogenase/reductase (SDR) enzyme family are nicotinamide adenine
dinucleotide NAD (phosphate (P))-dependent enzymes sharing a common core structure of up to seven
parallel stranded β–sheets flanked by three to four α–helices on each side, the so-called Rossmann
fold, for NAD(P) binding and a catalytic center characterized by a Tyr-(Xaa)3-Lys motif. This motif is
often found in combination with a conserved serine residue that stabilizes the orientation of the bound
substrate (Figure 5) [63]. SDRs typically share a low sequence identity between 20%–30%, but with
considerable structural similarity in the core domain.
The SDR family contains HSDs that play key roles in adrenal and gonadal steroidogenesis as
well as in the metabolism of steroids in peripheral tissues [64]. Some of these HSDs are considered
as promising therapeutic targets for the treatment of estrogen- and androgen-dependent diseases
such as osteoporosis, endometriosis, and breast and prostate cancer, and other enzymes gained
interest regarding the treatment of corticosteroid-related diseases such as diabetes, visceral obesity and
dyslipidemia, atherosclerosis, wound healing, glaucoma, neurodegenerative disease, and cognitive
impairment [53,65–67].
The development of specific SDR inhibitors needs to take into account the structural similarity
of the various SDR enzymes in order to exclude the inhibition of members causing adverse effects,
so-called off-targets. Suitable enzyme activity assays are fundamental for selectivity testing of potential
inhibitors. Koch et al. proposed that structural similarity rather than primary sequence similarity
should be chosen as the criterion for whether a certain chemical affects the activity of a related
enzyme [54]. Therefore, the closest structurally related enzymes should be included for selectivity
testing—using pharmacophore models and cell-based assays. Another application of the modeling
approaches is the identification of toxic xenobiotics including industrial and environmentally relevant
chemicals [68–70]. The role of several SDRs in xenobiotics metabolism and in steroid synthesis and
metabolism makes them prone as targets for endocrine disruption [71–76].
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Figure 5. The general structure of SDR enzymes exemplified on 17β-HSD1 (PDB entry 1EQU [5]).
(A) The Rossmann fold consists of parallel stranded β-sheets (yellow), which are flanked by α-helices on
both sides (green). This structural domain forms the binding site of the co-factor NADP+. The residues
Tyr155 and Lys159 of the Tyr-(Xaa)3-Lys motif as well as the conserved Ser142 are highlighted in rose;
(B) 2D depiction of 17β-HSD1 (PDB entry 1EQU). Yellow triangles display β-sheets and barrel symbols
α-helices. Apart from the Rossmann fold, structurally conserved regions are highlighted in red. The
conserved glycine-rich motif GxxxGxG is important for cofactor binding and the + indicates a positive
charged residue crucial for cofactor (NADP+) stabilization.
3. Examples from the SDR Family
3.1. 11β-Hydroxysteroid Dehydrogenase Type 1
The two isoenzymes of 11β-HSD catalyze the interconversion of the biologically inactive
cortisone and the active cortisol (Figure 6). The 11β-HSD1 is ubiquitously expressed and mediates
the regeneration of active glucocorticoids [77,78], whereas 11β-HSD2 catalyzes the inactivation of
glucocorticoids mainly in the kidney, colon and placenta. There is evidence for beneficial effects of
11β-HSD1 inhibition in the metabolic syndrome [79–87], atherosclerosis [88–91], osteoporosis [66,92],
glaucoma [93–95], cognitive functions [96–100], skin aging [101], and wound healing [102,103]. Thus,
inhibition of 11β-HSD1 has substantial therapeutic potential for glucocorticoid-related diseases.
Numerous 11β-HSD1 inhibitors have already been identified and some have reached the clinical
phase, but to date still no 11β-HSD1 inhibitor is on the market [104]. Although structural variety is
prevalent among the 11β-HSD1 inhibitors, the crystal structures are rather similar [105]. Nevertheless,
the observed differences are useful in selecting a structure for further in silico evaluations. To date, 27
human, four mouse, and three guinea pig 11β-HSD1 crystal structures are accessible through the PDB;
however, there is currently no 3D structure of human 11β-HSD1 in -complex with a substrate available.
In addition, structural information about 11β-HSD2 is entirely missing.
Figure 6. Interconversion of cortisone and cortisol catalyzed by the 11β-HSD enzymes.
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Schuster and Maurer et al. [106] were the first to introduce pharmacophore models for the
identification of novel classes of 11β-HSD1 inhibitors. As there was no X-ray crystal structure of
11β-HSD1 available at the beginning of their study, they employed two ligand-based pharmacophore
models as VS tools. Depending on the 11β-HSD activity of the training compounds used for the model
generation, a model for 11β-HSD1-selective (Figure 7A) and one for nonselective 11β-HSD inhibitors
(Figure 7B), preferably targeting 11β-HSD2, were developed. These models identified compounds
resembling the structure of the known unselective 11β-HSD inhibitor glycyrrhetinic acid (GA),
steroid-like compounds, and novel structural classes. A comparison of the training set compounds
used for the generation of the 11β-HSD1-selective and the 11β-HSD-nonselective pharmacophore
models with the compounds from the VS showed similar inhibition profiles towards 11β-HSD1 and
11β-HSD2.
Figure 7. The selective (A) and nonselective (B) 11β-HSD1 pharmacophore models reported in the
study by Schuster and Maurer [106]. The training compounds CAS 376638-65-2 (A) and carbenoxolone
(B) are aligned to the models. The 11β-HSD1-selective model consisted of four H features (blue), one
HBA (green) and one HBD (magenta) feature and a shape restriction. The nonselective 11β-HSD model
contained five H, four HBA features and also a shape restriction.
Testing the inhibitory potential of their VS hits, Schuster and Maurer et al. determined biological
activities for human 11β-HSD1, 11β-HSD2, 17β-HSD1 and 17β-HSD2 [106]. Out of 30 tested
compounds, seven inhibited 11β-HSD1 activity by more than 70% at 10 µM and only three showed
reasonable selectivity over the other tested enzymes.
The potential of the selective 11β-HSD1 ligand-based pharmacophore model obtained by
Schuster and Maurer et al. [106] was further evaluated by Hofer et al. [107]. VS and subsequent
lead optimization by classical bioisosteric studies revealed a class of selective 11β-HSD1 inhibitors
bearing an arylsulfonylpiperazine scaffold. Docking studies, performed to rationalize the biological
data, showed good alignment of all active compounds with the co-crystallized ligand, belonging
to the same chemical scaffold. This structure-based approach further validated the ligand-based
pharmacophore model.
Rollinger et al. used the same pharmacophore model as a query for the screening of a database
consisting of constituents from medicinal plants, in order to identify natural compounds selectively
inhibiting 11β-HSD1 [108]. The chemical class of triterpenoids displayed one of the dominating
chemical scaffolds in the virtual hit list. Earlier investigations led to the assumption that extracts
from the anti-diabetic medical plant loquat (Eriobotrya japonica) dose-dependently and preferentially
inhibit 11β-HSD1 over 11β-HSD2 [109]. Therefore, the virtual screening hit corosolic acid, a known
constituent of E. japonica, was tested and identified as potent inhibitor of human 11β-HSD1 with an
IC50 of 810 nM [108]. Subsequent bioassay-guided phytochemical analyses revealed further secondary
metabolites from the triterpenoid ursane type as 11β-HSD1 inhibitors with IC50 in the micromolar
range. Importantly, a mixture of the constituents with moderate inhibitory activities displayed an
additive effect. This is a common observation in phytotherapy, where a mixture of constituents is
often responsible for the therapeutic effect. Docking studies for binding mode prediction suggested a
flipped binding mode, where these triterpenoids would not interact with the catalytic amino acids but
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with Thr124 and Tyr177 (Figure 8). Based on the most active compounds, a pharmacophore model
was generated that enriched active molecules on the top of the hit list and successfully reflected the
substructures important for binding. Additionally, this study demonstrates a further application in the
drug discovery process—finding inhibitors from natural origins.
Figure 8. The docking pose of the potent inhibitor corosolic acid in the binding pocket of 11β-HSD1
(PDB entry 2BEL [110]) suggests interactions with Thr124 and Tyr177.
Considering the ongoing search for novel 11β-HSD1 inhibitors, high predictivity and performance
of pharmacophores are essential. Thus, to maintain high quality standards, pharmacophore models
have to be continuously re-evaluated and improved. Vuorinen et al. [29] performed a refinement study
of the 11β-HSD pharmacophore models previously described by Schuster and Maurer et al. [106] and
Kratschmar et al. [78]. In a first step, the selective 11β-HSD1 model was refined by exchanging a
chemical feature and removing shape restriction using literature data. Whereas the unrefined model
was only able to recognize two out of 14 test compounds, the refined model found 13. Subsequent
prospective VS and biological testing revealed better performance of the refined model. However,
although the refinement improved the sensitivity of the model and more active compounds were
found, it decreased specificity and also more inactive compounds fitted into the model. Adding
a shape restriction, following newly identified selective 11β-HSD1 inhibitors, increased specificity,
whereas the sensitivity remained the same. For additional testing of the model quality on a different
dataset, literature-based validation was performed with structurally diverse compounds, which had
not been used in the model development. Specificity was increased, whereas sensitivity decreased.
This illustrates that improvement of model quality is accompanied by balancing the specificity and
sensitivity of a model. Refinement of the 11β-HSD2-selective model was equally conducted. Since there
is no 3D structure of 11β-HSD2 available and only a few selective, mainly triterpenoid scaffold-based
11β-HSD2 inhibitors are known, the 11β-HSD2 model data are biased. They were, however, able to
improve 11β-HSD2 model quality, and novel active scaffolds selectively inhibiting both 11β-HSD1
(Figure 9A) and 11β-HSD2 (Figure 9B) were discovered [29].
Using the refined 11β-HSD1 model, Vuorinen et al. applied a VS to filter a database consisting of
constituents from medicinal plants to identify potential 11β-HSD1 inhibitors focusing on triterpenoids
present in Pistacia lentiscus (P. lentiscus), so-called mastic gum that is used in traditional Greek medicine
for the treatment of diabetes [111]. The VS hit list contained eight hits of P. lentiscus constituents. The
two main constituents of mastic gum, masticadienonic acid and isomasticadienonic acid, were chosen
for further biological evaluation. Both compounds were shown to selectively inhibit 11β-HSD1 over
11β-HSD2 with IC50 values of 2.51 µM for masticadienonic acid and 1.94 µM for isomasticadienonic
acid, respectively. Examination of the whole resin’s activity revealed half the IC50 value of the single
molecules, suggesting an additive inhibitory effect. Thus, the hypothesis of 11β-HSD1 involvement
in the antidiabetic activity of mastic gum was supported. Analyzing the binding orientation of the
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two substances by docking revealed interactions comparable to that of the co-crystallized ligand
carbenoxolone, suggesting a competitive binding mode. Thus, the refined pharmacophore model has
proven its ability to identify novel 11β-HSD1 inhibitors from natural sources.
Figure 9. Both the refined 11β-HSD1 (A) and 11β-HSD2 (B) model identified novel scaffolds [29].
The inhibitor fenofibrate maps the 11β-HSD1 model (A) and ketoconazole matches the 11β-HSD2
model (B). Both models were screened with one omitted feature. The 2D structures of the novel
inhibitors are depicted underneath the alignments.
Yang et al. performed a study using different 11β-HSD1 crystal structures in order to identify
synthetic 11β-HSD1 inhibitors [112]. They applied a combined approach of molecular docking
and ligand-based pharmacophore modeling. For virtual docking calculations the crystal structure
1XU9 [113] and the program DOCK4.0 [114] were used to screen a commercial compound database.
The 3000 compounds with the highest docking score were selected for a second docking run using
Glide [115]. Additionally, a ligand-based pharmacophore model for selective 11β-HSD1 inhibitors
was constructed using Catalyst 4.10 [116], which was used for screening the 3000 compounds with
the Best Flexible Search mode. Compounds with high docking and good fit score were further
evaluated by filtering for drug likeness and finally selected for biological testing on human and
mouse 11β-HSD1. Importantly, other studies showed significant species-specific variability in the
potency of various 11β-HSD1 inhibitors, indicating significant differences in the 3D organization
of the hydrophobic substrate-binding pocket of human and mouse 11β-HSD1 [117,118]. Due to
this issue, the tested compounds showed different inhibition profiles for the mouse and human
enzyme. Eleven out of 121 tested compounds inhibited the human 11β-HSD1 with IC50 values of
0.26–14.6 µM, whereas six molecules inhibited the mouse 11β-HSD1 with IC50 values of 0.48–12.49 µM.
Two substances displayed overlapping hits with IC50 for the human 11β-HSD1 of 0.69 µM and
3.57 µM and for the mouse isoenzyme of 0.48 µM and 2.09 µM, respectively. In order to test the
selectivity over 11β-HSD2 for subsequent animal studies, only compounds inhibiting mouse 11β-HSD1
were tested for the inhibition of mouse 11β-HSD2. All compounds selectively inhibited 11β-HSD1.
Nevertheless, selectivity assessment needs to include human 11β-HSD2 and, ideally, other SDRs.
Cross-species activity would be the optimal situation for preclinical evaluation in the development of
novel drug candidates.
A consecutive in silico study of Yang et al. includes virtual screening with 11β-HSD1
structure-based pharmacophore models and subsequent docking for hit selection [119].
Compounds chosen in the docking process were able to form hydrogen bonds with the amino acids
Tyr183 and Ser170 from the catalytic triade. Nine out of 56 enzymatically tested compounds exhibited
dose-dependent and selective inhibition of human 11β-HSD1 with IC50 values between 0.85–7.98 µM
and six substances inhibited the mouse 11β-HSD1 with IC50 values between 0.44 µM and 8.48 µM.
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Four substances inhibited both isoenzymes with similar IC50 values. In contrast, during their first
11β-HSD1 in silico study, Yang et al. identified 11 out of 121 tested compounds from the same database
as actives against 11β-HSD1, with IC50 values between 0.26–14.6 µM [113]. Four of the identified
11β-HSD1 inhibitors incorporate an arylsulfamido scaffold, an already reported scaffold to inhibit
11β-HSD1 [118]. Besides, three new scaffolds were identified as displayed in Figure 10.
Figure 10. The three new identified scaffolds by Yang et al. [119].
Table 1 summarizes the pharmacophore-based virtual screening studies and illustrates the
scaffold-hopping of the different 11β-HSD1 inhibitors.
3.1.1. 17β-Hydroxysteroid Dehydrogenase Type 1
To date, 14 different human 17β-hydroxysteroid dehydrogenase (17β-HSD) enzymes have been
reported, all of which except the aldo-keto reductase (AKR) member 17β-HSD5 (AKR1C3) belong to
the SDR family [120]. The 17β-HSDs essentially regulate the local metabolism and activity of estrogens
and androgens (Figure 11).
Figure 11. 17β-HSDs involved in sex steroid metabolism.
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Table 1. 11β-HSD1 pharmacophore-based virtual screening studies summarized.
Reference Study Aim Pharmacophore
Model
Database Used
for VS
Hits Biological Testing
Most Active Hit Number ofVirtual Hits
Tested in
Vitro Actives Assay IC50 Selectivity
Schuster and
Maurer et al. [106]
11β-HSD1 inhibitors
Ligand-based
using Catalyst
Asinex Gold and
Platinum, Bionet
2003, ChemBridge
DBS, Clab and
IDC, Enamine 03,
Interbioscreen 03
nat and syn,
Maybridge 2003,
NCI, Specs 09 03
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The enzyme 17β-HSD1 catalyzes the NADP (H)-dependent reduction of the weak estrogen
estrone to the potent estradiol and to a minor extent of dehydroepiandrosterone (DHEA) to
5-androstene-3β,17β-diol [121]. 17β-HSD1 is predominantly expressed in the human placenta,
ovaries, and mammary gland, and is of major importance for the peripheral and gonadal estradiol
synthesis [122]. Several studies provide evidence for the association of 17β-HSD1 with breast
cancer [123–125], endometriosis [52,126], endometrial cancer [127] and uterine leiomyoma [128].
Despite the recently increasing numbers of reported 17β-HSD1 inhibitors, still no compound
reached clinical trials. To date, more than 20 crystal structures have been published. The binding
pocket of 17β-HSD1 is an elongated hydrophobic tunnel, with key roles for Leu149, Val225, Phe226,
and Phe259, and polar areas at each end formed by His221 and Glu282 on one side and the catalytically
essential residues Ser142 and Tyr155 on the other side. The active site is limited by a flexible loop
(amino acids 188–201), which is not well resolved in the crystal structures (Figure 12) [13].
Figure 12. Shape binding site of 17β-HSD1 with equilin as co-crystallized ligand, key residues, a
flexible loop and the cofactor NADP+ (PDB 1EQU).
In 2001, Hoffren et al. were the first to report structure-based pharmacophore models for the
discovery of 17β-HSD1 inhibitors [129]. The pharmacophore models were validated to specifically
recognize compounds possessing the structural and chemical features of steroids and flavonoids.
Coumestrol displayed the most potent 17β-HSD1 inhibiting activity among the test compounds
used for model validation. However, coumestrol also inhibited 17β-HSD5 and is, therefore, not
selective [130]. Unfortunately, the virtual hits were not confirmed by biological validation [129].
To support the development of therapeutic inhibitors, database creation for pharmacophore model
validation should focus on selective inhibitors to increase model selectivity and sensitivity. Since
steroidal inhibitors and natural phytoestrogens, including flavonoids, often exhibit cross-reactivity
with other enzymes and hormone receptors involved in the steroidogenesis, non-steroidal scaffolds
are more favorable for virtual screening and drug development. However, although highly selective
inhibitors are needed for many therapeutic applications, polyvalent inhibitors acting on synergistic
pathways may be advantageous in some situations.
The 17β-HSD1 can be inhibited by several modes: competing reversibly and irreversibly with the
natural substrate for its binding site, competing with NADP(H) for its binding site at the Rossmann
fold or occupying the ligand and the cofactor binding site by so-called hybrid compounds consisting of
a steroidal core and extended side-chains of NADP(H) moieties [131,132]. Since only crystal structures
containing steroidal inhibitors were available at that time, Schuster and Nashev et al. generated
structure-based pharmacophore models based on steroidal inhibitors [133]. They developed two
pharmacophore models, representing, on one hand, reversible competitive inhibitors based on the
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steroidal core equilin (Figure 13A) and, on the other hand, hybrid inhibitors (Figure 13B). Whereas
the first model was suggested to be suitable as a general screening tool, expecting many false positive
hits, the hybrid model was more restrictive due to the unique scaffold of the underlying hybrid
inhibitors. VS and subsequent in vitro validation of 14 selected compounds from the virtual hit list
revealed, amongst others, two nonsteroidal hits with IC50 of 5.7 µM and 19 µM, respectively. As
mentioned above, the SDR enzymes share substantial structural similarity. For selectivity assessment,
11β-HSD1, 11β-HSD2, 17β-HSD2, 17β-HSD3 and the AKR 17β-HSD5 were tested. Two additional
inhibitors were selective. One was a steroidal compound with an IC50 of 3.8 µM for 11β-HSD1 and
47 µM for 17β-HSD1, and one a nonsteroidal 11β-HSD1 inhibitor with IC50 of 6.2 µM and comparable
activity on 17β-HSD3. These observations emphasize the importance of including structurally related
enzymes for selectivity assessment. In addition to the biological selectivity assessment, Schuster
and Nashev et al. applied pharmacophore models of structurally related enzymes as an alternative
strategy to identify unspecific inhibitors [133]. These pharmacophores should act as initial filters to
eliminate compounds with a low degree of selectivity that may exhibit off-target effects. Screening the
compounds identified as actives for 11β-HSD1 with their previously established selective 11β-HSD1
pharmacophore model resulted in retrieving one hit [106]. By deleting the shape restriction, the second
hit was found as well and, at the same time, showed higher best fit values than an inactive compound.
Thus, screening of pharmacophore models of related enzymes may facilitate the discrimination of
selective and nonselective inhibitors and the virtual hit selection for in vitro testing, similar to the study
by Guasch et al. described above [56].
Figure 13. (A) 17β-HSD1 model based on the equilin crystal structure (PDB entry 1EQU [5]); (B) The
potent inhibitor STX 1040 maps the hybrid 17β-HSD1 pharmacophore model [133].
For pharmacophore model generation, Sparado et al. [134] superimposed five 17β-HSD1 crystal
structures, covering most of the chemical space occupied by the co-crystallized ligands. Performing
a VS of an in-house compound library led to the identification of one virtual hit with moderate
inhibitory activity against 17β-HSD1. Application of the rigidification strategy, scaffold hopping
and further SAR analysis resulted in two far more potent benzothiazole-scaffold-bearing inhibitors
with IC50 in cell lysates of 44 and 243 nM, respectively. Both hits were selective against 17β-HSD2.
Furthermore, the less active compound still potently inhibited estrogen formation, with a comparable
IC50 value to the lysates, in a human cell model endogenously expressing 17β-HSD1. The more potent
compound showed pronounced affinity to bind to ERα and ERβ. Depending on whether binding to
ERα and ERβ results in agonistic or antagonistic effects, this could cause beneficial or adverse effects.
Interestingly, although the two hits differ only in a carbonyl and amide bridge, respectively, binding
mode investigations by docking showed a 180˝ flipped orientation of the two molecules (Figure 14). The
observation of a flipped binding mode was also discovered for corosolic acid and other triterpenoides
in the binding pocket of 11β-HSD1 as described earlier [108]. A follow-up lead optimization study to
improve activity and selectivity of the two compounds for in vivo applications, without the help of
molecular modeling techniques, led to the discovery of two new lead compounds [135]. They showed
selectivity over 17β-HSD2, no ER binding and promising activity in the intact cell model.
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Figure 14. 17β-HSD1 in complex with the two hits from Sparado et al. [134], (doi:10.1371/journal.
pone.0029252.g010, doi:10.1371/journal.pone.0029252.g011) showing a 180˝ flipped orientation. IC50
values of 44 nM (A) and 243 nM (B).
Table 2 shows a summary of the prospective pharmacophore-based virtual screening studies and
illustrates the scaffold-hopping potential for 17β-HSD1 inhibitors.
Structure-based and ligand-based pharmacophore modeling was performed by Karkola et al. [136].
They generated four pharmacophore models with different methods based on a crystal structure, a
relaxed crystal structure, alignment of thienopyrimidinone inhibitors, and a docked complex of
17β-HSD1 with a potent inhibitor. By VS, they found several compounds fitting into the active site of
17β-HSD1 without determining the activity of the hits. However, to validate these hits as 17β-HSD1
inhibitors, biological testing is needed. In addition, they could apply their differently generated
pharmacophore models to calculate selectivity and sensitivity.
3.1.2. 17β-Hydroxysteroid Dehydrogenase Type 2
The oxidative inactivation of estradiol to estrone is predominantly catalyzed by 17β-HSD2.
Additionally, 17β-HSD2 is capable of converting testosterone into 4-androstene-3,17-dione
(androstenedione), 5α-dihydrotestosterone (DHT) into 5α-androstanedione, 5-androstene-3β,17β-diol
to DHEA, and 20α-dihydroprogesterone into progesterone using the cofactor NAD+ [137,138].
The 17β-HSD2 is expressed in various tissues such as bone, placenta, endometrium, breast, uterus,
prostate, stomach, small intestine, and colon epithelium [139,140]. The current treatment options for
osteoporosis bear several limitations. Since 17β-HSD2 is expressed in osteoblasts, its inhibition may
provide a new approach to treat osteoporosis by increasing the local availability of estradiol.
Since 17β-HSD2 contains an N-terminal transmembrane anchor, the experimental 3D structure
determination remains a challenge and, to date, still no crystal structure is available. Due to this
lack, Vuorinen et al. constructed three ligand-based pharmacophore models as virtual screening
filters [141]. Virtual hit-testing in a cell-free assay revealed seven out of 29 compounds with IC50 values
against 17β-HSD2 ranging between 0.24 µM and 33 µM. Most of the active compounds represented
phenylbenzene-sulfonamides and -sulfonates. With the new structural classes of 17β-HSD2 inhibitors,
they performed a SAR study using two different approaches: first, by a 2D similarity search without
fitting the compounds into the pharmacophore models, and second, using a pharmacophore model
for VS. From the 2D search, one out of 16 compounds inhibited 17β-HSD2 with an IC50 of 3.3 µM,
whereas the VS showed five out of 14 compounds with IC50 between 1–15 µM. Selectivity of all
active compounds was tested against inhibition of 17β-HSD1, 17β-HSD3, 11β-HSD1, and 11β-HSD2.
The activity data of the phenylbenzene-sulfonamide and -sulfonate inhibitors revealed a phenolic
hydroxyl group with hydrogen bond donor functionality, which was important for 17β-HSD2
inhibition. This feature was confirmed by a ligand-based pharmacophore model that was developed
based on several of the newly identified active compounds (Figure 15). Furthermore, to improve
the initial pharmacophore model, a refinement database was created, including the original test set
compounds and the newly identified inhibitors as well as the inactive compounds. The specificity of
the model was increased by adding exclusion volumes. This approach is an important step to enhance
a model’s ability to enrich active compounds from a database.
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Figure 15. The selective 17β-HSD2 model contains a HBD feature (green sphere), which is important
for 17β-HSD2 inhibitors such as the newly identified phenylbenzene-sulfonamide derivative 13 [141].
3.1.3. 17β-Hydroxysteroid Dehydrogenase Type 3
The 17β-HSD3 is almost exclusively expressed in the testes and catalyzes the reduction of
androstenedione to testosterone in the presence of NADPH [142]. Although 17β-HSD3 is mainly
found in the testes, there is evidence for 17β-HSD3 mRNA up-regulation in prostate cancer [143].
Co-expression of 17β-HSD5, catalyzing the same reaction, might limit the therapeutic efficacy
of 17β-HSD3 inhibitors and a combined treatment with inhibitors against both enzymes should
be envisaged.
The enzyme is anchored through an N-terminal transmembrane domain to the endoplasmic
reticulum, and, like 17β-HSD2, its catalytic domain faces the cytoplasmic compartment [144,145].
As for 17β-HSD2, there is still no crystal structure available for the membrane protein 17β-HSD3.
Figure 16. (A) The novel 17β-HSD3 inhibitor 1–7 was identified with the steroid-based model consisting
of two HBAs (green) and four H features (blue); (B) The non-selective inhibitor 2-2 mapped the
nonsteroid-based 17β-HSD3 model containing two HBAs, two AR (orange), one H and one H-AR
feature [146].
Two ligand-based pharmacophore models, based on steroidal and nonsteroidal 17β-HSD3
inhibitors, were developed by Schuster et al. [146] (Figure 16). These ligand-based models supported
the observations by Vicker et al. of a highly hydrophobic active site of 17β-HSD3 [147]. The models
were then used to screen eight commercial databases and the hit list was further filtered prior to the
selection of hits. Enzymatic tests showed that, from the steroid-based model, two out of 15 tested
substances inhibited 17β-HSD3, with one also inhibiting 17β-HSD1 [146]. At the same time, three
other compounds inhibiting the AKR 17β-HSD5 were identified. The 17β-HSD5 is a multifunctional
enzyme and, like 17β-HSD3, catalyzes the conversion of androstenedione into testosterone. The most
potent compound was not selective and also inhibited 11β-HSD1 and 11β-HSD2. Similar results were
obtained with the nonsteroidal model. The nonsteroidal model and its training compounds displayed
several overlapping features with the lead compound identified earlier by Vicker et al. [147]; thus,
the examination of their compounds for 17β-HSD5 inhibitory activity would be interesting. These
observations again emphasize the importance of including structurally related enzymes, independently
of their enzymatic classes, for selectivity profiling. A summary of the 17β-HSD3 pharmacophore-based
virtual screening study presented by Schuster et al. is provided in Table 3.
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Table 2. 17β-HSD1 pharmacophore-based virtual screening studies summarized.
Reference
Study Aim Pharmacophore Model
Database Used
for VS
Hits Biological Testing
Most Active Hit Number ofVirtual Hits
Tested
in Vitro Actives Assay IC50 Selectivity
Schuster and
Nashev et al. [133]
17β-HSD1
inhibitors
Structure-based Using
LigandScout and
Catalyst 1I5R model (4 H,
2HBA, 2 HBD) Based on
a hybrid inhibitor
NCI, SPECS
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3.2. Applications in Toxicology
3.2.1. Anti-Target Screening
Although the actual virtual screening process is analogous to lead identification, anti-target
screening pursues a different aim. Lead identification focuses on the discovery of ligands for
therapeutically relevant targets, whereas anti-target screening aims at predicting the interaction
of molecules with macromolecules mediating potentially harmful effects (so-called anti-targets). These
investigations support the identification of (serious) adverse events already at an early stage in drug
development. This strategy is powerful, as recently shown by Kratz et al. [148], who successfully
applied pharmacophore models to identify inhibitors of the human ether-a-go-go-related gene (hERG)
potassium channel, thereby predicting the cardiotoxic potential of the investigated molecules [148].
3.2.2. Parallel Screening
Parallel screening represents an extension to lead identification and anti-target screening protocols.
It investigates not a single target but a whole collection of macromolecules with the aim of obtaining
activity profiles of compounds of interest in order to prioritize further investigation. Thus, the focus of
this technique shifts from the target of interest to the compound of interest, which is screened against
a collection of pharmacophores, representing a plethora of different targets. Parallel screening has
the potential to identify macromolecular interaction partners of the investigated molecule, thereby
providing novel insight into its biological activities. These activities may include beneficial (i.e.,
therapeutic) and harmful (i.e., toxic) effects. Therefore, the results support the evaluation of a
compound both with regard to the occurrence of adverse events and potential novel application
fields (whenever this aspect represents the main aim of the parallel screening, this technique is also
referred to as drug repurposing or drug repositioning). In the attempt to explore the biological
activity of leoligin, a lignan isolated from the alpine plant Edelweiss (Leontopodium alpinum), the
compound was screened against the Inte:Ligand pharmacophore collection in the course of a parallel
screening [149]. Among the proposed targets, wascholesteryl ester transfer protein (CETP), a target
involved in lipoprotein metabolism, was shown to be activated by leoligin in subsequent experimental
testing. On the other side, leoligin was also predicted to inhibit the cytochrome P450 (CYP) isoforms
1A2, 2C9, and 3A4 [150], which are involved in the metabolic clearance of exogenous compounds.
While it was not active on CYP1A2, it was a weak inhibitor on CYP2C9, and a sub-micromolar IC50
was determined for CYP3A4 [150]. Inhibition of CYP enzymes can cause severe drug-drug interactions
that may lead to serious adverse effects and eventually require the termination of a drug development
project. Accordingly, both potentially beneficial (CETP activation) and potentially harmful (CYP
inhibition) effects can be detected during a parallel screening.
3.2.3. Examples
There is a great demand for improved methods for the safety assessment of man-made chemicals
released into the environment [68,151]. Endocrine-disrupting chemicals (EDCs) are exogenous
substances interfering with hormone synthesis, metabolism and/or hormonal regulation, thereby
adversely affecting human health by contributing to developmental and reproductive disorders,
cardio-metabolic diseases, cancer, and immune-related diseases and psychiatric disorders [152]. EDCs
include substances used in agriculture, industrial production, dyes, food preservatives, or body care
products and cosmetics. Several SDRs are essentially involved in the control of the local availability of
active glucocorticoids, androgens and estrogens, and these enzymes should therefore be considered in
the assessment of potential EDCs. In silico tools are well established in the drug discovery process;
however, they can also display a valuable part in the identification of new EDCs or the mechanism of
action of known EDCs [68].
Nashev and Vuorinen et al. [70] reported a pharmacophore-based virtual screening using a
ligand-based 11β-HSD pharmacophore model preferentially focusing on 11β-HSD2 [106]. The 11β-HSD2
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protects the mineralocorticoid receptor (MR) from activation by cortisol and renders specificity for the
much less abundant aldosterone to activate this receptor. Genetic defects of this enzyme cause the
syndrome of apparent mineralocorticoid excess (AME), characterized by hypokalemia, hypernatremia,
and severe hypertension [153,154]. In addition, placental 11β-HSD2 protects the fetus from enhanced
maternal cortisol exposure [155,156]. Therefore, disrupting corticosteroid action by EDCs can be expected
to cause substantial adverse health effects. VS of an EDC database predicted 29 compounds fitting into the
model of which five hits were selected for biological evaluation. Two compounds were found to inhibit
11βHSD2, the silane coupling agent AB110873 and the antibiotic lasalocid, with IC50 values of 6.1 µM and
14 µM, respectively. The silane AB110873 is widely used as a rubber additive for the production of tires,
mechanical goods, or shoe soles and lasalocid is used as a feed additive for the prevention of infections in
the breeding of chicken and turkeys. Docking studies were implemented to understand the binding mode
of AB110873 in 11β-HSD2 (Figure 17) and MR.
Figure 17. Docking of silane into the homology model of 11β-HSD2 [78] suggests hydrogen bond
interactions with Ser219 and Tyr232 [70].
Genetic defects resulting in 17β-HSD3 deficiency cause 46,XY disorder of sex development [142,157,158].
Inhibition of 17β-HSD3 activity by EDCs might reduce plasma testosterone levels, thereby interfering
with male sexual development and contributing to male reproductive disorders. To identify potential
EDCs inhibiting 17β-HSD3, Nashev and Schuster et al. generated a ligand-based pharmacophore
model [74]. VS of an EDC database predicted several organic UV filters containing a benzophenone
as a bioactive chemical scaffold. UV filters are a structurally diverse class of chemicals widely used in
sunscreens and cosmetics as well as plastic additives. In vitro testing of selected virtual hits and similar
environmentally relevant derivatives led to the identification of benzophenone-1 (BP-1) as the most
potent 17β-HSD3 inhibitor with an IC50 of 1.05 µM in intact cells. BP-2,3-benzylidene camphor (3-BC)
and 4-methylbenzylidene camphor (4-MBC) moderately inhibited 17β-HSD3 with IC50 values between
10.7 µM and 33.3 µM, but showed substantial inhibitory activity on 17β-HSD2 with IC50 between 5.9 µM
and 10.3 µM. Importantly, the most active compound, BP-1, as well as 3-BC and 4-MBC were not included
in the initial virtual hit list but added to the biological testing due to their use as UV filters. Hence, VS
displays an initial filter for the identification of potential EDC compound classes and aims at prioritizing
the compounds to be included for biological investigations. In analogy to the drug discovery process,
it is important to test structurally related enzymes in order to know whether they are affected by a
given EDC. Importantly, major metabolites should also be included in the analysis. For example, BP-3
showed no activity against 17β-HSD3, but it is demethylated in vivo to the potent inhibitor BP-1 [159].
To explain the differential inhibitory activities of the tested UV filters, Schuster and Nashev conducted
pharmacophore-based SAR studies, suggesting that the ether group on BP-3 and BP-8 instead of a
hydroxyl group on BP-1 and BP-2 was the reason for the loss of activity of BP-3 and BP-8 (Figure 18). To
further study the toxicological relevance of 17β-HSD3 inhibition by BP-1, concentrations reached in vivo,
especially in the testes, need to be determined.
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Figure 18. SAR analysis revealed that the etherification of the hydroxyl group (as indicated by the
arrows) was responsible for the loss of activity observed for BP-3 and BP-8 [74]. *Remaining enzyme
activity at a compound concentration of 20 µM compared to vehicle control.
4. Limitations
As with every method, pharmacophore modeling and pharmacophore-based virtual screening
also have their limits. A recent study compared the performances of two pharmacophore modeling
programs, LigandScout and Discovery Studio, on the identification of novel cyclooxygenase
inhibitors [160]. Intriguingly, although both programs succeeded in the identification of novel bioactive
molecules, the virtual hit lists retrieved with the two tools were highly complementary. It is of note
that not a single overlap in the hit lists was observed, even when the identical crystal structure of a
ligand-target complex was employed for model generation. This illustrates that neither of the two
programs was capable of comprehensively covering the active space and that models from different
programs need to be combined whenever a more complete retrieval of active molecules is required. The
authors suggested that the reasons for this finding may be found in the different screening algorithms
and feature definitions deployed by the programs.
Feature definitions can be improved in general, as highlighted by the treatment of halogens.
Some pharmacophore modeling programs consider halogens solely as hydrophobic moieties in the
default settings [7,8,161]. LigandScout, in addition, matches fluorine to HBA features [6]. In 2013,
a study by Sirimulla et al. [162] revealed that in many ligand-target complexes, halogens participate in
strong halogen bond formation, e.g., with aromatic rings, and thereby considerably contribute to the
interaction between the ligand and the target. These types of interactions, although often employed by
medicinal chemists to improve the binding affinity of compounds [162], are not yet implemented in
common pharmacophore-based virtual screening tools.
A major limitation, not only for pharmacophore modeling but for virtual screening tools in general,
is the fact that the quality of a pharmacophore model critically depends on the data employed for
model generation, refinement, and theoretical validation. Many public data repositories are available
that can be explored to build a model. However, caution is required as, apparently, parts of the data
are erroneous. Fourches et al. investigated six different datasets, and after curation, up to 10% of
the original structures were removed [163]. Besides several other preventive measures, the authors
suggest to include a final manual inspection step to check the structures of the input compounds. We
fully support this recommendation and would even go one step further: Not only the structures of the
compounds included in the modeling dataset need to be critically evaluated, but also the annotated
biological data. This starts with inclusion/exclusion criteria for appropriate/inappropriate testing
systems applied to determine the biological activity of a compound (for example, data obtained from
intact cell assays or from animal tissue preparations are of limited use for human enzyme models),
the application of suitable activity cut-offs (distinguishing between specific and unspecific effects,
depending on the investigated target), and ends at a critical comparison with the original literature
as errors can also happen during the transfer of data to depositories. These procedures may be quite
elaborate; nevertheless, they are crucial for the generation of high quality models and every modeler is
well advised to carefully review the data on which the models are based.
Another limitation is a lack of compounds confirmed as inactive for a specific target. Results
on proven inactives for model validation are often not accessible because, unfortunately, negative
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results are rarely published. The information from confirmed inactive compounds is important
for the balancing between selectivity and sensitivity of a model during the validation step. In
the drug development process, restrictive models are required because, finally, only one or a few
lead compounds are selected for further optimization steps, whereas in a toxicology screening, it is
important to correctly find preferably all of the potentially harmful substances. Albeit considerably
more successful than random screening, the success rate of VS may still be a limiting factor for
toxicological projects. However, it has the ability to identify structural compound classes that then can
be further evaluated. Obviously, the database used for VS might be self-limiting as not all potential
active compounds are included.
One caveat of pharmacophore modeling is that a modeler needs to be aware of concerns
about detailed interaction patterns of the active compounds in the dataset. Although high quality
experimental data confirming their binding and activity may be available for these ligands, the exact
binding site is still not clearly defined for most of them. Many molecules may occupy a similar yet
slightly different part of the binding pocket, e.g., compared to the co-crystallized ligand in an X-ray
crystallographic complex employed for model generation. Accordingly, the interaction patterns may
differ. This factor is even more pronounced in ligands affecting the function of a protein by binding to
allosteric sites, disrupting conformational changes, or interfering with post-translational modifications.
Similar concerns also apply for the experimental validation of the in silico predictions, as it is, in the
end, often not known whether the newly identified compounds indeed exert the predicted binding
mode [164]. An X-ray crystal structure of the ligand-target complex would provide the ultimate
confirmation of the exact interaction patterns; however, 3D structure resolution of transmembrane
proteins by crystallization remains difficult. Several SDRs belong to this class of proteins such as, for
instance, 11βHSD2, 17βHSD2, and 17βHSD3. For these proteins, structure-based pharmacophore
modeling is currently not possible, and homology modeling remains challenging due to the low
sequence similarity of SDRs. However, for these cases, ligand-based pharmacophore modeling
displays an elegant solution.
Pharmacophore-based VS proved to be a powerful tool to support drug discovery and
development, especially concerning the enrichment of active molecules among test compounds.
Nevertheless, expectations concerning the results of VS need to remain realistic. Although sometimes
potent compounds are discovered via VS, the majority of virtual hits usually display only weak activity.
For this concern, the initial virtual hits from VS should be considered similar to initial experimental
hits discovered in a HTS campaign, which also require further chemical optimization steps to develop
to potential drug candidates [164].
5. Conclusions
The current work summarizes prospective pharmacophore-based studies conducted in the field
of steroid biology, with special focus on SDRs, and highlights success stories reported in this area.
Pharmacophore models are suitable to address a wide range of issues relevant for both drug discovery
and toxicology. This is of special relevance for SDRs, because members of this target class are both
associated with therapeutic value (e.g., 17β-HSD1 inhibition for the treatment of hormone-sensitive
cancers) and toxicological liabilities (disruption of 11β-HSD2 actions). Although the method itself
still has room for improvement as pointed out in the “Limits” section, the caveats associated with
pharmacophore modeling largely also apply for other virtual screening techniques. In addition, in case
of a lack of available structural data on macromolecular targets, ligand-based modeling strategies offer
a useful alternative. The identification of structurally diverse molecules may, to a certain extent, be
restricted to the data employed for model generation and refinement. However, the extraction of crucial
interactions and their representation via abstract chemical features proved to be a powerful approach
to step beyond the initial chemical space. As highlighted in this review, pharmacophore-based VS is a
valuable scaffold-hopping tool. Importantly, this allows for the application of pharmacophore-based
virtual screening also for compound classes that do not fall into the category of “small drug-like
22822
32
Molecules 2015, 20, 22799–22832
compounds” or whose properties differ from that of synthetic compounds: For example, natural
products provide a vast resource for bioactive compounds that can be exploited for therapeutic
purposes. On the other hand, the in silico-driven investigation of environmental chemicals, which often
chemically differ from drug-like molecules, facilitates the rapid identification of potentially harmful
compounds that need to be prioritized for experimental evaluation. Given the many application fields
of pharmacophore-based virtual screening and the successful examples summarized in this review, an
increasing number of studies, also in the field of SDR research, can be expected in the future.
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PDB Protein Data Bank
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A B S T R A C T
Several members of the short-chain dehydrogenase/reductase (SDR) enzyme family play fundamental
roles in adrenal and gonadal steroidogenesis as well as in the metabolism of steroids, oxysterols, bile
acids, and retinoids in peripheral tissues, thereby controlling the local activation of their cognate
receptors. Some of these SDRs are considered as promising therapeutic targets, for example to treat
estrogen-/androgen-dependent and corticosteroid-related diseases, whereas others are considered as
anti-targets as their inhibition may lead to disturbances of endocrine functions, thereby contributing to
the development and progression of diseases. Nevertheless, the physiological functions of about half of
all SDR members are still unknown. In this respect, in silico tools are highly valuable in drug discovery for
lead molecule identiﬁcation, in toxicology screenings to facilitate the identiﬁcation of hazardous
chemicals, and in fundamental research for substrate identiﬁcation and enzyme characterization.
Regarding SDRs, computational methods have been employed for a variety of applications including drug
discovery, enzyme characterization and substrate identiﬁcation, as well as identiﬁcation of potential
endocrine disrupting chemicals (EDC). This review provides an overview of the efforts undertaken in the
ﬁeld of virtual screening supported identiﬁcation of bioactive molecules in SDR research. In addition, it
presents an outlook and addresses the opportunities and limitations of computational modeling and in
vitro validation methods.
© 2017 Elsevier Ltd. All rights reserved.
Contents
1. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
1.1. The short-chain dehydrogenase/reductase (SDR) superfamily . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
1.2. Computer-aided drug design . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
2. Examples from the SDR family . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
2.1. Drug development . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
2.1.1. 11b-hydroxysteroid dehydrogenase type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 159
Abbreviations: 3-BC, 3-benzylidene camphor; 4-MBC, 4-methylbenzylidene camphor; Ab, amyloid-b; ABAD, Ab-binding alcohol dehydrogenase; AD, Alzheimer’s
disease; AI, aromatase inhibitor; AKR, aldo-keto reductase; AME, apparent mineralocorticoid excess; AR, androgen receptor; Aro, aromatic feature; BP, benzophenone; CBR,
carbonyl reductase; CYP, cytochrome P450; DASI, dual aromatase-sulfatase inhibitor; DHEA, dehydroepiandrosterone; DHT, 5a-dihydrotestosterone; EDCs, endocrine
disrupting chemicals; ER, estrogen receptor; FXR, farnesoid X receptor; GA, glycyrrhetinic acid; GPCR, G-protein-coupled receptor; GR, glucocorticoid receptor; H6PDH,
Hexose-6-phosphate dehydrogenase; H, hydrophobic feature HBA hydrogen bond acceptor; HBD, hydrogen bond donor; hERG, human ether-a-go-go related gene; HSD,
hydroxysteroid dehydrogenase; HTS, high-throughput screening; LDH, lactate dehydrogenase; MR, mineralocorticoid receptor; MD, molecular dynamics; MOE, Molecular
Operating Environment; NI, negatively ionizable; PAINS, Pan-Assay Interference Compounds; PI, positively ionizable; PDB, Protein Data Bank; PR, progesterone receptor; ROS,
reactive oxygen species; SAR, structure-activity relationship; SDR, short-chain dehydrogenase/reductase; SERM, selective estrogen receptor modulator; SPA, scintillation
proximity assay; STS, steroid sulfatase; Tc, Tanimoto coefﬁcient; TRL, tropinone reductase-like; UDCA, ursodeoxycholic acid; UFSRAT, Ultra-fast recognition with atom types;
Contents lists available at ScienceDirect
Journal of Steroid Biochemistry & Molecular Biology
journal homepage: www.else vie r .com/locate / j sbmbVS, virtual screening; XVols, exclusion volumes.
* Correspondence authors.
E-mail addresses: Daniela.Schuster@uibk.ac.at (D. Schuster), Alex.Odermatt@unibas.ch (A. Odermatt).
http://dx.doi.org/10.1016/j.jsbmb.2017.03.008
0960-0760/© 2017 Elsevier Ltd. All rights reserved.
44
158 K.R. Beck et al. / Journal of Steroid Biochemistry & Molecular Biology 171 (2017) 157–1772.1.2. 17b-hydroxysteroid dehydrogenase type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
2.1.3. 17b-hydroxysteroid dehydrogenase type 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
2.1.4. 17b-hydroxysteroid dehydrogenase type 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
2.2. Enzyme characterization and substrate identiﬁcation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
2.2.1. 17b-hydroxysteroid dehydrogenase type 10 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
2.2.2. 17b-hydroxysteroid dehydrogenase type 14 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
2.2.3. Application of structural modeling for substrate identiﬁcation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
2.3. Virtual screening applications in toxicology focusing on SDRs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 169
2.4. Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
2.4.1. Computational applications . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
2.4.2. Biological validation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
3. Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
Conﬂicts of interest . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1721. Introduction
1.1. The short-chain dehydrogenase/reductase (SDR) superfamily
The SDR enzyme family consists of over 47,000 members found
in archaea, bacteria, and eukaryota, with more than 80 members
identiﬁed in the human genome [1]. They share a common core
structure, the so-called Rossmann-fold, consisting of up to seven
stranded parallel b–sheets ﬂanked by three a–helices on each side.
This core structure is crucial for NAD(P)(H) binding and includes a
Tyr-(Xaa)3-Lys motif essential for the catalytic center. The
conserved Tyr residue acts as a catalytic amino acid promoting
the proton transfer by the support of a hydrogen bond between Lys
and nicotinamide ribose, which lowers the pKa of the Tyr [2]. The
catalytic center is frequently occurring with a conserved Ser
residue, stabilizing the bound substrate. Despite this substantial
structural similarity, SDRs generally share low sequence identity of
20–30%. In addition to the classic SDRs, consisting of one globular
structure, there are extended forms with additional domains fused
to the N- or C-terminus [3].
SDRs are catalyzing carbonyl-alcohol oxidoreduction, isomeri-
zation, decarboxylation, epimerization, C¼N reduction, enoyl-CoA
reduction, dehydration, and dehalogenation reactions. They are
involved in the metabolism of a wide range of molecules, including
steroid hormones, oxysterols, bile acids, prostaglandins, retinoids,
fatty acids, amino acids, sugars, and various xenobiotics [3].
Probably the most extensively studied SDRs are hydroxysteroid
dehydrogenases (HSDs) with key roles in adrenal and gonadal
steroidogenesis, including 3b-HSDs and 17b-HSDs, as well as
enzymes with 3a-HSD, 11b-HSD and 17b-HSD activities catalyz-
ing the metabolism of steroids in peripheral tissues and thereby
controlling local steroid hormone action [4]. Generally, 3a-HSDs
are assigned to the family of aldo-keto reductases (AKR); however,
several SDRs are reported to have 3a-HSD activity such as 17b-
HSD6, 17b-HSD10 or members of the retinol dehydrogenase
(RODH) subfamily [5,6].
Some of these HSDs are investigated as potential therapeutic
targets for estrogen- and androgen-dependent diseases such as
osteoporosis, endometriosis, and breast and prostate cancer or
corticosteroid-related diseases such as dyslipidemia, visceral
obesity and diabetes, wound healing, atherosclerosis, osteoporosis,
glaucoma, neurodegenerative disease, and cognitive impairment
[7–13].
The similarity of the core structure of various SDRs needs to be
taken into account when developing speciﬁc inhibitors to avoid the
inhibition of other members causing off-target effects. In this
respect, a major challenge remains the identiﬁcation of the
substrates and functions of “orphan” enzymes with yet unknown
substrates and physiological functions. Approximately 50% of theSDRs have been poorly or not investigated so far, although some of
these orphan enzymes have been associated with diseases [14–17].
Molecular modeling and virtual screening (VS) approaches can not
only facilitate the identiﬁcation of selective inhibitors by excluding
molecules that bind to off-targets, but they may also support the
identiﬁcation of substrates for orphan enzymes [18]. Another
application of the modeling approach includes the identiﬁcation of
toxic industrial and environmentally relevant chemicals [19–21].
Due to their involvement in steroid biosynthesis and metabolism,
SDRs represent potential sites for molecular initiating events of
endocrine disrupting chemicals (EDCs) [22–27].
1.2. Computer-aided drug design
Besides experimental methods, a plethora of computational
techniques is available to support the identiﬁcation of novel
bioactive molecules in the context of both drug discovery and
toxicology. The majority of these techniques rely on the concept of
similarity introduced by Johnson and Maggiora, based on the
assumption that similar compounds exert similar bioactivities
[28]. Computational models can be generated based on the
properties of known active compounds (preferably in comparison
to known inactive molecules) to search for similar compounds in
large chemical databases in the course of a VS. For example, 2D
similarity-based methods (Fig. 1A) can employ molecular ﬁnger-
prints to represent the 2D structure of molecules. The degree of
similarity among the molecules is then determined with similarity
coefﬁcients, most prominently among them the Tanimoto coefﬁ-
cient (Tc) [29,30].
Structure-based pharmacophore models (Fig. 1B) use a higher
degree of abstraction, as they solely represent the interaction
patterns between a ligand and its macromolecular target.
According to IUPAC, pharmacophore models are deﬁned as “the
ensemble of steric and electronic features that is necessary to
ensure the optimal supra-molecular interactions with a speciﬁc
biological target and to trigger (or block) its biological response”
[31]. These features do not describe speciﬁc functional groups, but
the type of interactions these chemical functionalities can be
involved in. For example, many pharmacophore modeling tools
include hydrogen bond donor (HBD) and acceptor (HBA),
hydrophobic (H), positively (PI) or negatively (NI) ionizable, and
aromatic (Aro) features in their default settings [32–35]. In
addition, some types of steric constraints, either shape or exclusion
volumes (XVols) (or both) are commonly available. XVols for
example can be added to mimic the binding site and to prevent the
mapping of compounds that would clash with the binding site and
therefore be inactive. The shape of a known active molecule can
also be added to a model to restrict the virtual hits to those with
similar volumes and geometries compared to the initial training45
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well a compound geometrically ﬁts a pharmacophore model.
Widely used pharmacophore modeling programs include Phase
(Schrödinger Inc.), DS Catalyst (Biovia), LigandScout (Inte:Ligand
GmbH), Molecular Operating Environment (MOE), and others (as
reviewed in [36]).
Shape-based methods (Fig. 1C) in principle rely on the shape
similarity between a query compound and the molecules under
investigation to prioritize compounds for biological testing.
Additionally, many shape-based modeling tools provide the option
to include chemical information such as pharmacophore features
[37,38] (also referred to as color features in ROCS [39,40]), atom
types as in Phase Shape [41], or electrostatic potentials in ShaEP
[42] to improve the performance of the shape model. Similar to
pharmacophore modeling, scoring functions are employed to
determine the degree of shape overlay and, if applicable, the extent
to which a compound fulﬁlls additional requirements of the model.
Other than the methods mentioned so far, docking does not rely
on the concept of similarity, but rather aims to calculate the free
binding energy between a macromolecular target and potential
ligands. For this purpose, the molecules under investigation are
placed within the empty binding pocket of the target, which needs
to be deﬁned by the user prior to docking. Each created docking
pose is then evaluated with a score estimating the binding energy
[43], thus predicting the likelihood of binding (Fig. 1D). For a
comprehensive description of docking and scoring as well as
frequently used programs, a recent work by Sotriffer is recom-
mended [44]. In some docking programs, also the ﬂexibility of
amino acids in the binding site is considered, e.g. in GOLD [45].
The in silico methods described in this section have also been
employed for the investigation of SDRs. Successful applicationFig. 1. Principles of commonly applied virtual screening tools exempliﬁed on the crysta
structure of the inhibitor (the estradiol analogue E2B, 3-[30 ,170b-dihydroxyestra-10,30 ,
compounds can be retrieved from a compound database in the course of a 2D similarity-b
interactions patterns in the crystal complex. Exclusion volumes (XVols, gray spheres)
constraints of the pocket. Red arrows: HBA, green arrows: HBD, yellow spheres: H feature
may ﬁt. (D) Diverse compounds from a chemical database docked into the binding pocket
reader is referred to the web version of this article.)examples for selected SDRs are described in detail in the following
sections.
2. Examples from the SDR family
2.1. Drug development
2.1.1. 11b-hydroxysteroid dehydrogenase type 1
The inactive glucocorticoid cortisone is converted to the
biologically active cortisol by 11b-hydroxysteroid dehydrogenase
type 1 (11b-HSD1) using NADPH as cofactor (Fig. 2). 11b-HSD1 is
expressed in tissues such as liver, adipose tissue, adrenals, skeletal
muscle, skin, pancreas, hippocampus, as well as in macrophages
[46,47]. The reverse reaction is catalyzed by 11b-HSD2, thereby
ensuring mineralocorticoid receptor (MR) activation by aldoste-
rone in kidney and colon as well as fetal protection in the placenta
from excess amounts of maternal glucocorticoids [48]. Transgenic
mice selectively overexpressing 11b-HSD1 in the adipose tissue
develop metabolic syndrome including insulin-resistant diabetes,
hyperlipidemia, hypertension, and visceral obesity [49,50], where-
as hepatic overexpression of 11b-HSD1 caused metabolic syn-
drome without obesity [51]. Enhanced 11b-HSD1 expression can
also be detected in adipose tissue of obese patients and in skeletal
muscles of diabetic patients [52–56]. In contrast, 11b-HSD1 knock-
out mice were found to be resistant against the development of
diet- or stress-induced diabetes [57], suggesting pharmacological
inhibition of this enzyme as a therapeutic option for metabolic
diseases. Furthermore, inhibition of 11b-HSD1 showed favorable
therapeutic effects in wound healing [58,59], skin aging [60],
osteoporosis [8,61], atherosclerosis [62–65], glaucoma [66–68],
and cognitive functions [69–73]. Although various 11b-HSD1l structure of 17b-HSD1 in complex with a steroidal inhibitor. (A) Based on the 2D
50(100)-trien-160b-methyl]benzamide, PDB code 3HB5 [211]), structurally similar
ased search. (B) A pharmacophore model can be created based on the ligand-target
 can be added on residues lining the binding site, thereby mimicking the steric
s. (C) The shape of the inhibitor deﬁnes the 3D space in which other active chemicals
 of 17b-HSD1. (For interpretation of the references to colour in this ﬁgure legend, the
46
Fig. 2. Conversion of cortisone to cortisol by 11b-HSD1 using NADPH, supplied by hexose-6-phosphate dehydrogenase (H6PDH), and oxidation of cortisol to cortisone
catalyzed by 11b-HSD2 using NAD+ as cofactor.
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trials, no 11b-HSD1 inhibitor has reached the market so far [74].
Structural variety is prevailing between the different 11b-HSD1
inhibitors; nevertheless, the crystalized protein structures are
comparable [75]. However, for selection of a protein structure for
in silico evaluations, the detected dissimilarities upon ligand
binding should be considered. The protein data bank (PDB)
currently contains 29 human, 5 mouse, and 3 guinea-pig 11b-
HSD1 crystal structures. To date, only X-ray crystal structures in
complex with inhibitors but not with a substrate are accessible for
the human isoenzyme. In contrast, no crystal structure of 11b-
HSD2 is available to date.
Schuster et al. ﬁrst reported the use of pharmacophore
modeling to identify structurally new classes of 11b-HSD1
inhibitors [76]. To perform VS of different databases, they designed
two ligand-based multi-feature pharmacophore models as the
11b-HSD1 protein structure was not experimentally resolved at
the beginning of their study. They classiﬁed their pharmacophore
models according to the 11b-HSD activity of the training
compounds employed for the model generation as 11b-HSD1-
selective and 11b-HSD non-selective. The virtual hits found by the
pharmacophore models contained steroid-like compounds, the
known unselective 11b-HSD inhibitor glycyrrhetinic acid (GA),
related triterpenoids, and novel structural classes. The in vitro 11b-
HSD1 and 11b-HSD2 inhibition proﬁle of the active VS hits showed
similar selectivities as the training set compounds used for the
11b-HSD1-selective and the 11b-HSD-unselective pharmacophore
model construction.
Suitable enzyme activity assays are fundamental for selectivity
testing of potential inhibitors. Regarding 11b-HSD1 inhibitors,
11b-HSD2 is usually chosen as counter screen because cross-
inhibition of 11b-HSD2 would cause cortisol-induced MR activa-
tion in the kidney, resulting in hypertension. Taking into account
that the different SDR family members share considerable
structural similarity, but rather low primary sequence similarity,
other enzymes such as 3b-HSDs and 17b-HSDs should be included
in the selectivity assessment of 11b-HSD1 inhibitors.
By determining the biological activities in HEK-293 cell lysates
or intact cells expressing human recombinant 11b-HSD1, 11b-
HSD2, 17b-HSD1 or 17b-HSD2, Schuster et al. tested the potency
and selectivity of their VS hits [76]. 11b-HSD1 activity was
inhibited by more than 70% at 10 mM by 7 out of 30 tested
compounds, but only 3 of them displayed reasonable selectivity
over the other tested SDRs. This is not surprising as some of the
unselective hits belonged to the class of triterpenoids resembling
GA. The authors observed similar kinetic parameters for the three
11b-HSD1-selective chemicals in differentiated mouse adipocytes
and myotubes, metabolically relevant tissues endogenously
expressing 11b-HSD1. Other studies showed signiﬁcant species-
speciﬁc variability in the potency of various 11b-HSD1 inhibitors
[77–79], indicating signiﬁcant differences in the 3D organization of
the hydrophobic substrate-binding pocket of human and mouse
11b-HSD1. Thus, species-speciﬁc variability must be consideredand the use of suitable human cell lines endogenously expressing
11b-HSD1 is indicated.
Glucocorticoids are recognized by several different proteins
during synthesis (CYP11B1), distribution (cortisol-binding globu-
lin, transport proteins such as P-glycoprotein), peripheral metab-
olism (11b-HSDs), receptor action (MR, glucocorticoid receptor
(GR)), and degradation (5b-reductase, CYP3A4). These proteins
recognize some common structural features and inhibitors of 11b-
HSD1 might therefore bind to other glucocorticoid recognizing
proteins as well. To address this, Schuster et al. tested their most
active hits in GR- and MR-dependent reporter gene assays.
Reduced tissue-speciﬁc glucocorticoid reactivation and therefore
blockade of the GR-mediated gene expression are responsible for
the therapeutic effects of an 11b-HSD1 inhibitor. The ability of an
11b-HSD1 inhibitor to also act as a GR or MR antagonist would
rather enhance its therapeutic beneﬁt by reducing GR-dependent
stimulation of hepatic gluconeogenesis and decreasing cortisol-
mediated MR activation in macrophages. Their most active
compound showed only weak GR and MR antagonistic effects,
with a 6–10-fold preference for 11b-HSD1 inhibition and can
therefore be used as starting point for further investigations.
The selective 11b-HSD1 pharmacophore model generated by
Schuster et al. [76] was further used to assess its potential to
identify new lead structures for 11b-HSD1 inhibitor development
[80]. Enzymatic testing of the virtual hits led to the discovery of an
11b-HSD1 inhibitor with an IC50 of 4.8 mM. Lead optimization
studies revealed arylsulfonylpiperazine scaffolds as a new class of
selective 11b-HSD1 inhibitors.
This pharmacophore model was additionally employed to
search for selective 11b-HSD1 inhibitors derived from constituents
of medicinal plants [81]. The virtual hit list contained to a large
extent scaffolds from the chemical class of triterpenoids such as
corosolic acid. This is a known constituent of Eriobotrya japonica,
which is used in the traditional Chinese medicine as antidiabetic
treatment. An earlier study, investigating the potential of extracts
from traditionally used antidiabetic medical plants to inhibit 11b-
HSD1 activity, found leave extracts of E. japonica preferentially
inhibiting 11b-HSD1 over 11b-HSD2 [82]. Thus, the VS hit
corosolic acid was tested for inhibition of the human 11b-HSD
enzymes in a lysate-based assay and revealed selective inhibition
of 11b-HSD1 with an IC50 of 810 nM. In order to discover additional
secondary metabolites inhibiting 11b-HSD1, bioassay-guided
phytochemical analyses were implemented. These investigations
led to the identiﬁcation of several molecules from the triterpenoid
ursane type with IC50 between 1.9 and 17.4 mM. However, an
enhanced 11b-HSD1 inhibitory activity could be detected by
mixtures of these moderately active compounds. Additive effects
of constituent mixtures are a common ﬁnding in phytotherapy and
often explain their therapeutic effect. Binding mode prediction
performed by docking studies indicated a ﬂipped interaction
pattern of the triterpenoids with interactions to Thr124 and Tyr177
instead of the catalytic residues. The identiﬁcation of 11b-HSD1
inhibitors in traditionally used antidiabetic medical plants47
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pharmacophore modeling.
Further studies using the 11b-HSD pharmacophore models
from Schuster et al. [76] for model reﬁnement [83] and
subsequently as screening tool for 11b-HSD1 inhibitor identiﬁca-
tion among constituents of the traditionally used Greek medical
plant Pistacia lenticus [84], are described in the Supplementary
information.
For the identiﬁcation of new 11b-HSD1 inhibitors Miguet et al.
[85] developed a homology model to predict the 3D structure of
11b-HSD1. Structure-based VS of a reference database composed
of molecules with known activities towards 11b-HSD1 was used to
validate the model showing its ability to discriminate between
11b-HSD1 inhibitors. The reference database included 19 11b-
HSD1 inhibitors, 3 weak inhibitors, 3 non-inhibitors, and 2
substrates. To distinguish between virtual hits based on activity
data of a reference database, it would be advantageous if the
different activity categories would be more equal. Scoring
calculations were further used as numerical cut-offs, ﬁltering
the virtual hit list after VS of a natural molecules database. As in the
meantime, the ﬁrst experimentally derived 11b-HSD1 X-ray
structure became available, the results derived from the homology
model were conﬁrmed by molecular modeling based on the
crystallographic structure. Several hits of the VS belonged to the
ﬂavonoids, with 2 hits already known as 11b-HSD1 inhibitors. The
remaining candidates were not enzymatically tested, and, unfor-
tunately, no follow up evaluation of these hits was reported.
Yang et al. combined ligand-based pharmacophore modeling
and molecular docking for the identiﬁcation of synthetic 11b-
HSD1 inhibitors [86]. In a virtual docking approach, the SPECS
database was screened and the 3000 compounds with the highest
docking score were selected for a second, more computationally
expensive docking calculation. Furthermore, a ligand-based
pharmacophore model on the basis of three selective 11b-HSD1
inhibitors was generated and used as a query to additionally ﬁlter
the 3000 selected compounds. High ﬁt and docking scores, as well
as drug likeness were selection criterions for compounds to be
further biologically tested for their activity on human and mouse
11b-HSDs. Therefore, a scintillation proximity assay (SPA) was
performed using microsomes prepared from HEK-293 cells stably
expressing human and mouse 11b-HSD1 or 11b-HSD2, respec-
tively. Signiﬁcant differences in the inhibitory potential of the
compounds were observed when comparing their activities
against human and mouse 11b-HSD1. Whereas 11 out of 121
tested compounds revealed IC50 values of 0.26–14.6 mM against
the human enzyme, 6 substances showed IC50 values between
0.48–12.49 mM against the mouse enzyme. Among these inhib-
itors, only two displayed overlapping activity for human and
mouse 11b-HSD1 with IC50 values of 0.69 mM and 3.57 mM, and
0.48 mM and 2.09 mM, respectively. In regard to subsequent animal
studies, selectivity over 11b-HSD2 was tested only for the mouse
isoenzyme and just for compounds inhibiting mouse 11b-HSD1.
Selectivity was ensured; however, appropriate selectivity deter-
mination requires at least the inclusion of human 11b-HSD2, and
ideally also other SDRs. The ideal case for preclinical assessments
in drug development would include cross-species activity.
Importantly, signiﬁcant species-speciﬁc differences regarding
the potency of diverse 11b-HSD1 inhibitors have previously been
reported, implying critical variability in the 3D conformation of the
active site of human and mouse 11b-HSD1 [77–79].
In a consecutive study, Yang et al. successfully used 11b-HSD1
structure-based pharmacophore models as initial screening tools,
followed by a docking approach for hit selection [87]. Only
compounds interacting with the catalytic residues Tyr183 and
Ser170 were chosen after the docking evaluation for further
biological assessment. In contrast to their earlier study where theyfound 11 out of 121 hits as inhibitors for the human 11b-HSD1 [86],
9 out of 56 tested compounds displayed selective and dose-
dependent 11b-HSD1 inhibition with IC50 values of 0.85–7.98 mM.
The mouse enzyme was inhibited by 6 compounds with IC50 values
between 0.44 mM and 8.48 mM, of which 4 inhibited human and
mouse 11b-HSD1 with comparable IC50 values.
Shape-based screening combined with fast rigid docking was
applied by Xia et al. to ﬁnd 11b-HSD1 inhibitors [88]. The 1000 best
ranked compounds of each screening were combined for further
ligand-ﬂexible docking calculations. By manual inspection of the
top 200 molecules in the ﬁnal hit list, 70 structurally diverse
molecules were chosen for biological testing by SPA, of which 14
compounds inhibited 11b-HSD1 by more than 50% at 1 mM, 8 of
them had IC50 values 100 nM, and 3 inhibitors already being
reported [89–91]. In addition, by analyzing the binding mode
conformations, a new hydrophobic sub-pocket was discovered.
However, the interacting residues of this sub-pocket were not
described, although this would further support inhibitor develop-
ment. During the validation of this ﬁnding with a molecule ﬁtting
into this pocket, a novel scaffold was identiﬁed that inhibited 11b-
HSD1 with an IC50 of 45 nM. Selectivity over 11b-HSD2 was only
veriﬁed for the two compounds with the most favorable ADME
prediction proﬁles. However, since pharmacokinetics can be
improved after lead identiﬁcation, it would be of interest to
obtain selectivity information for all 11b-HSD1 inhibitors.
Moreover, to improve further study designs, it would be important
to know the difference between the hit rates of shape-based
screening and rigid docking. In an independent, subsequently
performed study, Xia et al. designed a new class of derivatives of 1-
arylsulfonyl piperidine-3-carboxamides using medicinal chemis-
try tools [92]. For lead structure selection and following animal
studies, the compounds were tested against mouse and human
11b-HSD1 and 11b-HSD2. They found a large lipophilic group at
the amino moiety as favorable for cross-species potency. Unfortu-
nately, they did not mention if this bulky lipophilic group also
targets their previously identiﬁed hydrophobic sub-pocket, which
could be interesting for further inhibitor development studies.
A similar approach was performed by Lagos et al. who used
shape-based query hypotheses as a ﬁlter during a structure-based
VS process [93]. Steroidal compounds were excluded from the
query in order to avoid similarity of the virtual hits with this
scaffold type. Top scored compounds were visually analyzed for
their binding features and selected for testing in cell-based assays.
For this purpose, they used the liposarcoma-derived adipose cell
line LS14, differentiated into adipocytes and endogenously
expressing 11b-HSD1 [94]. Of 39 compounds tested, two
selectively inhibited 11b-HSD1 over 11b-HSD2 with IC50 values
around 5 mM. Selectivity over 11b-HSD2 was also tested in
differentiated LS14 cells, although its expression was marginal.
However, the use of an intact cell-based testing system as an initial
biological assessment tool has the disadvantage that the com-
pounds do not have direct access to their target and the ranking of
the obtained biological activities cannot be used to draw
conclusions on the performance of the VS approach.
Shave et al. employed another method containing shape-based
calculations but without the need for any detailed structural
information of the target [95]. They used Ultra-fast Recognition
with Atom Types (UFSRAT), an algorithm that considers the shape
and the electrostatics of atoms to score and retrieve candidate
molecules capable to make similar interactions to those of the
supplied query. The non-selective 11b-HSD1 inhibitor carbenox-
olone was used to generate the query. VS of a database against the
query resulted in a hit list of the most similar compounds.
Biological testing was implemented against 11b-HSD1 reductase
and dehydrogenase activity. Out of 26 tested compounds, 4
inhibited the reductase activity in a SPA cell-based assay with IC5048
Fig. 3. Carbenoxolone (top) and hit molecule with a preserved key pattern of atoms
involved in hydrogen bonding [95].
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of recombinant human 11b-HSD1 protein with Kiapp of 26–
248 mM. Interestingly, the top virtual hits displayed totally
different scaffolds compared to the query molecule but showed
similarity to already known 11b-HSD1 inhibitors (Fig. 3). Thus,
UFSRAT has demonstrated its ability for scaffold hopping during
the VS screening process. However, the query molecule carbenox-
olone is an unselective 11b-HSD inhibitor, exhibiting activity
against 11b-HSD1 and 11b-HSD2. For this reason, biological
testing of the selected virtual hits against 11b-HSD2 would be
required for further development of these compounds. Moreover,
choosing a selective 11b-HSD1 inhibitor as a query molecule for
the UFSRAT algorithm may even improve the success of this
approach.
A number of adamantine-containing selective 11b-HSD1
inhibitors have been reported [96]. Tice et al. used them to
generate models of the 11b-HSD1 binding site with the help of a
proprietary structure-based drug design program of Vitae Phar-
maceuticals called Contour [97]. The most satisfactory poses were
selected, and based on them a medicinal chemistry program was
initiated to improve potency, selectivity, and physical properties,
supported by additional modeling. This led to the identiﬁcation of a
class of spirocyclic ureas selectively inhibiting 11b-HSD1 with IC50
values in the lower nanomolar range.
Using the same drug design platform Contour, Xu et al.
developed a novel class of 11b-HSD1 inhibitors by incorporating
a 1,3-oxazinan-2-one ring system [98]. Prior to the medicinal
chemistry program, the available 11b-HSD1 X-ray structures were
examined and a template compound bearing a 1,3-oxazinan-2-one
ring docked into the 2BEL structure of 11b-HSD1. Subsequently,
more than 5000 molecules were designed in silico by addingFig. 4. Selected 17b-HSDs involved in estrofragments directly to the template compound. Structure-based
drug design and lead compound optimization studies revealed a
highly potent 11b-HSD1 inhibitor with IC50 values of 0.8 nM using
recombinant human 11b-HSD1 in a microsomal preparation of
CHO cells and 2.5 nM in differentiated human adipocytes. Testing
inhibitory activity against 11b-HSD2, 17b-HSD1, 3b-HSD2, and
three CYP isoenzymes showed >1000-fold selectivity for 11b-
HSD1. The same results were observed when examining its
potential to bind to GR, MR, FXR or hERG. In regard to subsequently
performed animal studies, pharmacokinetic parameters were
measured in several species. In addition, distribution into mouse
adipose tissue could be observed with proportional plasma
concentrations levels and three times higher concentrations in
the liver. However, due to the poor potency against mouse 11b-
HSD1, but comparable activity towards human and cynomolgus
monkey 11b-HSD1, the latter species was selected as in vivo model
for 11b-HSD1 inhibition. Oral administration, after suppression of
endogenous plasma glucocorticoid levels with dexamethasone and
challenge with cortisone 21-acetate after 5 h of compound
administration, revealed reduced cortisol production by 85%
compared to the vehicle control. However, the authors described
no further details how the animal study was conducted as for
instance the number of animals used. As they aimed to speciﬁcally
target the adipose tissue, this measurement only provides data
about the overall 11b-HSD1 activity. Therefore, they determined in
a consecutive preclinical characterization study the inhibitory
activity of their lead compound ex vivo in cynomolgus monkey and
human adipose tissue [99]. Remarkably, the enzyme inhibition was
minor in cynomolgus monkey tissue and 30-fold less pronounced
in human adipose tissue compared to cultured differentiated
preadipocytes. They proposed the high lipophilic nature of the
compound and therefore its uptake and sequestration into lipid
droplets as a possible reason for this observation. Based on these
investigations, they established a modiﬁed assay strategy for lead
compound identiﬁcation, newly including analysis in human and
non-human primate adipose tissue. This approach led to the
identiﬁcation of a new 11b-HSD1 inhibitor candidate, of which
toxicological assessment was introduced in regard to Phase I
clinical studies. An adapted, more general version of this testing
cascade is shown in the biological limitation section.
Several different computational methods have been applied to
discover new selective 11b-HSD1 inhibitors and successfully
identiﬁed structurally diverse virtual hits in biological assays as
potential lead compounds for further drug development. However,
computer-aided drug design is also advantageous for lead
optimization. In order to improve selectivity, potency and
pharmacokinetic parameters of initially discovered 11b-HSD1
inhibitors, several groups implemented scaffold hopping and
structure-activity relationship (SAR) studies on the basis of
docking studies [100–105]. Following chemical synthesis the samegen and androgen steroid metabolism.
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108].
2.1.2. 17b-hydroxysteroid dehydrogenase type 1
To date,14 different human 17b-hydroxysteroid dehydrogenase
(17b-HSD) enzymes, belonging to the SDR family with the
exception of the aldo-keto reductase AKR1C3 (17b-HSD5), have
been described [109]. Several of the 17b-HSDs are essentially
involved in the local metabolism of estrogens and androgens,
thereby controlling ER and AR signaling in a tissue- and cell-
dependent manner (Fig. 4).
17b-HSD1 reduces in an NADPH-dependent reaction the weak
estrogen estrone to the potent estradiol. It also catalyzes the
conversion of dehydroepiandrosterone (DHEA) to 5-androstene-
3b,17b-diol [110]. The human placenta, ovaries, and mammary
gland are the predominant expression sites of 17b-HSD1 and
therefore of considerable relevance for the gonadal and peripheral
synthesis of estradiol [111]. Studies demonstrating a correlation of
17b-HSD1 mRNA expression levels and poor breast cancer
prognosis [112–114] suggest the local inhibition of estradiol
biosynthesis by targeting 17b-HSD1 as a promising therapeutic
strategy against breast cancer, especially in postmenopausal
women, where estradiol originates mainly from extragonadal
sites. Importantly, in vivo studies found a reduction in tumor size in
mice stimulated with exogenous estrone after co-treatment with
speciﬁc 17b-HSD1 inhibitors [115,116]. In addition, high 17b-HSD1
expression levels were shown to be associated with endometriosis
[117,118], endometrial cancer [119], and uterine leiomyoma [120],
offering additional therapeutic opportunities.
Although the number of reported 17b-HSD1 inhibitors is
increasing, to date no compound made it into clinical trials.
Currently, over 20 crystal structures of the 17b-HSD1 protein have
been published. The binding pocket consists of an elongated
hydrophobic channel, formed by Leu149, Val225, Phe226, and
Phe259, and hydrophilic residues at each end allowing interactions
with the catalytic essential residues Ser142 and Tyr155 on one side
and His221 and Glu282 on the other side. A ﬂexible loop (amino
acids 188–201) in the crystal structure, which compromises the
exact deﬁnition of the substrate binding pocket and therefore
inﬂuences the predictivity of VS studies, is not well resolved [121]
(Fig. 5).
Hoffrén et al. were the ﬁrst to describe structure-based
pharmacophore models for the discovery of 17b-HSD1 inhibitors
[122]. They validated their pharmacophore models with molecules
bearing the structural and chemical features of steroids andFig. 5. Substrate binding pocket of 17b-HSD1 with the co-crystallized ligand
equilin (PDB 1EQU), catalytic key residues (Ser142 and Tyr155), a ﬂexible loop
(residues 188–201) and NADP+.ﬂavonoids. The most potent training compound applied in the
model validation was coumestrol. However, coumestrol also
displays inhibitory activity against 17b-HSD5 and is not selective
for 17b-HSD1, which needs to be taken into account in model and
hit validation [123]. The selectivity and sensitivity of a pharma-
cophore model strongly depend on the compounds selected for its
generation and validation. Ideally, if available, selective inhibitors
are chosen for model development. Thus, because phytoestrogens
and steroidal scaffolds frequently display cross-reactivity against
other enzymes and receptors involved in steroid action, non-
steroidal structures are preferred, not only for the modeling and
validation, but also as lead structures to increase selectivity. Since
the VS hits from Hoffrén et al. were not validated by biological
testing, no further information is available on the selectivity of the
pharmacophore model as well as on the identiﬁed hits.
Even though selective inhibitors are usually chosen for
therapeutic applications, polyvalent inhibitors with synergistic
beneﬁcial effects may be advantageous in some circumstances.
Chanplakorn et al. reported a signiﬁcant increase of estrogen
sulfatase and 17b-HSD1 expression after neoadjuvant therapy
with aromatase inhibitors (AIs) in postmenopausal women
suffering from estrogen receptor-a (ERa)-positive breast cancer
[124]. They proposed that the observed expression changes are a
result of compensatory responses to estrogen depletion in breast
carcinoma tissue. To prevent the compensatory estradiol produc-
tion triggered by chronic treatment with AIs, Dual Aromatase-
Sulfatase Inhibitors (DASI) have been developed as an alternative
to administration of a combination of drugs for each target [125–
127]. Aromatase catalyzes the conversion of 4-androstene-3,7-
dione to estrone, which is then conjugated by estrogen sulfo-
transferase to estrone sulfate that can serve as a storage upon
hydrolysis in breast cancer tissue by steroid sulfatase (STS), and
further reduction by 17b-HSD1 leads to estradiol production. Thus,
hormone-dependent breast cancer might be more effectively
treated using a polyvalent drug. Designing these DASIs, Woo et al.
integrated the inhibitory STS pharmacophore into the scaffold
search for AIs, allowing minimal structural changes to preserve
aromatase inhibition [128]. Thus, the use of speciﬁc inhibitors for
each relevant target as well as inhibitors with activities against
synergistic targets represents a promising approach to prevent the
development of resistance.
Focusing exclusively on 17b-HSD1, inhibitors can target several
sites including reversible and irreversible inhibition of the binding
of the substrate, of the cofactor NADPH at the Rossmann-fold, or
both by so-called hybrid compounds (Fig. 6) consisting of a
steroidal core and extended side chains to occupy the cofactor
binding site [129,130].Fig. 6. The hybrid inhibitor EM1745 (gray) occupies both the steroid and the co-
factor (green) binding site in 17b-HSD1 (PDB entry 1I5R). The co-factor
conformation was taken from the PDB entry 3HB5. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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Fig. 7. Equilin and E respectively Z form of 2-benzylidenebenzofuran-3(2H)-one
structure.
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with nonsteroidal inhibitors, Schuster et al. constructed two
structure-based pharmacophore models based on crystal struc-
tures containing steroidal inhibitors in order to ﬁnd new
nonsteroidal 17b-HSD1 inhibitor scaffolds [131]. Whereas one
model was developed based on the steroidal scaffold equilin and
expected to be an appropriate general screening tool, yielding a
higher number of false positive and unselective hits, the second
model was constructed based on a hybrid inhibitor, suggested to be
more restrictive because of the underlying unique scaffold. In vitro
testing of 14 selected virtual hits led to the identiﬁcation of two
nonsteroidal, selective 17b-HSD1 inhibitors with moderate
activities (IC50 5.7 mM and 19 mM). Selectivity was tested against
17b-HSD2, 17b-HSD3, the AKR 17b-HSD5, 11b-HSD1, and 11b-
HSD2, additionally revealing a nonsteroidal and a steroidal 11b-
HSD1 inhibitor (IC50 6.2 mM and 3.8 mM, respectively) and a
nonsteroidal 17b-HSD3 inhibitor (IC50 19 mM). These results
emphasize the relevance of including several structurally related
enzymes for selectivity evaluation. To increase the exclusion rate of
compounds potentially causing off-target effects, Schuster et al.
tested an alternative approach using pharmacophore models of
structurally related enzymes [131]. Using these models as
additional ﬁlters to exclude compounds with a low degree of
selectivity enriched the virtual hit list with more selective
compounds and therefore reduced the efforts for laborious
biological testing. They applied their previously constructed
selective 11b-HSD1 pharmacophore model for a VS of the scaffolds
identiﬁed as 11b-HSD1 inhibitors [76]. The nonsteroidal 11b-
HSD1 inhibitor mentioned above was identiﬁed as hit, and it was
also found when removing the shape restriction. Therefore,
applying nonrestrictive pharmacophore models of related
enzymes as additional ﬁlter tools can assist the selection of virtual
hits for biological testing by eliminating promiscuous inhibitors.
Regarding the structural similarity of different proteins, Brown
et al. demonstrated inhibition of human lactate dehydrogenase
(LDH) and of 17b-HSD1 by binding of gossypol derivatives to the
Rossmann fold [132]. Thus, on one hand structural conservation
provides a basis for lead compounds targeting several related
proteins but on the other hand it raises concerns about their
selectivity. Brown et al. did not test their gossypol derivatives
against other SDRs. Since gossypol was also found to inhibit 3b-
HSD1, 17b-HSD3 [133], and 11b-HSD2 [134], testing of the
gossypol derivatives against other structurally related enzymes
will be crucial.
To create a pharmacophore model and deﬁne the ligand-protein
interactions for both, the ligand and the active site of the protein,
Sparado et al. [135] superimposed ﬁve 17b-HSD1 X-ray structures.
VS of a small in-house compound library and experimental
validation of the hits in a cell-free assay led to the identiﬁcation of a
moderately active 17b-HSD1 inhibitor. Further SAR analysis,
including scaffold hopping and rigidiﬁcation, resulted in two
benzothiazole-scaffold bearing 17b-HSD1 inhibitors with IC50
values of 44 and 243 nM, respectively. The subsequent selectivity
testing not only consisted of an assay for the related enzyme 17b-
HSD2, but also for the ERa and ERb. Depending on whether a
compound also binds to ERa and/or ERb and acts as agonist or
antagonist, different effects on ER-mediated signaling can be
expected. Both compounds showed selectivity over 17b-HSD2 but
differences regarding their binding afﬁnities against both ERs. The
more potent compound displayed considerable afﬁnity to bind to
ERa and ERb, whereas the less active compound was marginally
active against both ERs. Further biological evaluation in a human
cell system endogenously expressing 17b-HSD1 (T47-D cells)
revealed potent inhibition of estrogen formation with an IC50 of
245 nM for the less active compound. Moreover, docking inves-
tigations revealed a 180 ﬂipped orientation of the twocompounds, although they differ only in a carbonyl and an
amide-bridge, respectively. As described earlier, a ﬂipped binding
orientation was also observed for corosolic acid and other
triterpenes inhibiting 11b-HSD1 [81]. To improve the activity
and selectivity for in vivo use of their two 17b-HSD1 inhibitors,
Sparado et al. conducted a follow-up optimization study [136]. SAR
experiments led to the identiﬁcation of two new lead compounds,
which were highly active against 17b-HSD1 with IC50 values in a
cell-free assay of 27 nM and 13 nM and in T47-D cells of 258 nM and
37 nM, respectively. Both inhibitors were selective over 17b-HSD2
and ERa/b. Furthermore, the potency of the inhibitors was tested
against marmoset 17b-HSD1 and 17b-HSD2 as the marmoset
monkey can be used as an animal model for endometriosis. The
lead compounds almost completely inhibited 17b-HSD1 at 50 nM
when tested in marmoset placenta microsomes. However, the
compounds were less selective towards marmoset 17b-HSD2
compared to the human enzymes (50 nM of the compounds
inhibited marmoset 17b-HSD2 activity by 51% and 40%, respec-
tively).
Pharmacophore modeling using structure-based and ligand-
based concepts were also applied by Karkola et al. [137]. Four
different approaches using docking, alignment of known inhib-
itors, molecular dynamics (MD) simulation, and automated model
generation on the basis of a 17b-HSD1 crystal structure were
implemented. VS led to the discovery of several potential 17b-
HSD1 inhibitors; however, their biological activities were not
determined. Biological testing of these hits would allow validating
them as 17b-HSD1 inhibitors and could provide information on the
selectivity and sensitivity of the different pharmacophore models.
Star9cevic et al. [138] performed a virtual high-throughput
screening based on the 3D structure of 17b-HSD1 in complex with
equilin. The database was pre-ﬁltered to reduce it to compounds
with similar size and shape as estrone. Concerning the large
scaffold of hybrid inhibitors, this approach may bias the VS and its
hit list, and potentially active hits may be missed. During the visual
inspection of the virtual hit list, compounds with potential
estrogenic effects such as steroids, ﬂavonoids, or other phytoes-
trogens were eliminated. Of 18 enzymatically tested substances,
three compounds bearing the central scaffold of aurones, a 2-
benzylidenebenzofuan-3(2H)-one structure, showed potent inhi-
bition with IC50 values in the lower nanomolar range (Fig. 7).
Additionally, one hit was an already known 17b-HSD1 inhibitor,
thus validating the approach. However, a 2D similarity search with51
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inhibitors. A SAR analysis revealed the presence of a 6-OH group as
essential for potent 17b-HSD1 inhibition by 2-benzylidenebenzo-
fuan-3(2H)-ones. Docking studies suggested that these inhibitors
occupy an ideal orientation in the active site by forming triple
hydrogen bonds with the catalytic residues Ser142 and Tyr155 and
the cofactor.
A docking approach was also applied by Frotscher et al. [139],
who studied the 3D architecture of 17b-HSD1 in complex with
estradiol for important chemical features involved in the protein-
ligand interactions to design steroid mimetics with nonsteroidal
scaffolds. These inhibitors should contain two polar groups with
11 Å distance in between to imitate the A-ring and the D-ring and a
ﬂat conformation similar to the steroids. In addition, they
discovered two residues in the active site, Tyr218 and Ser222,
which are not directly involved in steroid binding but may display
promising new interaction partners for the development of new
inhibitors. Accordingly, phenyltetralone, phenylnaphthalene, phe-
nylquinoline, and phenylindole scaffolds were chosen for a
medicinal chemistry program with scaffold hopping and SAR
analysis based on biological analysis with 17b-HSD1 and 17b-
HSD2. Docking and MD simulations thereby helped to reveal the
molecular interactions of the synthesized compounds with the
protein. This led to the discovery of a (hydroxyphenyl)naphthalene
derivative as potent 17b-HSD1 inhibitor with selectivity towards
17b-HSD2, ERa, and ERb. Moreover, pharmacokinetic studies
demonstrated Caco-2 penetration, low inhibitory effects on the
most important hepatic CYP enzymes, and moderate metabolic
stability in rat liver microsomes. For optimization of inhibitory
activity, selectivity and pharmacokinetic properties, novel substi-
tuted 6-phenyl-2-naphtols were synthesized [140]. Molecular
modeling supported SAR and binding mode explanation. The new
lead compound showed improved overall properties and can be
further tested in vivo. The inhibitory activity was tested only
against human 17b-HSD1. Thus, prior to animal experiments,
possible species-speciﬁc differences should be considered.
In a follow-up project, Marchais-Oberwinkler et al. [141]
performed a SAR study to optimize the 17b-HSD1 pharmacophore
of Frotscher et al. [139] (Fig. 8). The study highlights the restricted
ﬂexibility of the active site of 17b-HSD1. Therefore, the enzyme
might not be able to adjust its geometry upon inhibitor binding.
Targeting the polar ends of the active site, the positions of the
hydroxyl groups of the (hydroxphenyl)naphthalene derivatives
were optimized in order to allow formation of hydrogen bonds. By
the introduction of a hydrophobic core, the inhibitors are stabilized
in the hydrophobic tunnel of the enzyme. Furthermore, biological
results and modeling studies indicated that the amino acids Tyr218
and Ser222, characterized by Frotscher et al. as potentialFig. 8. Revised pharmacophore for 17b-HSD1 inhibitors (adapted from Marchais-
Oberwinkler et al. [141]).interaction partners [139], are unlikely to form hydrogen bonds
with this class of inhibitors. Available space with potential p-p
interactions close to position 1 of the naphthalene ring may be
exploited by introducing an aromatic substituent.
Applying a similar strategy of a ligand- and structure-based
drug design mimicking steroids, Bey et al. identiﬁed bis(hydrox-
yphenyl) azoles as potent 17b-HSD1 inhibitors [121]. Different
azoles and hydroxyl substitutions were synthesized and evaluated
for activity and selectivity. Thereby, a 2,5-disubstituted oxazole
displayed the most potent inhibitory effects with good selectivity
and pharmacokinetic properties. Further structural optimization
resulted in enhanced IC50 values in the low nanomolar range, high
selectivity proﬁles, and good pharmacokinetic properties [142].
Interestingly, compared to the (hydroxyphenyl)naphthalene class
of 17b-HSD1 inhibitors, the active bis(hydroxyphenyl) azoles were
predicted to form hydrogen bonds with Tyr218.
The approach of identifying new 17b-HSD1 inhibitors by
structure-based drug design was applied by several groups and led
to the discovery of 17b-HSD1 inhibitors based on 2-substitutions
of estrone and D-homo-estrone [143] and on pyrimidinones [144].
This strategy is commonly used in medicinal chemistry for
optimization of known inhibitors and lead compounds in a
rational manner. Thus, VS offers an inexpensive and rapid approach
to identify novel compounds and helps to enrich compounds
within a set of similar compounds from the same scaffold [145].
2.1.3. 17b-hydroxysteroid dehydrogenase type 2
17b-HSD2 catalyzes the NAD+-dependent conversion of the
active estradiol into the weak estrogen estrone. Moreover, 17b-
HSD2 is able to convert testosterone to 4-androstene-3,17-dione
(androstenedione), 5a-dihydrotestosterone (DHT) to 5a-andros-
tanedione, 5-androstene-3b,17b-diol to DHEA, and 20a-dihydro-
progesterone to progesterone (Fig. 4) [146,147]. Several tissues
such as bone, endometrium, uterus, breast, placenta, stomach,
small intestine, and colon epithelium express 17b-HSD2 [148,149].
In the placenta, 17b-HSD2 protects the fetus from maternal
androgens and estrogens. Decreased levels of estrogens in
postmenopausal women and androgens in elderly men result in
an imbalance between bone formation and bone loss, ultimately
causing osteoporosis [150]. Among the most frequent pharmaco-
logical interventions in Europe against osteoporosis is the
administration of bisphosphonates and selective estrogen-recep-
tor modulators (SERMs) [151]. However, both treatment options
have limitations and there is a great demand for novel therapies.
Especially SERMs are associated with an increased risk for
cardiovascular complications. Since 17b-HSD2 is expressed in
osteoblasts, its inhibition may provide a new approach to treat
osteoporosis by increasing local estradiol availability. This strategy
is supported by an in vivo study in ovariectomized cynomolgus
monkeys, where oral administration of a 17b-HSD2 inhibitor led to
maintenance of bone formation and strength [152]. Nevertheless,
as increased estradiol concentrations can also be related to severe
disorders such as endometriosis or breast cancer, it may be
important to design 17b-HSD2 inhibitors that exclusively act in
bone tissue. Thus, the application route of these inhibitors might
be a major challenge to overcome.
Because of the lack of 17b-HSD2 crystal structures, Vuorinen
et al. applied ligand-based pharmacophore modeling to ﬁnd novel
inhibitors [153]. Biological testing of the VS hits in a cell-free assay
revealed 7 out of 29 tested compounds (of initially 202,906
compounds subjected to in silico screening) with IC50 values
between 0.24 mM and 33 mM. Among the active compounds,
phenylbenzene-sulfonamides and sulfonates displayed the main
class of structural scaffolds. In addition, a search for structurally
similar molecules was performed using this new class of 17b-HSD2
inhibitors. With a simple 2D similarity search, one (IC50 of 3.3 mM)52
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the pharmacophore model was reﬁned, used for VS, and 14
derivatives were biologically tested. Among them, 5 hits revealed
IC50 values between 1 and 15 mM. Although the compounds used
for pharmacophore model generation were selective against 17b-
HSD1, the selectivity of the newly identiﬁed 17b-HSD2 inhibitors
remains to be determined. The active inhibitor-derivatives were
tested for their selectivity against 17b-HSD1, 17b-HSD3, 11b-
HSD1, and 11b-HSD2. Only one of the overall 13 discovered
inhibitors showed activity against 17b-HSD1 (IC50 18 mM), being
still 18 times more active against 17b-HSD2. Unfortunately, the
most potent 17b-HSD2 inhibitor (IC50 0.24 mM) was also active
against 17b-HSD3 (IC50 8.5 mM) and 11b-HSD1 (IC50 2.1 mM). Two
compounds were equipotent against 17b-HSD2 and 11b-HSD1 and
two substances showed even higher inhibitory activity against
17b-HSD3 than 17b-HSD2. However, all tested compounds were
selective against 11b-HSD2. In addition, the speciﬁcity of the initial
pharmacophore model was improved by creating a reﬁnement
database including the original training compounds, the newly
discovered active compounds, as well as the inactive substances.
Thus, the ability of the model was enhanced to ﬁnd active hits from
a database.
Wetzel et al. [154] used the ﬁndings from their previous 17b-
HSD1 inhibitor study [155] for the development of a new class of
17b-HSD2 inhibitors. Their former project was based on a
structure- and ligand-based design strategy including docking of
two potent heterocyclic substituted biphenylol 17b-HSD1 inhib-
itors and evaluation of their interaction pattern in the active site of
the enzyme. A three-point pharmacophore model built the basis
for a medicinal chemistry inhibitor design concept. One of the most
promising 17b-HSD1 inhibitors (IC50 8 nM) showed 48-fold
selectivity against 17b-HSD2 (IC50 382 nM) in cell-free lysate
assays. Nevertheless, this compound was selected by Wetzel et al.
as starting point for 17b-HSD2 activity optimization experiments
in order to gain selectivity against 17b-HSD1. However, consider-
ably more potent 17b-HSD2 inhibitors with lower selectivity
factors toward 17b-HSD1 were obtained as well. Unfortunately,
the authors did not provide a reason for their particular selection of
the starting compound. Structural optimization led to the
discovery of bicyclic substituted hydroxyphenylmethanone deriv-
atives as a new class of 17b-HSD2 inhibitors. The most promising
compound displayed 13-fold selectivity over 17b-HSD1 with an
IC50 value of 101 nM.Fig. 9. Virtual screening hit compared to 17b-HSD32.1.4. 17b-hydroxysteroid dehydrogenase type 3
17b-HSD3 reduces androstenedione to testosterone using as
cofactor NADPH. It is almost exclusively expressed in the testis
[156]. The rare autosomal recessive disorder 46, XY disorder of sex
development (also known as male pseudohermadophroditism)
emphasizes the importance of 17b-HSD3 for testosterone produc-
tion [157,158]. 17b-HSD3 deﬁciency leads to impaired masculini-
zation of male external genitalia and the affected individuals are
born with female or ambiguous external genitalia [159]. However,
even though 17b-HSD3 is predominantly expressed in testis, it was
reported that 17b-HSD3 mRNA was upregulated in prostate cancer
[160]. Importantly, Day et al. recently reported that treatment with
speciﬁc 17b-HSD3 inhibitors signiﬁcantly decreased androgen-
dependent growth of xenografts expressing 17b-HSD3 in castrated
mice [161]. The therapeutic efﬁcacy of 17b-HSD3 inhibitors might
be limited by the coexpression of 17b-HSD5 (AKR1C3), which
catalyzes the same reaction and is expressed in prostate cancer
[162,163]. Therefore, a combined treatment targeting both
enzymes should be envisaged. Like 17b-HSD2, 17b-HSD3 is
anchored to the endoplasmic reticulum membrane by an N-
terminal transmembrane domain, and its catalytic domain faces
the cytoplasmic compartment [164,165]. For both membrane
proteins experimentally derived 3D structures are still not
available.
Thus, Vicker et al. built a homology model, validated by known
17b-HSD3 inhibitors, to support structure-based drug design
[166]. Homology models depict the active site not as accurate as
crystal structure-derived models. However, used in a docking
approach, it allows for a prediction of an inhibitor’s interactions
with the active site and helps to uncover the chemical features that
are important for its activity. The established 17b-HSD3 homology
model revealed the highly hydrophobic nature of the active site.
Potential interactions include p-p interactions of aromatic rings
with Phe205 and other hydrophobic interactions with residues
such as Val213, Ile148, Phe151, Trp153, and Leu252. The homology
model was then used for docking-based VS. Biological testing in a
cell-based assay revealed a novel lead compound with an IC50 of
770 nM for 17b-HSD3, with selectivity over 17b-HSD1 and 17b-
HSD2. Docking into the homology model and subsequent scaffold
hopping, considering potential interactions with the active site, led
to the discovery of new compounds, with the most potent inhibitor
showing an IC50 of 200 nM in intact cells of human origin (Fig. 9).
The activity of this 17b-HSD3 inhibitor was further conﬁrmed in an inhibitor STX2171 found by Vicker et al. [166].
53
Fig. 10. Binding pocket of 17b-HSD10 with residues of the catalytic triad and co-
crystallized ligand covalently bound to NAD+ (PDB 1U7T).
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castrated mice showed signiﬁcantly decreased androgen-depen-
dent growth of tumor xenografts expressing human 17b-HSD3
[161]. Moreover, signiﬁcantly lowered plasma testosterone levels
were observed in treated mice.
The hydrophobic character of the active site of 17b-HSD3
described by Vicker et al. was further supported by two ligand-
based pharmacophore models generated by Schuster et al. [167].
One model was based on steroidal and another one on nonsteroidal
17b-HSD3 inhibitors as different interaction patterns might be
established within the binding pocket. After the screening of
several databases and an additional in silico ﬁltering approach, the
selected virtual hits were tested in a cell-based assay for 17b-HSD3
inhibition. In addition, speciﬁcity was tested against 17b-HSD1,
17b-HSD2, 17b-HSD4, 17b-HSD5, 17b-HSD7, 11b-HSD1, and 11b-
HSD2. Two out of 15 tested compounds found by the steroid-based
pharmacophore model and 2 out of 16 hits form the non-steroidal
model showed >40% inhibition of 17b-HSD3 at 2 mM of test
substance. Of the tested compounds, 3 derived from the steroidal
and 5 from the non-steroidal model revealed 2–4 fold more potent
inhibition against 17b-HSD5 (AKR1C3) than 17b-HSD3. Further-
more, one 17b-HSD3 inhibitor displayed equipotent activity to
17b-HSD5 and even stronger inhibition against 11b-HSD1,
whereas as a second 17b-HSD3 inhibitor was capable to inhibit
17b-HSD1. These investigations again emphasize the importance
of an expanded selectivity proﬁling including structurally and
functionally related enzymes.
2.2. Enzyme characterization and substrate identiﬁcation
Although the sequence of the human genome has been solved
and all genes are accessible, to date the physiological role of more
than half of all SDR members still remains unknown or poorly
examined. In silico approaches assist not only in the process of lead
compound identiﬁcation during drug development for well-
characterized enzymes, but can also support the deorphanization
and characterization of enzymes in order to explore their
physiological functions and to identify additional drug targets.
2.2.1. 17b-hydroxysteroid dehydrogenase type 10
The homotetrameric single domain multifunctional enzyme
17b-HSD10 has diverse substrate speciﬁcity and, in healthy tissues,
is located in mitochondria [168,169]. 17b-HSD10 is expressed in
various regions of the brain, the liver, heart, kidney, and gonads. In
addition to its promiscuous substrate spectrum, it was shown that
proteins and peptides such as the Alzheimer’s disease (AD) related
amyloid-b (Ab) peptide or ERa can bind to 17b-HSD10, thereby
inhibiting its activity [170]. 17b-HSD10 contains a unique
b-hairpin structure at residues 102–107, which is distinct from
all other NAD+-dependent SDRs and thought to be the recognition
site for Ab [171,172]. Thus, 17b-HSD10 is also known as Ab binding
alcohol dehydrogenase (ABAD). The inhibition of 17b-HSD10 by
ERa binding seems to be estrogen-dependent [173], and high
levels of intracellular estradiol disrupt the described interaction
and the released unbound 17b-HSD10 then was suggested to
convert estradiol to estrone. However, regarding its mitochondrial
localization it remains to be demonstrated that interaction of 17b-
HSD10 with Ab and ERa indeed occurs under patho-physiological
conditions. Furthermore, 17b-HSD10 has been proposed to
catalyze the oxidation of steroid modulators of GABA(A) receptors
[174]. Thus, clearly further research is needed to elucidate the
physiological substrates and interactions of this enzyme. Never-
theless, altered 17b-HSD10 function can be found in patients
suffering from AD, certain cognitive disabilities, multiple sclerosis,
and in chemotherapy-resistant osteosarcoma patients showing an
overexpression of 17b-HSD10 [170].In order to understand the molecular basis of the substrate
promiscuity of human 17b-HSD10, Nordling et al. [175] generated
a homology model and performed docking experiments with
known substrates to examine structure-function relationships. The
active site was found to be a wide cleft, consisting of mainly
hydrophobic residues and containing at the bottom of the pocket a
polar region with the highly conserved catalytic triad Ser155,
Tyr168, and Lys172. For the docking calculations different steroids
were selected to simulate the following site- and stereo-speciﬁc
enzyme activities: 3a-OH to 3-oxo conversion and 17b-OH
dehydrogenase activity. 17b-HSD activity was mimicked with
optimal distances and geometry for estradiol, testosterone, DHT,
and 3b-androstanediol. Five-a reduced steroids such as 3a,5a-
androstane,17-one revealed ideal hydrogen bond distances to
Tyr168, Ser155, and NAD+ for 3a-HSD activity. In contrast, 3b-
hydroxylated compounds or 5b-reduced steroids such as the bile
acid ursodeoxycholic acid (UDCA) showed inappropriate distances
to Ser155 (>4 Å), therefore restricting the oxidation reaction.
However, in an expanded follow-up study including kinetic
measurements, they found 17b-HSD10 acting as 7b-hydroxyste-
roid dehydrogenase for the bile acids UDCA and isoUDCA,
respectively [176]. To explain this novel substrate speciﬁcity on
both equatorial and axial positions of the steroidal compounds,
they generated again a homology model, this time based on the
orthologous rat crystal structure (PDB entry 1E6W [177]), whereas
the model of the former study was obtained using the related 7a-
HSD (PDB entry 1FMC [178]). Interestingly, the observed molecular
distances for isoUDCA to the catalytic triad were identical for the
hydroxyl group of Tyr and the C4 atom of NAD+, but decreased in
this docking application from 4.26 Å to 2.1 Å. Unfortunately, the
exact pose of isoUDCA and therefore the parts of the substrate
involved in the interaction, was not displayed for both approaches.
This might clarify structural differences of the homology models
and may explain the observed distance difference. In addition to
the 7b-hydroxysteroid dehydrogenase activity of 17b-HSD10, they
detected novel activities, namely the oxidation of 20b- and 21-
hydroxyl groups in C21 steroids such as glucocorticoids.
Although homology models are not as precise as high-
resolution X-ray structures, they represent a valuable basis for
the analysis of substrate recognition and speciﬁcity. Furthermore,
the 17b-HSD10 crystal structure resolved by Kissinger et al. [172]
almost entirely conﬁrmed the hydrophobic residues predicted by
the homology model generated by Nordling et al. to be involved in
substrate binding [175].54
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part of a structure-based drug design process, Kissinger et al.
crystallized the human 17b-HSD10 in complex with NAD+ and a
small molecule inhibitor (PDB 1U7T) (Fig. 10). In line with Nordling
et al., they described the substrate binding pocket as ﬂexible and
highly hydrophobic cleft, supporting the multi-substrate speciﬁc-
ity of the enzyme. Superimposition with the rat enzyme, for which
already three resolved protein structures were available, showed
very similar overall chain fold [177]. Interestingly, the inhibitor was
found to form covalent adducts with the bound cofactor NAD+.
Although the human protein structure was successfully resolved,
no molecular modeling studies for substrate or inhibitor identiﬁ-
cation were implemented so far.
2.2.2. 17b-hydroxysteroid dehydrogenase type 14
The physiological functions of 17b-HSD14 still remain unclear.
Expression analysis revealed a cytoplasmic localization of 17b-
HSD14 with high expression in liver, placenta, and brain, but
absence in steroidogenic tissues such as testis and ovary [179]. In
contrast, Sivik et al. [180] reported intense 17b-HSD14 immuno-
histochemical staining patterns in breast, ovary, and testis. The
observed discrepancy may be due to differences in antibody
speciﬁcity; thus, further conﬁrmatory expression studies are
necessary.
Lukacik et al. provided structural and functional information
building a basis for the deorphanization of this enzyme and leading
to the renaming of the DHRS10 gene to HSD17B14 [179]. The
resolution of the 17b-HSD14 holo enzyme crystal structure
represented a major achievement to deduce functional conse-
quences. Besides the typically conserved regions of SDRs, such as
the Rossmann-fold or the catalytic triad consisting of Ser141,
Tyr154, and Lys158, the active site of 17b-HSD14 displayed a deep
and broad hydrophobic cleft. An in vitro substrate screening using
puriﬁed recombinant 17b-HSD14 and including 50 different
steroids comprising androgens, estrogens, progestin, glucocorti-
coids, bile acids and oxysterols revealed rather low catalytic
turnover of estradiol and 5-androstene-3b,17b-diol using NAD+ as
cofactor. Non-saturable kinetics were found for testosterone.
Docking calculations for structural comparison of estradiol binding
within 17b-HSD1 and other 17b-HSDs showed a comparatively
loose binding of estradiol in the active site cleft of 17b-HSD14.
However, this extensive and open active cleft may also be due to
lack of a co-crystallized substrate in the X-ray structure, and
substrate binding might result in an induced ﬁt. Evidence for an
induced ﬁt upon cofactor binding was recently provided by
Bertoletti and Braun et al., who resolved the crystal structure of
17b-HSD14 as the holo form with NAD+ and as ternary complexes
with estrone and the ﬁrst nonsteroidal inhibitor of 17b-HSD14
[181]. The residues 189–212 were found to form a ﬂexible loop
adopting a closed conformation in the presence of cofactor and
reducing the size of the active site. The geometry of the active site
in the ternary complexes with the inhibitor or estrone bound
showed the same closed state delimiting an elongated, conical
shaped binding site with the catalytic triade at the apex of the cone
and a solvent-exposed opening site. However, estrone was found in
an atypical binding pose with the A-ring next to the nicotinamide
structure of the cofactor and forming an H-bond with Tyr154 of the
catalytic triade instead of the actual reaction position 17.
Furthermore, the position 17 itself was not observed to introduce
any other interaction. Chemical modiﬁcation of this inhibitor
scaffold applying a ligand-based approach led to the identiﬁcation
of ﬁve new 17b-HSD14 inhibitors with Ki values in the lower
nanomolar range [182]. The 17b-HSD14 crystal structure determi-
nation in complex with these new inhibitors revealed a highly
similar binding mode compared to previously reported non-
steroidal 17b-HSD14 inhibitor.2.2.3. Application of structural modeling for substrate identiﬁcation
Favia et al. [183] introduced a molecular docking protocol to
identify candidate substrates for 27 SDR members with resolved X-
ray structures and known catalytic function. The enzymes included
oxidoreductases, lyases, and isomerases, whereby half of the
proteins were from bacterial organisms and half from eukaryotes.
They docked the known substrates and products together with
>900 human metabolites from the KEGG pathway metabolite
database to each protein. In two thirds of all cases, the actual
known substrate or product was found within the top 5% of all
docked compounds. For the remaining third, allowing full
ﬂexibility of the side chains enhanced the rate of recognition of
their natural substrates. However, increasing the degrees of
freedom is not a practicable solution for docking of large libraries
as it also increases the required computational time and capacity.
Nevertheless, rigidity of a docking calculation can result in an
increased rate of false negative and false positive hits. A closer look
at the 2D structural similarity of the top-ranking compounds to the
substrate revealed rather weak correlation. Metabolites resem-
bling the natural substrate were indeed identiﬁed; however, only
some of the top-ranking compounds showed reasonable correla-
tion of the similarity with the docking rank. This may be explained
by the large hydrophobic binding pockets and induced ﬁt, allowing
the enzyme to bind various molecules, an essential property of
multi-functional SDR enzymes. In addition, Favia et al. clustered
the substrates into steroids, small polar molecules, coenzyme A
derivatives, nucleotide sugars, and others, and investigated
whether the use of representatives of each structural class might
provide similar information on substrate preferences of an enzyme
as the whole dataset. Even though they found that the rank of a
group representative correlated well with the mean rank of the
corresponding cluster, this approach seemed to be too abstract for
substrate identiﬁcation calculations. The diversity within a cluster
is important as it covers structurally related compounds with great
afﬁnity variations; thus deﬁning a class representative will
decrease the ability to identify potential candidate substrates.
In this respect, Hermann et al. conducted a structure-based
docking study on a selection of high-energy intermediate forms of
potential substrates for the amidohydrolase superfamily member
Tm0936, and they were able to predict three substrates with
substantial catalytic rate constants [184]. Their study was based on
two important facts: ﬁrst the X-ray structure was already resolved,
and second the number of possible catalytic reactions could be
reduced to a limited set of mechanistically associated conversions.
For this approach to be successful, it seems crucial to already have
some information on the mechanistic details of the enzyme.
Regarding SDRs, they show very broad substrate diversity, making
it difﬁcult to restrict possible substrates to a speciﬁc subclass of
molecules. A pharmacophore-based VS approach for substrate
identiﬁcation of enzymes not belonging to the SDR family where
no prior knowledge about the binding site of a protein is necessary
was employed by Mallipeddi and Joshi et al. [185]. Detailed
description of this study can be found in the Supplementary
information. However, all of the above mentioned studies
validated their approaches by modeling known substrates and
they did not include a subsequent in vitro evaluation of the
substrate-like compounds.
Reinhardt et al. examined tropinone reductase-like SDRs (TRLs)
of the Brassicaceae Cochlearia ofﬁcinalis and the closely related
Arabidopsis thaliana in silico and in vitro for their catalytic capacities
due to the uncertainty of their denomination and biological
function [186]. Two TRLs sharing 79% sequence identity and one
sharing 61% identity with a known tropinone reductase were
chosen for homology modeling, substrate docking and in vitro
validation. Although tropinone was successfully docked in a
favorable position into the binding pockets of all three enzymes,55
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analogues in vitro. A more detailed investigation of the substrate
binding sites revealed a small and hydrophobic pocket, where
compounds with a charged nitrogen atom can hardly be accepted
as substrates. Therefore, small lipophilic carbonyl compounds
were used for further docking applications, in which they were
predicted as substrates. Biological testing conﬁrmed these in silico
predictions, even though highly different kinetic characteristics
were obtained. These results enabled them to generate pharma-
cophore models to identify further substrates by VS of small
compound libraries. The resulting hit list was again docked into the
binding sites to evaluate for keto or aldehyde functions in the
reactive position. The four scaffolds recognized by all of the
pharmacophore models were selected for biological assays. All
three TRLs reduced the four compounds in vitro, however, with
different kinetics. Thus, this pharmacophore-based approach
succeeded in the identiﬁcation of new substrates. This study also
emphasizes the importance of in vitro testing of hits from VS when
using models based on reference proteins sharing high sequence
identity. Especially small scaffolds may easily adopt a favorable
docking pose without acting as a substrate. Nevertheless, VS
techniques for substrate identiﬁcation are always dependent on
the available database. A potential substrate can only be found if
contained in the database. Another limitation of pharmacophore
models is that only compounds matching the deﬁned chemical
features are retrieved. If a model contains one feature more or less
than a potential substrate, it will not be found in the virtual hit list.
Hence, applying this approach for substrate identiﬁcation should
rather include open models, retrieving a higher number of hits.
Another example of rather unusually high sequence identity
(71%) among SDRs can be found for carbonyl reductases (CBR) 1
and CBR3. CBR1 has a role in phase I metabolism of a wide range of
carbonyl containing xenobiotics, and it also catalyzes the conver-
sion of some endogenous substrates including prostaglandins,
steroids, and lipid aldehydes, although the physiological role in
converting these endogenous substrates requires further research.
In contrast, the function of CBR3 has not yet been extensively
characterized [187]. Pilka et al. established an in vitro substrate
proﬁle for CBR3 that they then used for an in silico structure-
activity relationship comparison with CBR1 [188]. The results
revealed a much narrower substrate spectrum for CBR3 compared
with CBR1. Orthoquinones, isatin-like compounds, and oracin were
the only tested substrates shared between the two enzymes. None
of the endogenous substrates of CBR1 served as substrate of CBR3.
The resolution of a CBR3 crystal structure, substrate docking
calculations, and site-directed mutagenesis studies allowed them
to identify residues that are critical for substrate recognition and
enzyme conformation. Although CBR1 and CBR3 share high
sequence similarity, their active sites differ in regard to shape,
size, and surface properties. A major difference lies in a short
segment of the substrate binding loop containing Trp229 and
Ala235 in CBR1 and Pro230 and Asp236 at analogous positions in
CBR3, respectively. Thus, a large hydrophobic barrier is formed in
CBR1 by Trp229, in contrast to a rather open binding pocket with
an additional charge contributed by Asp236 in CBR3. Furthermore,
Met141 and Gln142 in the active site of CBR1 and CBR3,
respectively, had signiﬁcantly different effects on the catalytic
activity, although the residues are of similar size. The observations
of this study were further supported by El-Hawari et al. [189]. Thus,
CBR3 clearly has a substrate spectrum distinct form that of CBR1.
CBR1 shares 27% sequence identity with the fruit-ﬂy Drosophila
melanogaster carbonyl reductase sniffer, which was reported to
prevent age-related neurodegeneration [190]. The mechanism
underlying the role of sniffer in neurodegeneration remains
incompletely understood. To study the substrate binding site of
sniffer and obtain hints towards potential physiological substrates,Sgraja et al. resolved the crystal structure of sniffer in complex with
NAD+ [191]. The structure revealed that the dinucleotide-binding
site and the substrate-binding loop adopt similar conformations
compared with porcine and human CBR1. Compared to other SDRs,
the substrate-binding loop is shorter in all three enzymes. For most
SDRs, this loop remains disordered until the substrate has bound.
However, in the sniffer protein this loop adopts a well-deﬁned
conformation even in the absence of a bound substrate.
Crystallization of the sniffer protein in complex with an artiﬁcial
substrate such as 9,10-phenanthrenequinone, p-nitrobenzalde-
hyde, or menadione, which were described earlier as sniffer
substrates, was not successful. Thus, these compounds were
computationally docked into the binding site after crystallization.
Plausible docking poses could be found for 9,10-phenanthrene-
quinone and menadione. The previously mentioned tryptophane
residue corresponding to position 229 in the human enzyme seems
to be highly conserved and was also found to be involved in
substrate binding in the sniffer protein. Furthermore, the observed
binding modes led the authors to suggest that the unoccupied
space in the binding pocket should allow binding of larger
substrate molecules such as steroids or prostaglandins. In this
respect, Martin et al. recently showed that sniffer is able to catalyze
the NADPH-dependent reduction of the lipid peroxidation product
4-oxonon-2-enal into the less reactive 4-hydroxynon-2-enal,
thereby providing a possible explanation for the mechanism of
protection from oxidative stress in Drosophila melanogaster [192].
2.3. Virtual screening applications in toxicology focusing on SDRs
Molecular modeling applications are not only useful for
substrate and lead compound identiﬁcation, but they can also
facilitate the identiﬁcation of hazardous chemicals in predicting
interactions of compounds with so-called anti-targets that may
lead to severe adverse health effects. Although the different
applications pursue distinct goals, the actual computational
algorithm distinguishes not between screening of a drug candi-
date, potential substrate or hazardous compound. There are only
few VS reports focusing on SDRs and toxicological questions so far,
and they will be introduced brieﬂy.
A large number of exogenous substances such as dyes, food
additives, body care products and cosmetics, as well as chemicals
used for industrial production or agriculture are produced and
placed on the market every year, often with insufﬁcient safety
assessment. Hazard characterization and risk evaluation of
synthetic chemicals on human health and the environment are
important for safety management strategies; and in this respect
the interference of xenobiotics with the endocrine system may
cause harmful effects and is a topic of high actual interest [19,193].
These so-called endocrine disrupting chemicals (EDCs) can disturb
hormone synthesis, metabolism, and hormonal signaling, thereby
potentially contributing to major diseases.
Nuclear steroid receptors such as ER, AR, MR, GR, and
progesterone receptor (PR) are among the most extensively
investigated targets for EDC action. However, biosynthesis and
peripheral metabolism essentially impact on tissue- and cell-
speciﬁc regulation of steroid levels and action. Several SDRs are
involved in the local interconversion of inactive and active steroid
metabolites, and it is important to include them in the evaluation
of potential EDCs. Covering all these potential enzymes and
receptors for biological testing represents a major challenge.
Computational approaches can be highly useful in a ﬁrst step to
identify new EDCs and to gain insights into the mechanism of
action, thus helping to prioritize the chemicals for further
biological evaluation [19].
In such a proof of concept study, Vuorinen et al. aimed at
identifying potential EDCs inhibiting 11b-HSD2, which converts56
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thereby protecting MR from excessive cortisol [21]. Elevated MR
activation by glucocorticoids due to 11b-HSD2 disruption or
congenital deﬁciency causes the syndrome of apparent mineralo-
corticoid excess (AME), characterized by severe hypertension,
hypokalemia, and hypernatremia [194,195]. 11b-HSD2 is also
expressed in non-mineralocorticoid target tissues such as the
placenta, where it ensures fetal protection from maternal
glucocorticoids [196,197]. Impaired 11b-HSD2 function has been
associated with altered fetal growth, impaired angiogenesis, and a
higher risk for cardio-metabolic and neuropsychiatric disorders in
later life [198,199]. Thus, Nashev et al. applied a ligand-based 11b-
HSD pharmacophore model for VS of a database containing
putative EDCs [21]. In total, 29 hit compounds virtually matched
with the chemical features of the model, of which 5 substances
were tested in a cell-free assay for 11b-HSD1 and 11b-HSD2
inhibition. AB110873, a silane-coupling agent used as rubber
additive, and the antibiotic lasalocid, applied in chicken and turkey
breeding, were thereby found to inhibit 11bHSD2 activity (IC50
6.1 mM and 14 mM, respectively). Besides 11b-HSD2 inhibition, the
silane AB110873 showed concentration-dependent MR activation,
which resulted in enhanced interleukin-6 (IL-6) expression and
mitochondrial reactive oxygen species (ROS) production in
macrophages exposed to this compound. Docking studies were
implemented to understand the binding mode of AB110873.
Interestingly, AB110873 adopted the same hydrophobic interac-
tions as aldosterone and in addition occupied a hydrophobic side
pocket of the receptor. A newly generated structure-based MR
pharmacophore recognized AB110873 as a hit, demonstrating the
ability to ﬁnd compounds with quite different, non-steroidal
scaffolds. However, regarding risk assessment, it remains to be
shown whether relevant concentrations of these substances can be
observed in the human body, especially in industry workers
producing and processing them.
The importance of 17b-HSD3 during male sexual development
is highlighted by speciﬁc defects in HSD17B3, leading to 46, XY
disorder of sex development [143–145]. Inhibition of 17b-HSD3
activity during early development until puberty by EDCs might
lower plasma testosterone levels, thereby disturbing the mascu-
linization process and contributing to male reproductive disorders.
For this purpose, Nashev et al. developed a ligand-based
pharmacophore model to search for 17b-HSD3 inhibitors from a
database containing putative EDCs [19]. VS revealed several
benzophenones (Fig. 11) used as UV-ﬁlters in cosmetics,Fig. 11. Benzophenones (BP-1, BP-2, BP-3), 3-benzylidene camphor (3-BC), and 4-
methylbenzylidene camphor (4-MBC).sunscreens, and as plastic additives. Upon biological testing of
selected virtual hits and structurally similar derivatives that are
environmentally relevant in intact cells, benzophenone-1 (BP-1)
was found to be the most potent 17b-HSD3 inhibitor with an IC50
value of 1.05 mM. Moderate inhibition with IC50 between 5.9 mM
and 10.3 mM were found for BP-2, 3-benzylidene camphor (3-BC)
and 4-methylbenzylidene camphor (4-MBC). Notably, BP-1, 3-BC
and 4-MBC were not found as virtual hits but were included in the
in vitro testing because of their structural similarity to the initially
identiﬁed UV-ﬁlter hits. In addition to 17b-HSD3, the related SDRs
17b-HSD2 and 11b-HSD1 were also inhibited by these UV-ﬁlter
chemicals (17b-HSD2: IC50 for BP-2, 3-BC and 4-MBC of 10.0 mM,
6.3 mM and 5.8 mM; 11b-HSD1: IC50 for BP-2, 3-BC and 4-MBC of
12.2 mM, 2.3 mM and 2.9 mM, respectively), emphasizing the need
to include several related SDRs for the safety assessment of these
chemicals.
As benzophenones may be regarded as steroid mimetics, they
may directly bind to nuclear steroid receptors. Therefore, the
investigated UV-ﬁlter chemicals were also tested for direct effects
on the androgen receptor (AR). Several UV-ﬁlters antagonized the
AR, with BP-1, BP-2, and BP-3 displaying the most potent activities
with IC50 values between 2.2 mM and 5.7 mM. These results
emphasize that VS as initial ﬁltering tool for the discovery of active
compound classes can aid the identiﬁcation of EDCs. Additionally,
as metabolites can be equally or even more active than their parent
substances, major metabolites should be included in safety
analyses. For example, whilst benzophenone-3 (BP-3) displayed
no inhibitory activity against 17b-HSD3, it is rapidly demethylated
in vivo to the potent 17b-HSD3 inhibitor BP-1 [200]. Of note,
pharmacophore-based SAR studies, implemented to analyze the
differences in the activities of the tested UV-ﬁlters on 17b-HSD3,
indicated that the loss of activity of BP-3 was due to the ether
group. Nevertheless, for the risk assessment, the concentrations of
BP-1 reached in vivo in the testes need to be determined in order to
assess the relevance of 17b-HSD3 inhibition.
2.4. Limitations
2.4.1. Computational applications
Despite the many reported success stories, in silico approaches
for the identiﬁcation of chemicals binding to a cognate protein are
facing several challenges. The predictive power of VS workﬂows is
determined by the quality of the data underlying the model or
workﬂow. Thus, the biological data of the training and test
compounds used for model generation and validation must be
critically evaluated [201]. The following aspects should therefore
be considered: the biological data should be based on suitable in
vitro testing systems employed for activity determination (i.e.
puriﬁed protein or cell lysates allowing for a direct access of a given
chemical to the corresponding protein), activity cut-offs to exclude
unspeciﬁc effects, use of suitable positive and negative controls,
consideration of species differences (i.e. data and model must be
for the same species), and veriﬁcation of the original references
when using compound databases. The majority of these issues is
equally important for the biological validation of virtual hits, to
guarantee a correct subsequent model reﬁnement. Hence, they are
discussed in more detail below. These issues refer not only to
compounds determined as active, but also to conﬁrm inactive
molecules. These data are scarce because proven inactive
compounds for a speciﬁc target, i.e. negative results, are rarely
reported. Compounds conﬁrmed as inactive can provide valuable
insights into unwanted properties that cannot be tolerated for a
compound to interact with a macromolecular target. In addition,
they can help estimating and adjusting the selectivity and
sensitivity of an in silico workﬂow. Rather restrictive models are
often employed in the drug development process to ﬁnd few57
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virtual hits low. In contrast, toxicological applications aim to
identify all conceivably harmful substances and can accept lower
VS hit rates. Additionally, most in silico workﬂows were generated
with drug-like compounds where a lot of data may already be
available. Toxicologically relevant molecules such as environmen-
tal chemicals occupy a different chemical space, for which a
workﬂow was not optimized. Nevertheless, the identiﬁcation of
structural compound classes acting on a given target, which are
then further biologically evaluated, can yield important informa-
tion for the prioritization of follow-on experiments.
For many members of the SDR family, structural information is
currently not or only partially available. For example, many
available crystal structures are not including the cofactor, and
several SDRs bear a transmembrane binding anchor that is usually
not covered in the crystal structures. The experimental 3D
resolution of these membrane proteins still remains challenging
as is the alternative approach of homology modeling due to the low
sequence similarity among SDRs. The lack of suitable x-ray
crystallographic data thus limits structure-guided design strate-
gies for several SDR family members. Alternatively, ligand-based
methods can be applied to target these molecules.
Different computational programs can generate different VS
results even when the same chemical library and protein structural
information are used, and each approach by its own yields valuable
results [202,203]. Thus, combining different computational pro-
grams may be crucial for substrate identiﬁcation or toxicological
approaches, where a more complete recovery of the active
compounds is needed [204]. Another drawback in the VS process,
especially for substrate identiﬁcation purposes, represents the fact
that the available chemical databases are not fully representative.
While a lot of databases containing small drug-like compounds are
available (e.g. ChEMBL [205]), less data is easily accessible for
endogenous substrates or environmental chemicals. The gaining
knowledge of existing metabolites and extending existing data-
bases such as the human metabolome database [206], will improve
future VS applications aiming at substrate identiﬁcation.
Regarding successful VS applications, in silico tools should not
be seen as isolated approaches, but rather as complementary to
experimental techniques. Thus, the biological validation of virtual
hits using appropriate in vitro testing systems is of utmost
importance and will therefore be discussed in detail in the
following section.
2.4.2. Biological validation
As mentioned above, biological assays are essential to validate
virtual hits. To avoid biased results, the limitations of the in vitro
testing systems should be known and considered for data
interpretation. The enzyme activity analysis of selected virtual hits
has to be conducted under cell-free conditions (i.e. puriﬁed protein
or lysates expressing the protein in an environment with very low
background). Equally important is the appropriate selection of the
assay detection technology. Compounds can be regarded as false
positive due to interference issues with the assay signaling (for
example autoﬂuorescence of certain compounds for ﬂuorescence
detectors). Data obtained from intact cells can only be used to verify
active hits but do not allow appropriate ranking of hits with
different activities, nor does it allow exclusion of inactive molecules.
Whereas a test compound has direct access to its target in cell-free
systems, a compound’s concentration in intact cells depends on the
presence of transport proteins, intracellular binding proteins, as
well as metabolizing enzymes. Thus, negative results in cell-based
assays do not allow drawing unambiguous conclusions about the
biological activity of a virtual hit. Moreover, results from cell-based
assays can be inﬂuenced by parameters such as passage number of a
cell line and therefore different expression levels, conditions of cellhandling, and medium composition. Similarly, problems may be
evident in preparation of cell lysates and proteinpuriﬁcation, where
different handling can lead to different activity of an enzyme
preparation. Thus, ideally data on a series of compounds should be
obtained with the same material. Using the same procedure and
inclusion of appropriate positive and negative controls facilitates
comparisonwith results obtained other studies. Nevertheless, upon
initial conﬁrmation, active hits need further comprehensive
biological characterization including selectivity assessment, analy-
sis of species-speciﬁc differences and in vivo pharmacodynamics
and pharmacokinetics.
Although the members of the SDR family share considerable
structural similarity, the primary sequence similarity is rather low.
Koch et al. [207] proposed that structural similarity rather than
primary sequence similarity should be chosen as criterion for
whether a certain chemical affects the activity of a related enzyme.
Therefore, the closest structurally related enzymes should be
included for selectivity testing. Because of the high number of
orphan SDRs, the function and substrate speciﬁcity of the closest
relatives of a given enzyme are often unknown and no suitable
assay read-outs for selectivity assessment are available. Thus,
deorphanization of SDRs is important to improve the physiological
understanding of these enzymes and to discover potentially novel
drug or anti-drug targets.
The lack of assay read-outs for testing potential substrates to
deorphanize enzymes hampers the attempt of substrate identi-
ﬁcations. Unlike other protein families, SDRs do not share a
common activity element that can be used as read-out. For
instance, the activation of G protein coupled-receptors (GPCRs)
involves well-described steps that can be monitored, such as the
accumulation of second messengers. This allows for the detection
of speciﬁc changes upon receptor activation [208]. SDRs, however,
are enzymes with a remarkably broad substrate speciﬁcity, which
impedes the monitoring of activation-speciﬁc changes.
Species-speciﬁc variabilities have been reported for inhibitors
and substrates of different HSDs [77,79,209]. These observations
suggested signiﬁcant differences in the 3D conformations of the
enzymes from different species. During the drug development
process, a lead compound ideally inhibits the human enzyme as
well as the orthologue of the species (usually rodents) in which the
preclinical or safety studies are conducted. However, Möller et al.
compared the activities of 17b-HSD1 inhibitors in different species
and found that the most potent inhibitors of the human enzyme
lacked inhibition of the rodent enzymes [209]. Moreover, they
were not able to predict the species-speciﬁc effects by molecular
docking calculations. In this regard, an initial enzymatic assay
including only the orthologue of the subsequently used animal
model species would miss potential inhibitors for human
applications. Abdelsamie et al. performed structural optimization
studies to enhance the potency of a 17b-HSD1 inhibitor against the
rodent enzyme and performed docking and homology modeling
applications to elucidate the interspecies differences [210]. The
observed species-speciﬁc protein-ligand interactions might offer
valuable information for the design of new inhibitors.
Achieving tissue-speciﬁc enzyme inhibition can be important
for therapeutic applications in order to reduce potential side
effects. Therefore, a compound should be tested in suitable in vitro
and in vivo testing systems to elucidate its tissue distribution.
Moreover, regarding toxicological studies, tissue distribution and
accumulation studies could help to assess the potential of
compounds acting as EDCs. In this context, Hamilton et al.
developed a test cascade for the development of 11b-HSD1
inhibitors as described above [99]. To summarize the limitations
involved in the biological validation of virtual hits described in this
review and to provide a potential solution approach, we adapted
the former cascade to a more general screening strategy (Fig. 12).58
Fig. 12. Potential screening strategy for biological validation of in silico derived hits.
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Computational tools offer a rational, cost-effective addition to
large high-throughput screening (HTS) studies by enriching virtual
hits from large databases applying target-speciﬁc ﬁlters. They can
be employed in various application ﬁelds such as lead compound
identiﬁcation during drug development, toxicological screenings
including EDC assessment, but also for substrate identiﬁcation and
enzyme characterization. This review highlights the efforts made
in these areas for the family of SDRs, particularly focusing on HSDs.
Several SDRs are involved in steroid synthesis and metabolism as
well as in the metabolism of xenobiotics, suggesting that these
enzymes may be susceptible to endocrine disruption. In silico
design for therapeutic 11b-HSD1 and 17b-HSD1 inhibitors
comprise the majority of studies conducted. Only few studies
investigated HSDs as EDC targets and applied VS tools as pre-ﬁlter
to identify compound classes rather than speciﬁc substances.
Regarding the large number of orphan SDRs, new methods are
required for substrate identiﬁcation, where computational
approaches could offer valuable support. However, these inves-
tigations into SDRs are rather at the beginning, and need to be
extended.For the appropriate application of in silico tools and subsequent
biological validation of virtual hits, careful consideration of the
limitations of the individual approaches is crucial. The reported
successful studies including computational and biological analyses
of SDRs raise the expectations of increasing numbers of studies
performed in this area.
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11β-HSD1 
inhibitors 
[1] High predictive power and good performance of 
pharmacophore models are fundamental for reliable in silico 
tools. This can be achieved by systematic evaluation and 
refinement of pharmacophore models. The 11β-HSD 
pharmacophore models from Schuster et al. [2] and an 11β-
HSD2-selective model reported by Kratschmar et al.[3] were 
re-evaluated and refined by Vuorinen et al. [1]. Repeated 
exchanging, removing, or adding of chemical features to the 
pharmacophore model in order to focus the model to find 
more active and respectively less inactive compounds which 
are described in newly available literature data is a key step in 
this process. However, subsequent prospective VS and 
biological evaluations are just as important to compare the 
effective improvement towards the unrefined model. Against 
the background that no crystal structure for 11β-HSD2 is 
available and the few known selective 11β-HSD2 inhibitors 
belong to the same chemical scaffold class, the data of the 
11β-HSD2 model are biased. Nevertheless, the authors were 
able to show improved model performance and discovered 
novel scaffolds as selective 11β-HSD2 inhibitors. 
11β-HSD1 
inhibitors 
[4] Vuorinen et al. used the refined 11β-HSD1 model as a query 
to screen a database for constituents of the traditionally used 
Greek medical plant Pistacia lenticus. P lenticus, so-called 
mastic gum, is used to treat diabetes or control cholesterol 
levels. The mode of action is currently unknown, but it is 
hypothesized that inhibition of 11β-HSD1 by secondary 
metabolites contributes to the antidiabetic activity of mastic 
gum. These secondary metabolites are proposed to belong to 
the class of triterpenes, as they are detected at high 
concentrations in the neutral and acidic fraction of Pistacia 
oleoresins. Therefore, the evaluation of the virtual hit list 
focused on triterpenes and revealed eight hits, which are 
constituents of P lenticus. Masticadienonic acid and 
isomasticadienonic acid were selected for biological 
assessments, because they displayed the two main 
constituents of the acidic fraction of the resin. 
Masticadienonic acid and isomasticadienonic acid selectively 
inhibited 11β-HSD1 over 11β-HSD2 in a cell-lysate based 
assay with IC50 of 2.51 μM and 1.94 μM, respectively. 
Analyzing the acidic fraction of the resin for 11β-HSD1 
inhibition showed a comparable IC50 of 2.1 μM, whereas the 
whole resin exhibited somewhat more potent activity against 
11β-HSD1 with an IC50 of 1.33 μM, suggesting an additive 
effect. Binding mode examinations of the two single 
substances by docking revealed an occupation of the binding 
site without interactions with the catalytic residues. Thus, 
masticadienonic acid and isomasticadienonic acid are 
suggested to competitively prevent cortisol from binding. 
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Substrate 
identification 
of non SDR 
enzymes 
[5] Mallipeddi and Joshi et al. used five resolved crystal 
structures for computational prediction of the binding 
site and mapping of energetically favorable positions of 
functional groups. Based on these analyses they 
converted the observed chemical features into a 
pharmacophore model which was then used for VS of 
metabolites from the KEGG ligand database. The filter 
function of the pharmacophore model was fulfilled by 
eliminating >92% of the database compounds and by 
ranking the known substrates or products within the top 
0.7% and substrate-like compounds in the top 1%. 
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3. Endocrine disrupting chemicals 
 
Annually, a substantial amount of synthetic chemicals in the form of body care products, cosmetics, 
dyes, food additives, pharmaceuticals as well as chemicals used for industrial production or agriculture 
are manufactured and released on the market. This occurs frequently with an inadequate safety 
assessment. The evaluation and characterization of potential risk factors on the environment and on 
human health originating from those exogenous chemicals is a topic of high actual interest addressed 
by several authorities as for instance the Registration, Evaluation, Authorization and Restriction of 
Chemicals (REACH) regulation of the European Union, the Toxicology in the 21st century (Tox21) inter-
agency collaboration program or the Toxicity Forecaster (ToxCast) from the U.S. Environmental 
Protection Agency/ Food and Drug Administration/ National Toxicology Program [11-14]. These so-
called endocrine disrupting chemicals (EDCs) can interfere with the hormone synthesis, metabolism or 
hormonal signaling and as a result of that, potentially contributing to major diseases. Although nuclear 
hormone receptors such as estrogen receptors (ER) and androgen receptor (AR) belong to the most 
extensively studied targets for EDC action, other receptors such as mineralocorticoid receptors (MR) 
or glucocorticoid receptors (GR) are much less well investigated. In addition, the enzymatic regulation 
of biosynthetic and metabolic pathways have a considerable impact on the tissue- and cell-specific 
steroid availability and thereby impact on steroid hormone action [15]. However, only a few steroid 
metabolizing enzymes are currently covered in the analysis of potential EDCs. The present thesis 
selected one SDR, 11β-hydroxysteroid dehydrogenase 2 (11β-HSD2), as an example to test the use of 
molecular modeling and biological assessment for the identification and characterization of potential 
inhibitors. 
 
3.1. 11β-hydroxysteroid dehydrogenase type 2 
 
Compared to the GR, the MR has a rather broad ligand specificity and binds the glucocorticoids cortisol 
and corticosterone as well as the mineralocorticoids aldosterone and 11-deoxycorticosterone with 
similar affinity [16-19]. 11β-HSD2 catalyzes the oxidation of the potent 11β-hydroxyglucocorticoids 
(cortisol, corticosterone) into their inactive 11-oxo forms (cortisone, 11-dehydrocorticosterone), 
thereby acting as gate-keeper to protect the MR from cortisol that is present in the circulation in excess 
amounts and rendering specificity for aldosterone and 11-deoxycorticosterone [20, 21]. Patients with 
genetic loss-of-function mutations in the HSD11B2 gene suffer from so-called apparent 
mineralocorticoid excess (AME), characterized by severe hypertension, hypernatremia, hypokalemia, 
metabolic alkalosis, low aldosterone, low renin, and increased plasma and urinary cortisol to cortisone 
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ratios, due to the excessive cortisol-dependent MR activation in the kidney and colon [22-24]. Besides 
the regulation of electrolyte balance and vascular function, the expression of 11β-HSD2 in the placenta 
ensures fetal protection from excess maternal glucocorticoids [22, 25]. Deficient placental 11β-HSD2 
activity has been associated with reduced birth weight, albeit in normal ranges, and a higher risk for 
cardio-metabolic and neuropsychiatric disorders in later life. Importantly, different animal models and 
human observational data (a more detailed overview is provided in the introduction of the published 
article ‘Inhibition of 11β-hydroxysteroid dehydrogenase 2 by the fungicides itraconazole and 
posaconazole’ [26], see the section below) supported the hypothesis that reduced placental 11β-HSD2 
activity is responsible for the high glucocorticoid concentrations reaching the fetus and subsequent 
programming of disease susceptibility [27]. Due to the important physiological roles of 11β-HSD2, it 
can be considered as an anti-target during the development of therapeutic SDR inhibitors but it should 
also be considered for risk assessment of potential EDCs. Currently, 11β-HSD2 is not part of the 
common off-target screening approaches. Therefore, possible inhibitory activities of approved drugs 
toward 11β-HSD2 were addressed in the following study using pharmacophore-based virtual screening 
(VS) and subsequent biological evaluation of selected hits.  
Furthermore, this study additionally served as proof of concept for the application of pharmacophore-
based VS techniques to identify potential inhibitors/substrates of proteins with unresolved structural 
information. To date, the structural information for many members of the SDR superfamily is either 
completely lacking, as it is the case for the ER membrane anchored protein 11β-HSD2, or only partially 
available. Several available crystal structures of SDRs do not include the transmembrane domain, 
which is found in about half of all SDRs, and in many structures the cofactor is missing (so-called 
apoenzymes). The experimental 3D resolution of the membrane bound SDR proteins still remains a 
major challenge as they require extraction from the membrane using detergents, whilst 
simultaneously trying to retain proper folding and stability in solution [28]. Homology modeling as an 
alternative approach is not less demanding because of the low sequence similarity among members of 
the SDR family. Thus, structure-guided design strategies are limited for several SDRs. Ligand-based 
methods can display an interesting alternative to target these proteins, provided that at least some 
information about the mechanistic details of the enzyme activity is known (several examples can be 
found in the two published review articles described in the section above [9, 10]).  
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GlucocorticoidImpaired 11b-hydroxysteroid dehydrogenase type 2 (11b-HSD2)-dependent cortisol inactivation can lead
to electrolyte dysbalance, hypertension and cardiometabolic disease. Furthermore, placental 11b-HSD2
essentially protects the fetus from high maternal glucocorticoid levels, and its impaired function has been
associated with altered fetal growth and a higher risk for cardio-metabolic diseases in later life. Despite
its important role, 11b-HSD2 is not included in current off-target screening approaches. To identify
potential 11b-HSD inhibitors among approved drugs, a pharmacophore model was used for virtual
screening, followed by biological assessment of selected hits. This led to the identification of several azole
fungicides as 11b-HSD inhibitors, showing a significant structure-activity relationship between azole
scaffold size, 11b-HSD enzyme selectivity and inhibitory potency. A hydrophobic linker connecting the
azole ring to the other, more polar end of the molecule was observed to be favorable for 11b-HSD2 inhi-
bition and selectivity over 11b-HSD1. The most potent 11b-HSD2 inhibition, using cell lysates expressing
recombinant human 11b-HSD2, was obtained for itraconazole (IC50 139 ± 14 nM), its active metabolite
hydroxyitraconazole (IC50 223 ± 31 nM) and posaconazole (IC50 460 ± 98 nM). Interestingly, experiments
with mouse and rat kidney homogenates showed considerably lower inhibitory activity of these com-
pounds towards 11b-HSD2, indicating important species-specific differences. Thus, 11b-HSD2 inhibition
by these compounds is likely to be overlooked in preclinical rodent studies. Inhibition of placental
11b-HSD2 by these compounds, in addition to the known inhibition of cytochrome P450 enzymes and
P-glycoprotein efflux transport, might contribute to elevated local cortisol levels, thereby affecting fetal
programming.
 2017 Elsevier Inc. All rights reserved.e; CRH,
eceptor;
tor; OHI,
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11b-Hydroxysteroid dehydrogenase 2 (11b-HSD2) converts
potent 11b-hydroxyglucocorticoids (cortisol, corticosterone)
into their inactive 11-keto forms (cortisone, 11-
dehydrocorticosterone), thereby controlling tissue-specific
activities of mineralocorticoid receptors (MR) and glucocorticoid
receptors (GR) [1]. 11b-HSD2 is essentially involved in the regula-
tion of electrolyte balance, vascular function, and angiogenesis, as
well as in the fetal-placental barrier to inactivate cortisol andprotect
the fetus from high maternal glucocorticoid levels [2,3].
The consequences of impaired 11b-HSD2 function are mani-
fested in patients with genetic loss-of-function mutations suffering
from apparent mineralocorticoid excess (AME) [2,4,5]. In these
patients the excessive cortisol-dependent MR activation in the kid-
ney and colon results in hypokalemia, hypernatremia and water
retention, leading to severe hypertension characterized by low
renin, low aldosterone and increased plasma and urinary cortisol
to cortisone ratios. 11b-HSD2 activity is essential since very early
on in life, because birth weights of individuals homozygous/com-
pound heterozygous for HSD11B2 mutations were found to be sig-
nificantly lower than those of their unaffected siblings [6]. Milder
acquired forms of AME can be caused by inhibition of 11b-HSD2,
for instance upon consumption of considerable amounts of licorice,
containing the potent 11b-HSD inhibitor glycyrrhetinic acid (GA) [7].
The exposure to 11b-HSD2 inhibitors is especially critical dur-
ing pregnancy. 11b-HSD2 builds a placental barrier by protecting
the fetus from the 5–10 times higher maternal glucocorticoid
levels in the course of a normal pregnancy [8–11]. Nevertheless,
this barrier is not entirely complete, as a minor proportion of
maternal cortisol is able to cross the placenta [11]. Glucocorticoids
are important mediators of fetal growth, development and organ
maturation. Rising total plasma cortisol levels during pregnancy,
peaking in the third trimester at threefold non-pregnant levels
[12], are in parallel with progressive maturation of fetal organs,
most notably the stimulation of surfactant production by the lung.
However, glucocorticoid administration, especially during late ges-
tation, has been associated with reduced birth weight, elevated
blood pressure, higher insulin, increased distractibility and atten-
tion deficit later in life [13–17]. The correlation between low birth
weight, albeit in normal ranges, and subsequent diseases in adult-
hood was found to be largely independent of confounding life style
factors such as smoking or obesity [15]. It has been hypothesized
that a reduced placental 11b-HSD2 activity is responsible for the
high glucocorticoid concentrations reaching the fetus and subse-
quent programming of disease susceptibility [18]. Importantly,
low 11b-HSD2 expression was found to be associated with
intrauterine growth restriction pregnancies in humans and in
rodent models [19–22]. Determination of osteocalcin concentra-
tion in human cord blood samples, which is a sensitive marker of
glucocorticoid exposure in adult humans, revealed a direct correla-
tion with placental 11b-HSD2 activity [23].
Treatment of pregnant rats with dexamethasone, which cannot
be inactivated by 11b-HSD2 [24], led to lower birth weights and
caused HPA axis hyperactivity, hypertension, hyperglycemia and
increased anxiety behavior [20,25]. Similarly, administration of
the unselective 11b-HSD inhibitor carbenoxolone to pregnant rats
resulted in reduced birth weight, and adult offspring showed
enhanced HPA activity with increased glucocorticoid and CRH
levels as well as elevated blood pressure [26,27]. Evidence for the
importance of placental 11b-HSD2 was contributed by studies with
placentas from 11b-HSD2-deficient mice showing increased amino
acid and reduced glucose transport as well as lower expression
levels of genes important for angiogenesis [28]. Furthermore,
maternal stress and malnutrition in rats were reported to be ableto down regulate placental 11b-HSD2 and program for diseases
in adult life [29–31]. Factors including sex steroids, nitric oxide,
prostaglandins, proinflammatory cytokines, infections and envi-
ronmental pollutants were shown to have the potential to reduce
11b-HSD2 activity in studies using placental cell lines [32,33].
Observational studies showed that pregnant Finnish women
consuming large amounts of licorice (containing the unselective
11b-HSD inhibitor glycyrrhetinic acid) had shorter gestation times
[34] and gave birth to children with behavioral disturbances and
poorer cognitive functions coupled with increased HPA axis activ-
ity, in a dose-dependent manner [35,36]. Compromised 11b-HSD2
function during pregnancy has also been implicated in preeclamp-
sia, a major cause of maternal and perinatal mortality; however,
the etiology is poorly understood [37,38].
Due to its important physiological role and the adverse effects
observed upon its inhibition, 11b-HSD2 can be considered as an
anti-target for drug development (with a few specific exceptions
where these effects are wanted); however, it is not included in cur-
rent off-target screening approaches. The present study addressed
possible inhibitory effects of approved drugs towards 11b-HSD2 by
performing a virtual screening (VS) of the DrugBank database using
an 11b-HSD pharmacophore model. This was followed by a biolog-
ical evaluation of selected hits, with a focus on the azole fungicides
itraconazole and posaconazole.
2. Materials and methods
2.1. Chemicals and reagents
[1,2,6,7-3H]-cortisol, [2,4,6,7-3H]-estrone and [2,4,6,7-3H]-
estradiol were purchased from PerkinElmer (Boston, MA, USA),
[1,2-3H]-cortisone from American Radiolabeled Chemicals (St.
Louis, MO), hydroxyitraconazole (OHI) from Carbosynth (Berkshire,
UK) and all other chemicals from Sigma Aldrich (Buchs, Switzer-
land) of the highest grade available. Cell culture media were
obtained from Sigma Aldrich (Buchs, Switzerland).
2.2. Pharmacophore modeling and virtual screening
The 11b-HSD inhibitor pharmacophore model used for this
study was previously reported and validated [39]. The model was
initially based on three potent, structurally diverse 11b-HSD inhi-
bitors [40] and refined with recent literature and novel screening
data (model 4new in reference [39], Fig. 1A).
To discover potential 11b-HSD inhibitors among FDA-approved
drugs and nutraceuticals, the DrugBank version 3.0 was down-
loaded as sd file (1543 approved drugs and 84 nutraceuticals)
and transformed into a 3D-multiconformational database using
the ‘‘build database” protocol of Discovery Studio 4.0 (Discovery
Studio, Version 4.0, Biovia Inc., San Diego, CA, 2014). For each com-
pound, a maximum of 255 conformers was calculated using fast
settings. For the VS, the ‘‘search 3D database” protocol with BEST
flexible search was used. The DrugBank database was screened
with the 11b-HSD inhibitors model using Discovery Studio 4.0.
2.3. Cell culture
Human Embryonic Kidney-293 cells (HEK-293) cells (used at
passage number 15–30), human SW-620 colon carcinoma cells
(passage number 11–15) and human MCF-7 breast cancer cells
(passage number 19–27) were obtained from ATCC (Manassas,
VA, USA) and were cultured in Dulbecco’s modified Eagle medium
(DMEM) supplemented with 10% fetal bovine serum, 4.5 g/L
glucose, 100 U/mL penicillin/streptomycin, 2 mM L-glutamine,
10 mM HEPES, pH 7.4, and 10% MEM non-essential amino acid
solution.71
Fig. 1. Pharmacophore model used for virtual screening of the DrugBank database. (A) The model consists of four hydrophobic (H) features (cyan), two hydrogen bond
acceptors (HBA, green) and a sterical shape restriction (grey) [39]. (B) Virtual hits from the DrugBank screening fitted into the model. Compounds are color-coded: red –
tioconazole; green – butoconazole; violet – sertaconazole.
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Enzyme activities were determined as described earlier using
lysates of HEK-293 cells stably expressing human 11b-HSD1 and
hexose-6-phosphate dehydrogenase (H6PDH; HHH7 clone) or
11b-HSD2 (AT8 clone) [41]. 11b-HSD1 reductase activity was mea-
sured by incubating the lysates for 10 min at 37 C in a total vol-
ume of 22 lL containing 200 nM radiolabeled cortisone, 500 lM
NADPH and test substance or vehicle (DMSO at a maximal concen-
tration of 0.1%). 11b-HSD2-dependent oxidation was assessed in
the presence of 200 nM radiolabeled cortisol and 500 lM NAD+.
The reactions were stopped by adding an excess amount of unla-
beled cortisone and cortisol (1:1, 2 mM in methanol). Approxi-
mately 20–25% of the substrate were converted to the
corresponding product. Steroids were separated by thin layer chro-
matography (TLC) using chloroform and methanol (9:1). Conver-
sion of radiolabeled substrate was measured by scintillation
counting. The substrate conversion was determined and compared
to the enzyme activity in the control sample.
To exclude irreversible 11b-HSD2 inhibition by the investigated
compounds, HEK cell lysates were preincubated with the
corresponding compounds for 0, 5 and 20 min at 4 C, followed
by determination of enzyme activity. Alternatively, lysate were
preincubated with the compounds for 10 min followed by subse-
quent dilution (1:2 or 1:4) and determination of enzyme activity
[42]. Data (mean ± SD) were normalized to vehicle control (DMSO)
and obtained from at least three independent experiments.2.5. Determination of 11b-HSD2 activity in intact cells
11b-HSD2 activity measurement in intact SW-620 and MCF-7
cells was determined as described earlier [43]. Briefly, 100,000
SW-620 and 50,000 MCF-7 cells per well were seeded in 96-well
plates. The medium was replaced after 24 h by 40 lL steroid-
and serum-free DMEM (DMEMsf) containing either vehicle or inhi-
bitor and 10 lL medium containing 10 nCi radiolabeled cortisol
and unlabeled cortisol to reach a final concentration of 50 nM.
SW-620 cells were incubated for 4 h and MCF-7 cells for 5 h at
37 C, followed by analysis of steroid conversion by TLC and scin-
tillation counting.2.6. Determination of 17b-HSD1 and 17b-HSD2 activity in cell lysates
Determination of 17b-HSD1 and 17b-HSD2 activity was con-
ducted as described earlier [44]. Briefly, lysates of HEK-293 cells
transiently expressing human 17b-HSD1 and 17b-HSD2 were incu-bated for 10 min at 37 C in a total volume of 22 lL in the presence
200 nM estrone containing 50 nCi of [2,4,6,7-3H]-estrone and
500 lM NAPDH for 17b-HSD1, and with 200 nM estradiol contain-
ing 50 nCi of [2,4,6,7-3H]-estradiol and 500 lMNAD+ for 17b-HSD2
activity measurements. Steroids were separated using TLC and
substrate conversion determined by scintillation counting. Data
(mean ± SD) were normalized to vehicle control (DMSO) and
obtained from at least three independent experiments.2.7. Determination of 11b-HSD activity in mouse and rat kidney
homogenates
Mouse (C57BL6) and rat (Wistar) kidney tissue from adult
males were snap frozen in liquid nitrogen and stored at 80 C
until further use. For homogenate preparation, frozen tissue was
sonicated in homogenization buffer (250 mM sucrose, 10 mM
HEPES, pH 7.4; 900 lL for 100 mg of kidney) and centrifuged at
2000g, 4 C for 10 min to remove cell debris. The total protein con-
centration was determined by BCA assay [45]. The homogenates
were prediluted to a protein concentration of 3.75 mg of protein/
mL (mouse) or 10 mg of protein/mL (rat) in homogenization buffer.
Reactions were performed in a total volume of 22 lL incubation
buffer (300 mM NaCl, 20 mM Tris(hydroxymethyl)aminome
thane-hydrochloride, 1 mM EDTA, 10% glycerol, pH 7.7) containing
0.075 mg/mL of mouse and 0.2 mg/mL of rat total kidney protein,
respectively, as well as 10 lM of test compound, 50 nM of corticos-
terone (containing 50 nCi [1,2,6,7-3H] corticosterone) and 500 lM
NAD+ at 37 C for 20 min. Approximately 20–25% of the substrate
were converted. The steroids were separated by TLC and conver-
sion of radiolabeled substrate was measured by scintillation
counting.2.8. Docking
Docking was performed using GOLD 5.2 (The Cambridge Crys-
tallographic Data Centre, Cambridge, UK, [46]) based on a crystal
structure of 11b-HSD1 (co-crystallized with (2R)-4-[4-fluoro-2-(tri
fluoromethyl)phenyl]-2-methyl-1-([3-(1H-1,2,4-triazol-1-yl)ph
enyl]sulfonyl)piperazine, PDB code 3HFG [47]) and a homology
model for human 11b-HSD2 [48] and murine 11b-HSD2 [49]. The
PDB entry 3HFG was chosen for two reasons. First, it was the tem-
plate for generating the homology model of human and murine
11b-HSD2. Second, the co-crystallized inhibitor is of similar size
as some of the investigated antifungals and contains a triazole moi-
ety. It therefore probably constitutes a binding site conformation
suitable for docking this class of 11b-HSD1 inhibitors.72
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radius around the coordinates X = 19.50 Y = 4.00, Z = 14.25.
ChemPLP was used as scoring function. As workflow validation,
redocking of the original ligand was performed using default set-
tings and the best ranked pose deviates from the crystal structure
with an RMSD of 0.856 for 11b-HSD1. As both the homology mod-
els for human and murine 11b-HSD2 were initially based on PDB
entry 3HFG, the same coordinates were used to define the binding
site for this docking. For human 11b-HSD2, the docking was addi-
tionally repeated setting Arg212 as flexible amino acid. The bind-
ing poses were analyzed using LigandScout 4.1 [50] (Inte:Ligand
GmbH, Vienna, Austria).
3. Results
3.1. Virtual screening of the DrugBank database using a 11b-HSD
pharmacophore model and virtual hit selection for biological
evaluation
Despite its role in the regulation of electrolyte balance and car-
diovascular function and its importance during pregnancy to con-
trol the in utero environment and therefore fetal growth and
development, 11b-HSD2 is not included in current drug off-target
screenings. Thus, the present project aimed to evaluate some
approved drugs for their ability to interfere with 11b-HSD2 activ-
ity. For this purpose, the FDA-approved small molecule drug
entries of the DrugBank database were subjected to VS using a pre-
viously developed 11b-HSD pharmacophore model (Fig. 1A) [39].
This model is not expected to discriminate between 11b-HSD1
and 11b-HSD2 inhibitors because no crystal structure is available
for 11b-HSD2 and the model is, at least in part, built based on
available 11b-HSD1 ligands. Of the 1543 DrugBank entries, 101
approved drugs fitted into the model. Not surprisingly, several
steroidal compounds (in total 18 hits) including mainly glucocorti-
coids, were among the hits. Besides, the virtual hit list contained
several prostaglandin analogues as well as anti-infective agents,
including antifungals, antibiotics and antiparasitic agents. Antifun-
gals were especially represented by the class of azole fungicides,
with sertaconazole, butoconazole and tioconazole as virtual hits
(Fig. 1B). The majority of antibiotics comprised b-lactam antibi-
otics and lincosamides, with cloxacillin, flucloxacillin and nafcillin,
as well as clindamycin and lincomycin as representative structural
classes. Further virtual hits included members of the classes of anti
hypertensives/antiarrhythmics, diuretics, lipid lowering drugs,
antidiabetics, analgesics and antipsychotics. Several hits from the
VS, belonging to the different structural classes mentioned above
and available through an in-house chemical repository, were
selected for biological assessment.
3.2. Effect of selected virtual hits and further structurally related
compounds on 11b-HSD activity
The selected compounds were first tested for their potential to
inhibit cortisol to cortisone conversion in lysates of HEK-293 cells
stably expressing human 11b-HSD2. The selectivity over the clo-
sely related 11b-HSD1 was then determined by measuring the
effect of the chemicals on the conversion of cortisone to cortisol.
The selected steroids (nandrolone), antiarrhythmics (amiodarone),
lipid lowering drugs (atorvastatin, simvastatin), diabetics (rosigli-
tazone), diuretics (ethacrynic acid), analgesics (indomethacin,
nabilone), antipsychotics/sedative (chlorpromazine), the uricosuric
probenecid, antiparasitic agents (amodiaquine, chloroquine and
pentamidine), b-lactam antibiotics (cloxacillin, flucloxacillin and
nafcillin), lincosamides (clindamycin and lincomycin) and the
steroid-like antibiotic fusidic acid showed no or weak inhibition
(less than 40% inhibition) of 11b-HSD1 and 11b-HSD2 enzymeactivity at a concentration of 20 lM (data not shown). However,
the azole fungicides sertaconazole, butoconazole and tioconazole
showed moderate activity and inhibited 11b-HSD2 at a concentra-
tion of 20 lM, resulting in 61%, 44% and 50% residual activity,
respectively. These azole fungicides were not selective, and they
equally well or preferentially inhibited 11b-HSD1, showing resid-
ual enzyme activities of 35%, 48% and 18%, respectively.
Due to their wide use and partial over-the-counter availability,
and their previous association with 11b-HSDs (triadimefon as a
substrate of 11b-HSD1 and ketoconazole as a weak inhibitor of
11b-HSD1 and 11b-HSD2 [39,51]), additional, structurally related
azole fungicides were selected for biological testing in order to pro-
vide proof of concept in applying pharmacophores as initial filter
for the identification of hazardous compound classes [52]. The bio-
logical analyses using HEK-293 cell lysates expressing recombinant
human enzymes revealed a clear structure-activity relationship
between 11b-HSD selectivity and structural size and shape of the
azoles: the larger the structural size the more potent its inhibitory
activity against 11b-HSD2 and the higher the selectivity over
11b-HSD1 (Fig. 2). One requirement of high activity was a
hydrophobic central region of the azole scaffold linked to a more
polar end. The compounds with a smaller scaffold preferentially
inhibited 11b-HSD1. In addition, the subdivision of azoles in imida-
zole and triazole derivatives revealed a further relationship. Imida-
zoles such as tioconazole, sertaconazole and butoconazole
preferably inhibited 11b-HSD1 over 11b-HSD2, whereas triazoles
such as terconazole, posaconazole and itraconazole more potently
inhibited 11b-HSD2. Albendazole, possessing a small azole scaffold
containing a benzimidazole structure, was inactive against both
enzymes. The most potent 11b-HSD2 inhibition was found for itra-
conazole and posaconazole, with IC50 values of 139 ± 14 nM and
460 ± 98 nM (Fig. 3), respectively, and selectivity over 11b-HSD1
(Fig. 2). Furthermore, as itraconazole is mainly metabolized to the
pharmacologically active OHI, this metabolite was also tested,
yielding an IC50 value of 223 ± 31 nM against 11b-HSD2. Irreversible
11b-HSD2 inhibition by itraconazole, OHI and posaconazole was
excluded by preincubation experiments; however, preincubation
did not alter the inhibitory effect, suggesting a competitive mode
of inhibition in line with competition for substrate binding.
3.3. Selectivity assessment of the azole fungicides over 17b-HSD1 and
17b-HSD2
Although 11b-HSD2 and 11b-HSD1 are responsible for the inter-
conversion of the same substrate, i.e. glucocorticoids, they are distant
homologs sharing only about 18% sequence identity [53]. In contrast,
human 17b-HSD2 is more closely related to 11b-HSD2 with about
45% amino acid sequence identity. 17b-HSD2 is predominantly
involved in the metabolism of sex steroid hormones, inactivating
estradiol to estrone, testosterone into D4-androstene-3,17-dione
(androstenedione), 5a-dihydrotestosterone (DHT) into 5a-
androstanedione or 5-androstene-3b,17b-diol to dehydroepiandros-
terone (DHEA). The reverse reaction of activating the weak estrogen
estrone to the potent estradiol and to aminor extent DHEA to 5-andros
tene-3b,17b-diol is catalyzed by 17b-HSD1. Due to the high expression
of 17b-HSD1 and 17b-HSD2 in placenta [54,55], itraconazole, OHI and
posaconazole were assessed for their potential to inhibit 17b-HSD1
and 17b-HSD2 enzyme activity in lysates of HEK-293 cells transiently
expressing human 17b-HSD1 and 17b-HSD2. None of the compounds
inhibited 17b-HSD1 or 17b-HSD2 activity (data not shown).
3.4. Species-specific 11b-HSD2 inhibition by the selected azole
fungicides
Earlier studies emphasized the importance to assess species-
specific differences of 11b-HSD1 and 11b-HSD2 inhibitors, espe-73
Fig. 2. Structure-activity relationship of azole fungicides inhibiting 11b-HSDs. 11b-HSD1-dependent reduction of cortisone (200 nM) to cortisol and 11b-HSD2-dependent
oxidation of cortisol (200 nM) to cortisone were measured using HEK-293 cell lysates in the presence of 500 lMNADPH or NAD+, respectively. Residual enzyme activity upon
exposure to 20 lM test substance (mean ± SD) and IC50 values (mean ± SD) were obtained from three independent experiments. For compounds with residual enzyme
activities (% of control) >40%, at a compound concentration of 20 lM, IC50 values were not determined (n.d.). a, values reported earlier by Vuorinen et al. [39].
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prior to designing a rodent study to assess the effect of the selected
azole fungicides on glucocorticoid inactivation, inhibition of 11b-
HSD2 by itraconazole, OHI and posaconazole was further analyzed
in rat and mouse kidney homogenates incubated with 50 nM of the
rodent substrate corticosterone in the absence or presence of
10 lM test compound. In a qualitative comparison to the potent
activity against recombinant human 11b-HSD2, which was
expressed in HEK-293 cells and measured upon incubation with
200 nM of the human substrate cortisol, considerably lower inhibi-
tory activity was detected against the rat and mouse enzymes. The
different concentrations of corticosterone and cortisol used for
rodent and human 11b-HSD2, respectively, reflect the approxi-
mately 5–10-fold affinity difference for these substrates [57,58].
Itraconazole (Fig. 4A) and OHI (Fig. 4B) were at least 10-fold less
potent towards rat and mouse 11b-HSD2 compared to the human
enzyme, while posaconazole (Fig. 4C) tended to be 2 times lessactive against rat 11b-HSD2 and was about 4 times less active
against mouse 11b-HSD2. Although the activities of the human
and rodent enzymes were measured under different conditions,
considering their different physiological substrates, the data sug-
gest a higher inhibitory activity of these azole fungicides towards
human 11b-HSD2 compared to the rodent enzymes.
3.5. Inhibition of 11b-HSD2 in cell models with endogenous enzyme
expression
To determine the inhibitory potential of itraconazole, OHI and
posaconazole in intact cell systems, SW-620 and MCF-7 cells
expressing relatively high endogenous 11b-HSD2 levels [43] were
applied. Itraconazole inhibited 11b-HSD2 in a concentration-
dependent manner with IC50 values of 1.07 ± 0.29 lM in SW-620
and 1.19 ± 0.24 lM in MCF-7 cells. In contrast to the inhibitory
potency ranking observed in lysates of stably transfected HEK-74
Fig. 3. Inhibition of 11b-HSD2 enzyme activity determined in HEK-293 cell lysates.
Lysates of HEK-293 cells stably expressing recombinant human 11b-HSD2 were
incubated for 10 min at 37 C with 200 nM radiolabeled cortisol, 500 lM NAD+ and
increasing concentrations of itraconazole (A), hydroxyitraconazole (OHI) (B) and
posaconazole (C). The substrate conversion was determined and compared to the
enzyme activity in the control samples (0.1% DMSO). Data represent mean ± SD
from three independent experiments.
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values of 0.82 ± 0.18 lM in SW-620 and 0.68 ± 0.20 lM in MCF-7
cells, respectively. Posaconazole did not substantially inhibit 11b-
HSD2 activity, resulting in approximately 60% and 40% residual
11b-HSD2 activity in SW-620 and MCF-7 cells at a concentration
of 5 lM.3.6. Predicted binding of selected fungicides to 11b-HSD1 and 11b-
HSD2
Docking studies with 11b-HSD1 showed two important protein-
ligand interactions for azole fungicides such as sertaconazole andtioconazole: a hydrophobic contact with Tyr183 and a hydrogen
bond of the azole ring with the backbone nitrogen of Ala172
(Fig. 5A). This hydrogen bond interaction was also the only
ligand-coordinating hydrogen bond observed in the 11b-HSD1
crystal structure co-crystallized with a sulfonyl-piperazine inhibi-
tor and thus, presumably essential for the inhibitory activity. In
contrast, terconazole does not form any hydrogen bonds with the
binding pocket of 11b-HSD1. Furthermore, docking of itraconazole
and posaconazole revealed steric clashes with Thr124, Thr222 and
Ala226 of the 11b-HSD1 substrate binding pocket, providing an
explanation for their inactivity towards 11b-HSD1. However, a
major difference between 11b-HSD1 and 11b-HSD2 is the shape
of the binding site entry. While Met233 flanks the binding site
entry of 11b-HSD1, Arg212 replaces this amino acid at the analo-
gous position in 11b-HSD2. The difference in size and electrostatic
properties of these amino acids likely influences the inhibitory
activity. Indeed, all 11b-HSD2 active compounds analyzed formed
an interaction with Arg212. Furthermore, the extended azole scaf-
folds were found to form additional interactions in their docking
poses with 11b-HSD2, pointing towards tighter binding to the pro-
tein. Interestingly, itraconazole and posaconazole did not fit
entirely into the binding site of 11b-HSD2 but rather lined the sur-
face next to the binding site entry with their azole part (Fig. 5B).
Moreover, the additional hydroxyl group of posaconazole was able
to form several hydrogen bonds with the phosphate moiety of
NADPH.
To rationalize the relative selectivity of the three azole com-
pounds to inhibit human 11b-HSD2, they were also docked into
the murine homology model [49]. The murine 11b-HSD2 homology
model revealed some crucial differences in the amino acid
sequence compared to the human 11b-HSD2. Unlike the equivalent
Arg212 on human 11b-HSD2, Arg279 on mouse 11b-HSD2 was not
flanking the binding pocket entrance but oriented away (Fig. 5C).
Furthermore, part of the binding cavity near the cofactor was occu-
pied by Trp276, a residue located outside the binding pocket in
human 11b-HSD2, and this residue caused itraconazole to adopt
a different angle within the binding cavity in the docking simula-
tion. Additionally, the docking poses for itraconazole predicted
no hydrogen bonds with the protein (Fig. 5D). This missing struc-
tural anchoring provides an explanation for the weak activity of
this fungicide towards murine 11b-HSD2. Interestingly, regarding
murine 11b-HSD2, posaconazole and OHI showed greater inhibi-
tory activity than itraconazole. Compared to itraconazole these
two fungicides formed interactions with the cofactor via their
hydroxyl groups (Fig. 5E).
One important aspect of in silico-driven screening studies is the
analysis of the predictions and a possible refinement of the model
that was used for screening. The screening model performance was
very powerful, as all three azole fungicides identified by the model
(tioconazole, sertaconazole and butoconazole) inhibited 11b-HSD1
enzyme activity at a concentration of 20 lM by at least 50%. How-
ever, although itraconazole and posaconazole were represented in
the DrugBank, they were not found by the model as virtual hits. A
previous refinement study on this model [39], addressed the shape
restriction as one major restrictivity aspect. Shape deletion and
subsequent VS of all tested compounds, including OHI, with this
model retrieved all compounds except for climbazole as hits. For
more thorough VS for potential 11b-HSD inhibitors, the shape-
less model version may therefore be more suitable.4. Discussion
Molecular modeling-based in silico approaches are important in
drug development for the identification of bioactive molecules.
Pharmacophore-based VS is a powerful strategy to enrich poten-75
Fig. 4. Inhibition of rat and mouse 11b-HSD2 activity measured in kidney homogenates, compared to human 11b-HSD2 in HEK-293 cell lysates. Rat and mouse kidney
homogenates were incubated for 20 min at 37 C with 50 nM radiolabeled corticosterone in the absence or presence of 10 lM itraconazole (A), 10 lM hydroxyitraconazole
(OHI) (B) or 10 lM posaconazole (C). Human 11b-HSD2 activity was measured in HEK-293 cells stably expressing recombinant human 11b-HSD2 upon incubation for 10 min
at 37 C with 200 nM radiolabeled cortisol, 500 lMNAD+ and the corresponding concentration of azole fungicide (10 lM itraconazole, 10 lM posaconazole or 5 lMOHI). The
substrate conversion was calculated (in nmoles/min) and normalized to the enzyme activity in the control sample (0.1% DMSO). Data represent mean ± SD from at least three
independent experiments. a, 5 lM was used (due to complete inhibition higher concentrations were not analyzed).
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thereby facilitating the identification of drug lead structures [59].
Such in silico tools are also applied in anti-target screenings; how-
ever, in contrast to lead compound identification this is more chal-
lenging since this approach aims to identify all potentially harmful
substances. The present study applied a pharmacophore model
based on 11b-HSD1 crystal structures for VS of the DrugBank data-
base to find approved drugs that might inhibit 11b-HSD2, an
enzyme not included in current off-target screenings during drug
development. The goal was to identify, as a first step, structural
compound classes inhibiting 11b-HSD2, followed by a more
detailed analysis of a selected compound class including an
in vitro validation of selected virtual hits.
The pharmacophore model used in this study demonstrated
already earlier high predictive power [60], and azole fungicides
have been previously associated with 11b-HSDs: The azole fungi-
cide triadimefon was reported to be a substrate of 11b-HSD1 (Km
3.5 lM), thereby acting as a weak competitive inhibitor (IC50
15 lM) [51]. Ketoconazole was found to have weak inhibitory
effects towards 11b-HSD1 and 11b-HSD2 [39,61]. Thus, this com-
pound class was chosen for further investigations. Biological eval-
uation revealed several azole fungicides as 11b-HSD inhibitors,
showing a significant structure-activity relationship between azole
scaffold size and 11b-HSD enzyme selectivity and potency of inhi-
bition. The large scaffolds of itraconazole and posaconazole, which
were not initial VS hits, potently inhibited 11b-HSD2 enzyme
activity. Compared to terconazole, which was considerably less
active on 11b-HSD2, itraconazole and posaconazole contain an
extended hydrophobic central region and an additional triazolone
side chain, which may form additional stabilizing interactions with
the binding pocket, including Arg212, thereby providing an expla-
nation for the potent inhibition. Thus, the VS approach has proven
useful to identify azole fungicides as 11b-HSD2 inhibitors and to
prioritize this compound class for further biological analyses,
which were necessary to identify the most potent compounds itra-
conazole and posaconazole.
Itraconazole and posaconazole are clinically used for the pro-
phylaxis and treatment of systemic mycotic infections and exert
their mode of action by inhibiting the biosynthesis of ergosterol,
an essential component of the fungal cell membrane [62,63]. They
can be applied for a prolonged period of time, up to years when
used as prophylactic treatment, especially in immunosuppressed
patients [64]. After oral exposure, itraconazole is extensively
metabolized in the liver by cytochrome P450 3A4 (CYP3A4) to itsmain metabolite OHI, which retains potent 11b-HSD2 inhibitory
activity. Thus, cortisol-dependent MR and GR activation due to
prolonged 11b-HSD2 inhibition may contribute to the observed
adverse effects of these fungicides. In contrast to itraconazole, hep-
atic metabolism of posaconazole plays a minor role and mainly
involves conjugation by UDP-glucuronyltransferase UGT1A4 [65].
Although posaconazole is not a substrate of CYP3A4, it acts like
itraconazole and OHI as a potent CYP3A4 inhibitor and it is there-
fore prone to considerable pharmacokinetic interactions with
CYP3A4 substrates, including glucocorticoids [66,67]. Inhibition
of CYP3A4 by a single dose of itraconazole was shown to signifi-
cantly decrease the formation clearance (CLf) of the metabolites
6b-hydroxycortisol and 6b-hydroxycortisone [68]. Plasma cortisol
and cortisone concentrations were not altered, indicating negative
feedback regulation by the HPA axis and suggesting that cortisol
levels are locally increased in CYP3A4 expressing tissues, particu-
larly in the liver. Itraconazole, OHI and posaconazole might further
promote local glucocorticoid effects by inhibiting P-glycoprotein
(P-gp) mediated cortisol efflux [69,70]. Besides its important role
in the liver, P-gp expression has been detected in the human pla-
centa from the first trimester to full-term [71] and P-gp was shown
in vitro to support the placental 11b-HSD2 glucocorticoid barrier
[72].
Inhibition of 11b-HSD2 by itraconazole and posaconazole might
impair glucocorticoid inactivation in the kidney, colon, vasculature
and placenta. Indeed, Denolle et al. reported a case study of a
patient on long-term itraconazole treatment developing hypokale-
mia, edema, hypertension, low plasma renin and aldosterone con-
centrations and normal serum cortisol, typical symptoms of AME
as a result of cortisol-dependent MR activation [73]. Similar side
effects including hypokalemia, edema, hypertension and mildly
reduced aldosterone serum levels were described by Sharkey
et al. for several patients during long-term itraconazole use [74].
Importantly, the drug safety sheet of Sporanox (itraconazole)
reports hypokalemia and edema as occasionally (P1/1000,
<1/100 patients) occurring, whereas the safety sheet for the i.v.
solution of Noxafil (posaconazole) notes hypokalemia as one of
the most likely occurring adverse effect (22% of the reports) and
a rise in blood pressure as frequent (1/100, <1/10) [75,76].
Due to the high plasma protein binding capacity of itraconazole
(99.8%), OHI (99.6%) and posaconazole (P98%), predominately to
albumin, the circulating fraction of unbound drug is low [75,76].
However, in specific situations the plasma protein binding capacity
can be reduced. Pregnancy leads to several metabolic and physio-76
Fig. 5. Predicted binding of selected fungicides to 11b-HSD1 and 11b-HSD2. (A) Representative binding poses of inhibitors in human 11b-HSD1 exemplified by tioconazole
and sertaconazole. Important interactions for protein-ligand binding and the cofactor are shown in ball-and-stick style. Hydrophobic contacts between the ligand and the
binding site are represented as yellow spheres, the HBA to Ala172 as red arrow and the aromatic stacking with Tyr183 as blue circle. (B) Binding mode of itraconazole docked
into the homology model of human 11b-HSD2. (C) Itraconazole docked into the homology model of murine 11b-HSD2. Arg279 (equivalent to Arg212 in human 11b-HSD2) is
pointing away from the binding pocket, while Trp276 blocks the binding pocket next to the cofactor NADPH. (D) Itraconazole docked into the homology model of murine 11b-
HSD2. The ligand is not anchored via hydrogen bonds or charged interactions, only hydrophobic contacts (yellow spheres) are formed. (E) Posaconazole (grey) and OHI
(green) docked into murine 11b-HSD2. Their hydroxyl groups form hydrogen bonds (green arrow) with the cofactor, which provides an explanation for their higher activity
compared to itraconazole.
100 K.R. Beck et al. / Biochemical Pharmacology 130 (2017) 93–103logic changes, including a decrease in serum albumin levels to
about half of those in non-pregnant women. Considering this
change, the unbound fraction of itraconazole/OHI and of posacona-
zole in plasma at steady state conditions during 200 mg b.d.i. itra-
conazole or 400 mg b.d.i posaconazole treatment [75,77] can be
roughly estimated to reach IC25 values of itraconazole (78 nM)
and posaconazole (237 nM) for 11b-HSD2 as determined in HEK-
293 cell lysates. Despite the high plasma protein binding ability,
extensive extravascular distribution and accumulation in tissues
are of considerable importance for these lipophilic compounds.
Itraconazole was found to exceed plasma concentrations in fat tis-
sue approximately 17-fold and in lung, liver, muscle and kidneyabout 2–3-fold [64]. Less data are available for posaconazole,
although it was shown that posaconazole concentrations are 31–
42-fold higher in pulmonary alveolar cells compared with plasma
[78]. Thus, the concentration of these triazole fungicides might also
be elevated in placental tissue compared with plasma and there-
fore may reach relevant concentrations to inhibit 11b-HSD2
enzyme activity.
Animal studies revealed embryotoxicity and teratogenicity with
craniofacial and skeletal anomalies at concentrations exceeding
those obtained at the maximum recommended human dose by
5–20-fold during itraconazole treatment but at concentrations
lower than those observed at therapeutic doses during posacona-77
K.R. Beck et al. / Biochemical Pharmacology 130 (2017) 93–103 101zole treatment [75,76]. Therefore, it is recommended to use these
drugs in pregnancy only if the benefit outweighs the potential risk.
Extrapolation of findings from animal studies to human is often
difficult due to species-specific differences. The present study pro-
vides evidence for a considerably weaker inhibition of mouse and
rat 11b-HSD2 by itraconazole and OHI, and lower activity of
posaconazole towards the rodent enzymes. Thus, 11b-HSD2-
related effects on electrolyte balance, cardiovascular system and
placental barrier function would be detected in rodent models only
at much higher concentrations than in humans. Furthermore,
regarding the latter, animal studies might be unreliable due to
the highly variable 11b-HSD2 expression levels during gestation
between different species. Mouse placental 11b-HSD2 mRNA drops
towards late gestation, while rat placental 11b-HSD2 reduction
occurs later and less pronounced. In contrast, human placental
11b-HSD2 levels are rising during gestation (reviewed by [13]).
In a prospective cohort study, de Santis et al. evaluated first tri-
mester exposure to itraconazole in 206 pregnant women compared
with 207 unexposed controls [79]. The mean duration of the ther-
apy was 6.9 ± 6.4 days with a daily dose of 182 ± 63 mg. No statis-
tical difference between the exposed and the control group was
found in terms of major congenital anomalies, premature birth or
birth weight, but rates of live births and spontaneous abortion
were higher in the exposed group. Bar-Oz et al. reported in a retro-
spective cohort study four times higher congenital malformation
rates after first trimester exposure to itraconazole; however,
strongly suggesting reporting bias due to retrospective data analy-
sis [80]. The same authors found no difference in the rate of mal-
formations compared to the control in a prospective cohort study
with 229 women exposed to 50–800 mg itraconazole daily
throughout 8.5 ± 12.4 days during the first trimester of pregnancy
[81]. However, the rate live birth and the mean birth weight were
lower in the exposed group compared to the control. No human
data for prenatal posaconazole exposure have been published so
far.
Developmental programming implies that an environmental
factor affects fetal development during a sensitive time window
to predispose the fetus towards diseases permanently throughout
life [15]. A critical parameter includes the duration of the exposure
to an environmental factor. The mean prenatal itraconazole expo-
sure reported by de Santis et al. and Bar-Oz et al. was 6.9–8.5 days,
thus shorter than the 15 days of treatment needed to reach plasma
steady-state levels of itraconazole. This is important regarding
11b-HSD2 inhibition and thus prenatal programming through glu-
cocorticoids. Several investigations found a reduction in birth
weight in infants exposed to multiple courses of antenatal gluco-
corticoid therapy when adjusting for gestational age [82–84]. In
addition, only first trimester itraconazole exposures were exam-
ined in the above described studies, but the effects of dexametha-
sone exposure on birth weight in rats was reported to be more
pronounced when administered during later stages of pregnancy
[85]. Chronic glucocorticoid treatment in mice was observed to
impair the development of the cerebellum through inhibition of
Sonic hedgehog (Shh) induced proliferation, a pathway important
during embryonic growth and postembryonic tissue homeostasis.
By upregulation of 11b-HSD2 expression Shh signaling partly
antagonized the glucocorticoid-dependent effects, thus represent-
ing a feedback mechanism [86]. Interestingly, itraconazole, OHI
and posaconazole were found to inhibit Shh signaling [87–89],
which may result in downregulation of 11b-HSD2 expression,
thereby adding to the direct inhibitory effect of these azole
fungicides.
Elevated glucocorticoid levels are known to inhibit angiogene-
sis, a crucial process during placental development that was shown
to be inhibited by itraconazole [88,90,91]. Insufficient placental
vascularization has been associated with intrauterine growthrestriction, preeclampsia and fetal death, both in human and ani-
mal studies (reviewed by [92]).
In conclusion, itraconazole, OHI and posaconazole were identi-
fied as novel potent inhibitors of human 11b-HSD2 by VS of the
DrugBank database using an 11b-HSD pharmacophore model. Inhi-
bition of placental 11b-HSD2 by these azole fungicides might con-
tribute to an elevated local increase in cortisol levels, in addition to
the known inhibition of cytochrome P450 enzymes and P-gp,
thereby affecting fetal programming. Due to the observed
species-specific differences, the consequences of placental 11b-
HSD2 inhibition may have been overlooked in preclinical studies
using rodents, although similar biological responses might be
detected in rodents, albeit at higher concentrations.
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3.1.2. Discussion 
 
Pharmacophore-based VS facilitates the identification of lead structures by enriching potentially active 
virtual hits among an abundant number of possible test compounds. While highly helpful during drug 
development, the implementation for anti-target screenings remains rather challenging as this 
application intends to find all conceivably active (and harmful) substances. To address this issue, the 
identification of compound classes, which can then be further biologically evaluated may be a 
promising alternative. The virtual hit list of the DrugBank Database screening for the identification of 
11β-HSD2 inhibitors, included among other hits, several antifungal agents, especially represented by 
the class of azole fungicides. In vitro assessment of the virtually retrieved azole fungicides and further 
structurally related compounds revealed a significant structure-activity relationship (SAR) between 
azole scaffold size, selectivity and inhibitory potency toward 11β-HSD2 and the closely related 11β-
HSD1. An extended hydrophobic central region of the azole scaffold connected to a more polar end 
was observed to be favorable for 11β-HSD2 inhibition, demonstrated by the most potent 11β-HSD2 
inhibitors itraconazole, its metabolite hydroxyitraconazole (OHI) and posaconazole. Docking 
calculations predicted major differences between 11β-HSD1 and 11β-HSD2 in the shape of their 
binding site entry, allowing the extended azole scaffolds to interact with Arg212, while a Met is situated 
at the binding site entry of 11β-HSD1. Importantly, these compounds were not retrieved as hits by the 
VS, although available in the screening library. This emphasizes and supports the approach of using VS 
as an initial filter to identify hazardous compound classes rather than individual compounds.  
Clinical evidence for 11β-HSD2 inhibition by itraconazole comes from case studies including patients 
on long-term treatment developing typical symptoms of AME [29, 30]. Due to the delayed market 
launch of posaconazole (Noxafil®), less data is available. However, a recent report described a case of 
AME secondary to posaconazole therapy and stated a serum posaconazole concentration in the 
patient that exceeded the IC50 value (460 ± 98 nM) determined in our published article [31]. 
Nevertheless, due to the high binding capacity of posaconazole (≥98%), as well as itraconazole (99.8%) 
and OHI (99.6%), to human serum albumin (HSA), the circulating fraction of unbound compound is low 
[32, 33]. This needs to be taken into account when comparing drug serum concentrations with IC50 
values determined in vitro as well as the effect on the binding capacity by diverse physiological and 
pathophysiological conditions such as pregnancy, inflammation, cancer or hemodialysis which can 
alter HSA levels [34]. Besides, extensive extravascular tissue distribution to liver, lung, kidney, fat tissue 
and muscles with concentrations exceeding those found in plasma have been reported for these 
lipophilic compounds [35, 36]. Thus, the concentration of azole fungicides can highly vary between 
different tissues and should be considered for data evaluation. Unfortunately, the authors did not 
specify further mechanisms additionally contributing to locally elevated cortisol levels such as the 
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potent inhibition of cytochrome P450 (CYP) 3A4 and P-glycoprotein (P-gp) efflux transport by 
posaconazole [37, 38].  
The effects mediated by azole-dependent 11β-HSD2 inhibition may have been overlooked in animal 
studies using rodents due to the observed species-specific differences. Considerable weaker rat and 
mouse 11β-HSD2 inhibition by itraconazole, OHI, and to a lesser extent by posaconazole, measured in 
kidney homogenates, was detected. Even though similar biological effects in rodents are expected at 
higher concentrations, these observations could be biased through the extended target promiscuity 
and/or unspecific binding at higher compound concentrations. Furthermore, the expression of 
placental 11β-HSD2 is highly variable during gestation between the different species, making the 
extrapolations from animals to humans even more difficult (reviewed in [39]). The molecular 
mechanisms behind the question how altered fetal glucocorticoid exposure may affect fetal growth 
and predispose the fetus towards diseases later in life are not yet understood. Hence, azole fungicides 
may exert their potential adverse effects towards the fetus by changing the environment through 
regulation of the glucocorticoid accessibility and thereby reduce glucose and increased amino acid 
transport through the placenta, as it was shown for 11β-HSD2-deficient mice [40]. Alternatively, azole 
fungicides may lead to an insufficient placental vascularization by inhibiting angiogenesis [41-43]; or 
may directly affect the fetal development by interfering with fetal target structures such as the Sonic 
hedgehog (Shh) signaling [41, 44-46]. Clearly further research is needed to address these questions.  
Another molecular mechanism potentially underlying the developmental programming effects involve 
epigenetic alterations in the target gene promoters. Epidemiological studies in humans revealed that 
early life environmental conditions can lead to epigenetic changes, which are retained throughout life. 
Individuals prenatally exposed to famine during the Dutch Hunger Winter showed, six decades later, 
less DNA methylation of the insulin-like growth factor II (IGF2) gene compared with their unexposed, 
same-sex siblings [47]. Several studies provided evidence suggesting epigenetic regulation of placental 
11β-HSD2 as a mechanistic connection linking maternal environment, infant birth and long-term 
consequences for an affected offspring [48-52]. This programming may affect the direct offspring as 
well as the subsequent generations. Rats that had been exposed prenatally to dexamethasone, but 
were not manipulated during their own pregnancy, had offspring with reduced birth weight and 
glucose intolerance, effects observed until the third generation [53]. Thus, epigenetic changes may 
display an important factor for the (intergenerational) appearance of the ‘programmed phenotype’ 
and needs further comprehensive investigations. However, to understand how early life exposure 
controls epigenetic changes and thus potentially the health over a lifetime, requires further epigenetic 
epidemiologic studies that need to be large and include replication [47]. This challenging suggestion 
may play a part in the mapping of the exposome, discussed below. 
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Metabolites can display equal or even higher potency towards certain targets compared to their parent 
substances. Thus, EDC safety evaluation studies should include in the assessment besides the parental 
compound also the main metabolites, as it was done in the present study for itraconazole and OHI. 
Moreover, a parental compound could be assessed in vitro as safe, but a metabolite may cause harmful 
effects. For instance, no inhibitory activity of the UV-filter benzophenone 3 (BP-3) was detected 
towards 17β-HSD3, whilst in vivo BP-3 is rapidly demethylated to the potent 17β-HSD3 inhibitor BP-1 
[54, 55]. However, these evaluations are often limited, due to incomplete knowledge of the metabolite 
spectrum or the implementation of cell-free testing systems, as it is typically the case in early screening 
phases with high throughput screenings (HTS), as for example in the Tox21 project. Intact cells as 
testing systems can only partially overcome this problem; for example, immortalized hepatocyte-
derived cell lines are highly dedifferentiated and show only very limited expression of metabolic 
enzymes. Although primary hepatocytes sustain the major drug-metabolizing enzymes for a certain 
time period in cell culture, they have a great variability in genotype, short life span, and limited 
availability [56, 57]. In addition, also the metabolism by phase II enzymes, which are involved in 
conjugation reactions, as well as transport proteins should be integrated due to their ability to facilitate 
and accelerate the excretion of compounds and therefore to reduce exposure levels and the 
probability to cause toxic effects (example in the section below in the published article: ‘Evaluation of 
tetrabromobisphenol A effects on human glucocorticoid and androgen receptors: a comparison of 
results from human- with yeast-based in vitro assays’ [58]). Thus, in vivo studies and a careful 
consideration of epidemiological data are vital and essential for an appropriate EDC safety assessment.  
This leads to another limitation of the ‘common’ way of EDC evaluation – mixtures. The majority of 
compounds are analyzed as single substances; however, an individual is concurrently exposed to a 
multitude of different exogenous compounds. Taking this into account, makes the safety assessment 
of EDCs even more difficult; compound-compound interactions, additive or opposite effects and 
synergistic action represent only a few and evident examples. Which compounds and at what ratios 
should they be selected; do they act on different target structures, tissue-specifically - to mention some 
questions which could arise. Hence, this issue was realized and resulted in the introduction of the 
exposome, the analysis of the life-course environmental exposures (including lifestyle factors), from 
the prenatal period onwards [59]. The evolving field of ‘omics’ approaches was thereby addresses as 
promising technologies to improve EDC risk assessment and to support the identification of individual 
susceptibilities by targeted biomarkers, which should reconstruct past exposure [60]. However, 
mapping the entire exposome might be extremely challenging if not even impossible due to the 
complexity of a life-time exposure burden [61]. The variety of confounding variables such as stress, 
genetic polymorphisms, socioeconomic status and general lifestyle including diet is immense, apart 
from knowing of an exposure to have been occurred (e.g. prenatally) or sensitive methods to detect 
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them. Another major challenge regarding exposome analysis remains the definition of normal range 
and distinguishing between deviations due to adaptive responses and adverse health effects. The 
concept, nevertheless, is a paradigm shift, albeit the feasibility is still questionable and further research 
is evidently required [62]. 
Further limitations of in vitro testing systems in EDC assessment and evaluation strategies are 
discussed in the section below.   
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3.2. In vitro testing systems – validation - limitations 
 
Successful application of in silico tools requires accurate in vitro validation strategies. However, the 
limitations of each in vitro testing system should be carefully taken into account and considered during 
data interpretation. The analysis of enzymatic activities demands conduction under cell-free conditions 
such as purified protein or cell lysates expressing the protein of interest at a low background 
environment. Data acquired in intact cell models lack direct target access and can therefore only be 
employed for the verification of active hits. Compound-target interactions in intact cell systems highly 
depend on the prevailing expression of transport proteins, intracellular binding proteins or other 
metabolizing enzymes, limiting thereby the availability of a compound at the target structure. Whereas 
parameters such as cell handling, passage number of a cell line or medium composition can influence 
cell-based assays, similar problems may arise in the preparation of purified proteins or cell lysates, 
where different handling procedures can lead to different enzyme activities, for example due to altered 
protein conformation, loss of interacting partner proteins and/or oligomer structure. The application 
of suitable positive and negative controls allows the detection of alterations in the testing system itself 
and facilitates the comparison with results obtained by other investigators. Nevertheless, 
comprehensive biological characterization and the usage of different assay read-outs are crucial for an 
in vitro validation. The published review ‘Virtual screening applications in short-chain 
dehydrogenase/reductase research’ provides further insight into the limitations of virtual hit validation 
in biological systems [9].  
The same challenges arise for all applications where in vitro testing systems are used. Such testing 
systems are widely employed during the safety evaluation process of EDCs and gained even more 
importance since chemicals used in body care products are no longer be allowed to be tested in 
animals. To study EDC action on hormone receptors, many assays make use of receptor-mediated 
activation of reporter genes in human cell lines. A cost-effective alternative are yeast reporter cell 
assays, often applied for HTS in ecotoxicology. However, the Organization for Economic Co-operation 
and Development (OECD) issued a guidance document for the assessment of EDCs in which they 
excluded yeast estrogen and yeast androgen screens as a result of transport issues, limited cell 
membrane permeability, and insufficient capability to distinguish between compounds activating or 
suppressing the receptor activity [63]. 
In this regard, the following study addressed the re-evaluation of a potential EDC on GR and AR 
function. The widely used flame retardant tetrabromobisphenol A (TBBPA) was reported to exert 
potent antagonistic activity on GR and to a lesser extent on AR in yeast-based reporter gene assays 
[64]. However, the applied yeast GR assay displayed very low sensitivity towards the potent GR ligand 
dexamethasone, resulting in a need of high dexamethasone concentrations (60 µM) used for reporter 
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gene activation. As already pointed out in the section above, the inclusion of suitable controls can lead 
to the identification of inconsistencies in the assay performance, for example such as the requirement 
for exceptionally high positive control concentrations. Unfortunately, the authors from this study did 
not provide further experiments to confirm their data obtained from the yeast reporter assays. Thus, 
the re-evaluation aimed to assess the impact of TBBPA on GR and AR function by performing cell-free 
receptor displacement and human cell-based transactivation assays.  
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A B S T R A C T
The incidence of immune-related diseases increased over the last years in industrialized countries,
suggesting a contribution of environmental factors. Impaired glucocorticoid action has been associated
with immune disorders. Thus, there is an increasing interest to identify chemicals disrupting
glucocorticoid action. The widely used ﬂame retardant tetrabromobisphenol A (TBBPA) was reported
earlier to potently inhibit glucocorticoid receptor (GR) and moderately androgen receptor (AR) activity in
yeast-based reporter gene assays. To further characterize possible GR disrupting effects of TBBPA,
transactivation experiments using a human HEK-293 cell-based reporter gene assay and cell-free
receptor binding experiments were performed in the present study. Both, transactivation and GR binding
experiments failed to detect any activity of TBBPA on GR function. Molecular docking calculations
supported this observation. Additionally, the current study could conﬁrm the antiandrogenic activity of
TBBPA seen in the yeast assay, although the effect was an order of magnitude less pronounced in the HEK-
293 cell-based system. In conclusion, TBBPA does not directly affect GR function and, considering its rapid
metabolism and low concentrations found in humans, it is unlikely to cause adverse effects by acting
through AR. This study emphasizes the use of cell-free assays in combination with cell-based assays for
the in vitro evaluation of endocrine disrupting chemicals.
ã 2016 Elsevier Ireland Ltd. All rights reserved.
Contents lists available at ScienceDirect
Toxicology
journal homepa ge: www.elsev ier .com/locate / tox icol1. Introduction
The annual production of chemicals for industry, agriculture,
personal care products, or food processing is continuously rising.
Programs initiated by the authorities such as the Registration,
Evaluation, Authorization and Restriction of Chemicals (REACH)
regulation of the European Union or the Endocrine Disruptor
Screening Program (EDSP) of the U.S. Environmental ProtectionAbbreviations: AR, androgen receptor; EDCs, endocrine disrupting chemicals;
EDSP, Endocrine Disruptor Screening Program; ER, estrogen receptor; GR,
glucocorticoid receptor; HSP, heat shock protein; IARC, International Agency for
Research on Cancer; LOD, limit of detection; MAPK, mitogen activated protein
kinase; NCoR, nuclear receptor corepressor; NK cell, natural killer cell; NTP, U. S.
National Toxicology Program; PCBs, polychlorinated biphenyls; PDB, Protein Data
Bank; P-gp, P-glycoprotein; PR, progesterone receptor; REACH, registration
evaluation authorization and restriction of chemicals; T3, triiodothyronine; T4,
thyroxine; TBBPA, tetrabromobisphenol A; TSH, thyroid stimulating hormone.
* Corresponding author.
E-mail address: alex.odermatt@unibas.ch (A. Odermatt).
http://dx.doi.org/10.1016/j.tox.2016.09.014
0300-483X/ã 2016 Elsevier Ireland Ltd. All rights reserved.Agency aim to improve the safety assessment of man-made
chemicals and thereby protect human health and the environment.
In the past, extensive research focused on endocrine disrupting
chemicals (EDCs) acting on sex steroid hormone action, with a
major focus on estrogen receptor (ER) and androgen receptor (AR)
function. In contrast, rather few studies addressed chemicals
disrupting glucocorticoid action (Macikova et al., 2014; Nashev
et al., 2012; Neel et al., 2013; Odermatt and Gumy 2008; Odermatt
et al., 2006; Stavreva et al., 2012).
Glucocorticoids are regulating the immune system, cell
proliferation and differentiation, brain function, energy metabo-
lism, blood pressure and electrolyte balance. Due to their
immunomodulatory effects, glucocorticoids are still among the
most widely prescribed drugs to prevent graft rejection and to
treat allergic or chronic inﬂammatory disease such as asthma, skin
infections or rheumatoid arthritis (Baschant and Tuckermann,
2010). Experiments in adult mice with keratinocyte-restricted GR
inactivation showed an exacerbated inﬂammatory response to
epidermal challenge, while postnatal mice displayed skin barrier88
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Importantly, the incidence of atopic dermatitis and asthma has
increased over the last decades, with signiﬁcant variations
between and within countries (Eder et al., 2006; Nutten 2015).
Thus, exposure to EDCs that antagonize glucocorticoid receptor
(GR) function may lead to impaired stress responses and
immunosuppression and result in an enhanced susceptibility to
allergies and aggravated inﬂammatory reactions. Environmental
chemicals associated with disturbed GR function at human
relevant concentrations are arsenic and dibutyltin (Gosse et al.,
2014; Gumy et al., 2008; Kaltreider et al., 2001). Arsenic has been
linked to type 2 diabetes, cardiovascular disease, several forms of
cancer, and reproductive and developmental disorders (Abernathy
et al., 1999), whereas dibutyltin is considered to be highly neuro-
and immunotoxic (Jenkins et al., 2004; Whalen et al., 1999). Part of
these effects might be due to interference with glucocorticoid
action. Furthermore, exposure to polychlorinated biphenyls (PCBs)
was observed to induce severe clinical symptoms including skin
lesions, respiratory distress, neurologic disorders, disturbed liver
function and suppression of cellular immunity (Nakanishi et al.,
1985; Reggiani and Bruppacher 1985). Interestingly, several methyl
sulfone metabolites have been shown to act as GR antagonists with
IC50 values in the low micromolar range (Johansson et al., 2005;
Johansson et al., 1998). Thus, it has been hypothesized that they
account at least partially for the respiratory symptoms (Grimm
et al., 2015).
In vitro testing systems are widely applied in the safety
assessment process, and the importance of such testing systems
increased by the decision that chemicals used in body care
products can no longer be tested in animals. Cell-based assays are
used to investigate potential EDCs. Many assays, including the ERa
b-lactamase reporter gene assay in HEK-293 cells, the ERa
luciferase reporter gene assay in BG-1 ovarian cells and the
multiplexed ER reporter gene assay in HepG2 cells that are also
used in the ToxCast21 testing battery (Rotroff et al., 2014), are
based on the receptor-mediated activation of a reporter gene in
human cell lines. Alternatively, green-ﬂuorescence protein report-
er gene assays in yeast cells are used for the detection of potential
EDCs due to the low costs and high throughput capacity of these
assays (Gaido et al., 1997; Routledge and Sumpter 1996). Yeast
strains expressing AR and progesterone receptor (PR) are also
available (Baker, 2001). However, the limitations of these assays
need to be taken into account for data interpretation. The OECD
issued a guidance document for the evaluation of EDCs in which
they excluded the yeast estrogen screen and yeast androgen screen
due to limited cell membrane permeability, transport issues and
insufﬁcient ability to discriminate between agonists and antag-
onists (OECD, 2012).
In a recent study Roelofs et al. investigated the widely used
ﬂame retardant tetrabromobisphenol A (TBBPA) for its potential to
interfere with GR function using recombinant yeast cells express-
ing the human GR and a GR-dependent green ﬂuorescence protein
(Roelofs et al., 2015). They reported a highly potent GR antagonistic
effect of TBBPA with an IC50 value of 22 nM. However, these authors
did not provide additional experiments to support their data from
the yeast GR reporter gene assay. Nevertheless, TBBPA was recently
shown to decrease the secretion of interferon-g from immune cells
(Almughamsi and Whalen, 2016). As possible mechanism, activa-
tion of the ERK1/2 MAPK pathway and of P38 kinase by TBBPA has
been suggested. Since there is a functional interaction between GR
activity and the MAPK pathway, and glucocorticoids are well-
known modulators of inﬂammatory cytokines and chemokines, a
block of GR function by TBBPA may disturb the regulation of the
immune system.
TBBPA covers more than half of the global annual production of
brominated ﬂame retardants (Law et al., 2006). It is mainly appliedin the laminate coating of printed circuit boards, where it is
covalently bound to a polymer matrix and cannot be released into
the environment (ECB, 2006). Nevertheless, up to 20% of the
manufactured TBBPA is used as an additive ﬂame retardant in
electronic equipment, furniture, building and construction mate-
rials, packaging, and consumer products (ECB, 2006). Since
additive ﬂame retardants do not chemically react with their
coated basis, they are prone to leach out of this matrix.
The aim of the current study was to re-evaluate the impact of
TBBPA on GR function by performing cell-free receptor binding
experiments and transactivation experiments in a human HEK-293
cell-based assay. Additionally, the effects of TBBPA on AR-mediated
transactivation and on binding to AR were investigated.
2. Materials and methods
2.1. Chemicals and reagents
[1,2,4,6,7-3H]-dexamethasone and [1,2,6,7-3H]-testosterone
were purchased from American Radiolabeled Chemicals (St. Louis,
MO). Cell culture medium and other chemicals were obtained from
Sigma Aldrich (Buchs, Switzerland).
2.2. Cell culture
Human Embryonic Kidney-293 cells (HEK-293) cells were
cultured in Dulbecco’s modiﬁed Eagle medium (DMEM) supple-
mented with 10% fetal bovine serum, 4.5 g/l glucose, 100 U/ml
penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, pH 7.4,
and 10% MEM non-essential amino acid solution. Sf9 cells were
cultured at 27 C in EX-Cell 420 medium supplemented with 10%
FBS and 100 U/ml penicillin/streptomycin.
2.3. Competitive cell-free receptor binding assay
Recombinant human glucocorticoid receptor a (GR) baculovi-
rus stock was produced using the Bac-to-Bac expression system
and recombinant GR was expressed in Sf9 cells according to the
instructions by the manufacturer (Invitrogen, Carlsbad, CA).
Human androgen receptor (AR) was transiently expressed in
HEK-293 cells upon transfection by the calcium phosphate
precipitation method and cultivation for 72 h. Cells transfected
with pcDNA3 vector served as control.
For preparation of lysates, cells were collected in ice-cold PBS and
centrifuged for 10 min at 3000  g and 4 C, resuspended in binding
buffer (50% glycerol,10 mM EDTA, 50 mM sodium tungstate, 50 mM
HEPES, pH 7.4) and homogenized with 50 strokes using a glass
puller. The lysates were centrifuged (160000  g, 10 min, 4 C) and
supernatants stored at 80 C.
Recombinant human GR lysates were incubated in the
presence of 10 nM [1,2,4,6,7-3H]-dexamethasone and unlabeled
competitor (either 10 mM or 100 nM cortisol or 10 mM TBBPA) for
4 h at 16 C. Human AR lysates were incubated with 10 nM
[1,2,6,7-3H]-testosterone and unlabeled competitor (either tes-
tosterone or TBBPA at different concentrations). Unbound ligand
was separated by adding 5% dextran coated charcoal into the
binding buffer, followed by incubation at 4 C for 10 min and
centrifugation for 10 min at 3200  g and 4 C. The receptor bound
fraction of radioligand in supernatants was measured by
scintillation counting.
2.4. GR- and AR-dependent transactivation assay
HEK-293 cells (100,000 cells/well for GR and 200,000 cell/well
for AR transfection) were seeded in poly-L-lysine coated 24-well
plates, incubated for 24 h and transiently transfected using calcium89
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were transfected with plasmid for human GR (0.3 mg/well), pCMV-
lacZ b-galactosidase transfection control (0.05 mg/well) and TAT3-
TATA luciferase reporter (0.45 mg/well). For the AR transactivation
assay cells were transfected with human AR (0.4 mg/well), pCMV-
lacZ b-galactosidase control (0.025 mg/well) and TAT3-TATA
luciferase reporter (0.375 mg/well). At 6 h post-transfection cells
were washed with DMEM and incubated for another 18 h. The cells
were then washed with steroid-free DMEM (cDMEM) and
cultivated for 3 h at 37 C. This culture medium was then replaced
with fresh cDMEM containing steroid hormones (10, 25 and
100 nM cortisol for GR, 10 nM testosterone for AR), receptor
antagonist (1 mM RU486 for GR and 0.5 mM ﬂutamide for AR) or
TBBPA (10 mM or 1 mM), followed by incubation for 24 h. Cells were
lysed in 60 ml of tropix lysis solution (Applied Biosystems, Foster
City, CA) supplemented with 0.5 mM dithiothreitol and frozen at
80 C for at least 20 min. Luciferase activity was determined in
20 ml lysate adding 100 ml of D-luciferin-ﬁreﬂy substrate solution
at a ﬁnal concentration of 0.47 mM D-luciferin, 53 mM ATP,
0.27 mM coenzyme A, 0.13 mM EDTA, 33.3 mM dithiothreitol,
8 mM MgSO4, 20 mM tricine, pH 7.8. b-galactosidase activity was
measured in 20 ml lysate using the Tropix kit. Samples were
measured using a SpectraMax-L luminometer (Molecular Devices,
Devon, UK).
2.5. Docking of TBBPA into the ligand binding pocket of GR
Docking was performed using the GOLD version 5.2 software
(Chambridge Crystallographic Data Centre, Cambridge, UK) (Jones
et al., 1997). This program applies a genetic algorithm for the
identiﬁcation of accurate docking poses for small molecules into
the binding pocket of a protein. The crystal structure with the
Protein Data Bank (PDB) entry 3H52 [DOI: http://dx.doi.org/
10.1016/j.jmb.2009.11.011] was chosen for the GR protein due to
the antagonistic conformation. First, the co-crystallized ligand
(RU486, also known as mifepristone) was deleted from the bindingFig. 1. Effect of TBBPA on GR binding and activity. (A) Impact of TBBPA on GR transa
corticosteroid receptor-sensitive luciferase reporter gene and a galactosidase transfectio
cortisol (F), 1 mM mifepristone (RU486) or different concentrations of TBBPA. The lucifera
normalized to vehicle control (0.2% DMSO) and represent mean  SD from three ind
radiolabeled [3H]-dexamethasone from GR by unlabeled competitor (either cortisol (F) o
[3H]-dexamethasone and either 10 mM or 100 nM unlabeled cortisol (F) or 10 mM TBBPA
binding of 10 nM [3H]-dexamethasone and represent the remaining [3H]-dexamethasosite and re-docked into the GR binding pocket to investigate
whether GOLD could restore the original binding orientation and
therefore validate the docking settings (RMSD value of 0.057). The
binding site was centered on the primary amine nitrogen of Gln570
(x  48.19; y 16.58; z  36.62) surrounded by a 10 Å sphere.
GoldScore was selected as scoring function. Interactions found
by the docking solutions between the ligand and the GR binding
pocket were evaluated using LigandScout 3.12 (inte:ligand GmbH,
Vienna, Austria). This program automatically analyzes the
observed interaction pattern between the docked ligand and the
protein, based on the chemical functionalities, the geometric
distances and the angles between neighboring structures (Wolber
and Langer, 2005).
2.6. Statistical analysis
Data were analyzed using t-test in the GraphPad Prism 5
software. Values represent mean  SD.
3. Results
3.1. Assessment of TBBPA effects on GR binding and transcriptional
activity
In order to evaluate the potent antagonistic activity of TBBPA on
GR (IC50 22 nM) that was observed in a recombinant yeast reporter
gene assay by Roelofs et al. (Roelofs et al., 2015), a transactivation
assay in HEK-293 cells was employed in the present study. For this
purpose, HEK-293 cells were transiently transfected with human
GR and a GR-dependent luciferase reporter gene (Fig. 1A). As
expected, cortisol at different concentrations induced the GR-
dependent expression of the luciferase activity; however, TBBPA
did not act as an antagonist and no decrease in the cortisol-
dependent GR activation, using 10 nM, 25 nM and 100 nM cortisol,
could be observed when cells were co-treated with 10 mM TBBPA.
A slight, statistically signiﬁcant, increase in reporter gene activityctivation in HEK-293 cells transiently transfected with plasmids for human GR, a
n control. Cells were incubated for 24 h in the presence of 10 nM, 25 nM and 100 nM
se reporter activity was normalized to the internal galactosidase control. Data were
ependent experiments each performed in triplicates. (B) Displacement of 10 nM
r TBBPA). Sf9 lysates expressing recombinant human GR were incubated with 10 nM
 until the binding equilibrium was reached. Values were normalized to the maximal
ne bound to GR. ns (not signiﬁcant); * p < 0.05.
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TBBPA. This may be explained by competition of TBBPA with
cortisol for unspeciﬁc binding sites. Unlike TBBPA, the antagonist
RU486 at 1 mM completely blocked the cortisol-induced GR
activation. Also, TBBPA was not able to induce GR-mediated
activation of the luciferase reporter gene, even at the high
concentration of 10 mM. Thus, an interference of TBBPA with
GR-mediated transactivation could not be demonstrated in this
human cell-based assay.
To exclude limited cellular uptake or potential efﬂux of TBBPA
as a reason for the lack of effect on GR, a competitive receptor
binding assay was performed under cell-free conditions. Lysates of
cells expressing recombinant human GR were co-incubated with
10 nM [3H]-dexamethasone and unlabeled competitor (either
different concentrations of cortisol (F) or 10 mM TBBPA), followed
by determination of the GR bound fraction of [3H]-dexamethasone
(Fig. 1B). TBBPA at a concentration of 10 mM did not substantially
displace the radiolabeled dexamethasone from the receptor, in
contrast to the known ligand cortisol. These results indicate that
TBBPA has no direct effect on GR ligand binding and does not affect
GR transcriptional activity.Fig. 2. Docking of TBBPA and mifepristone into the ligand binding site of GR. Co-crystall
binding domain and a receptor-interacting motif of the nuclear receptor corepressor 
automatically generated pharmacophore maps the important structural details of the liga
with spheres are H-bond interactions). Amino acid residues involved in ligand binding 
spheres) trigger a molecular switch of the helix 12 to reshape the corepressor site (red arr
modulate helix 12. Two-dimensional representation of the binding interactions of RU43.2. Structural modeling of ligand binding to GR
To computationally elucidate the results for TBBPA obtained in
the transactivation and binding assays, docking calculations were
performed to investigate the interactions formed with the GR
ligand binding site and therefore the potential to trigger a
molecular switch of the helix 12. In the X-ray crystal structure,
the GR antagonist RU486 (mifepristone) induces a relocation of the
helix 12 position to reshape the coactivator towards a corepressor
site with the possibility to bind nuclear receptor corepressor
(NCoR) (Schoch et al., 2010) (Fig. 2A and B). TBBPA adopts a
position similar to GR agonists without covering the side pocket
compared to the dimethyl amino phenyl moiety of RU486 in order
to interact with the helix 12 and induce a position change (Fig. 2C
and D). RU486 was found to form hydrophobic contacts with Ile756
and Met752 of helix 12 as well as with Leu2263 and Ile2266 of the
NCoR motif. The only interaction with the helix 12 and TBBPA
found is a hydrophobic interaction with Ile756, but with
considerable larger distances compared to RU486. Furthermore,
the interactions with the GR binding site observed for TBBPA are
mainly of hydrophobic nature with one additional hydrogen bond
(H-bond) involving the sulfur atom of Met560. H-bonds including a
sulfur center are generally considered as weak H-bonds compared
to interactions with oxygen or nitrogen groups. The sameized mifepristone (RU486) (A) and docked TBBPA (B) in complex with the GR ligand
(NCoR) in an active antagonistic conformation (PDB code 3H52, domain A). The
nd for binding (yellow spheres: hydrophobic interactions and red and green arrows
are depicted as sticks. Whereas the interactions formed by RU486 (marked yellow
ow), TBBPA is not able to cover this side pocket and form the required interactions to
86 (B) and TBBPA (D). The color code corresponds with part A and C.
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crystal structure with an agonistic conformation (data not shown).
3.3. Effect of TBBPA on human androgen receptor
The earlier study by Roelofs et al. reported an antiandrogenic
activity of TBBPA with an IC50 value of 982 nM in the yeast AR-
dependent reporter gene assay (Roelofs et al., 2015). In order to
compare these earlier observations from the yeast GR and AR
reporter gene assays with our human cell-based systems, an AR
transactivation assay in HEK-293 cells was conducted (Fig. 3A).
Treatment of the cells with 10 nM testosterone resulted in an
approximately eight fold increase in luciferase activity. Co-
treatment with the antagonist ﬂutamide partially reduced the
testosterone-mediated reporter gene activation. TBBPA did not
exert an antiandrogenic effect at a concentration of 1 mM;
however, at 10 mM it reduced the testosterone-dependent AR
activation by 37%. Moreover, at 10 mM TBBPA showed weak agonist
properties and resulted in the activation of the AR-dependent
luciferase reporter gene. Furthermore, a cell-free competitive
binding assay was conducted with cell lysates expressing
recombinant AR (Fig. 3B). TBBPA exhibited a concentration-
dependent displacement of the radiolabeled testosterone, where-
by 10 mM TBBPA displaced 62% of the AR-bound [3H]-testosterone.
At 1 mM TBBPA, which is close to the IC50 value reported by Roelofs
et al. (Roelofs et al., 2015), 31% of [3H]-testosterone were displaced
from the AR. Thus, these results could conﬁrm the antiandrogenic
activity of TBBPA, although the effect was less pronounced in the
human cell-based system compared with the yeast assay.
4. Discussion
The results of the present study suggest that TBBPA does not
affect GR function. TBBPA showed neither agonistic nor antago-
nistic effects in the GR transactivation assay in HEK-293 cells, andFig. 3. Effect of TBBPA on AR binding and activity. (A) Impact of TBBPA on AR transactiv
sensitive luciferase reporter gene and a galactosidase transfection control. Cells were i
(Fluta) or different concentrations of TBBPA. The luciferase reporter activity was norma
(0.2% DMSO) and represent mean  SD from four independent experiments each perform
unlabeled competitor (either testosterone or TBBPA). HEK-293 lysates expressing AR we
testosterone or TBBPA until the binding equilibrium was reached. Values were normaliz
fraction of [3H]-testosterone. ns (not signiﬁcant), * p  0.05, ** p  0.01, **** p  0.0001.TBBPA was not able to displace the radiolabeled ligand dexameth-
asone from the GR binding site in a cell-free assay. In addition,
molecular modeling was applied to study possible interactions of
TBBPA with residues of the GR ligand binding pocket. Although
TBBPA was not excluded from the GR ligand binding pocket due to
steric hindrance, key stabilizing interactions that are formed with
the agonist dexamethasone (not shown) or the antagonist RU486
(Fig. 2) are absent in the case of TBBPA. The antagonistic effect of
TBBPA observed by Roelofs et al. on AR in the yeast assay with an
IC50 of 982 nM (Roelofs et al., 2015) could also be detected in the
HEK-293 cell-based assay in the present study, although the effect
was much weaker with an estimated IC50 > 10 mM. TBBPA was
found to displace the bound radiolabeled ligand testosterone from
AR with an estimated IC50 between 5 and 10 mM. Thus, at least ten
fold weaker activity of TBBPA towards AR was found in the human
cell-based assay compared with the yeast assay.
The discrepancy of the current study with the potent
antagonistic activity of TBBPA on GR (IC50 22 nM) measured in
the yeast GR assay by Roelofs et al. (Roelofs et al., 2015) may be due
to limitations of the yeast assay. The applied yeast GR assay showed
a very low sensitivity to the potent ligand dexamethasone and a
very high concentration of 60 mM was used to activate the reporter
gene, an issue that has been observed before in yeast (Garabedian
and Yamamoto 1992; Picard et al., 1990). The low sensitivity of the
yeast GR assay is probably a result of limited access of
dexamethasone to the cytosolic compartment. The yeast ATP-
binding cassette transporter PDR5 was found to modulate the
intracellular amount of dexamethasone (Kralli et al., 1995). Lack of
PDR5 activity in a mutant yeast strain led to increased intracellular
dexamethasone concentration and an increased response to
glucocorticoids. Interestingly, PDR5 represents a functional homo-
logue of the human P-glycoprotein (P-gp), and TBBPA was shown to
inhibit P-gp, although at very high concentrations with an IC50
value of 25 mM (Dankers et al., 2013). Considering the supposed
anti-glucocorticoid effect of TBBPA, it is unlikely that TBBPA atation in HEK-293 cells transiently transfected with plasmids for human AR, an AR-
ncubated for 24 h in the presence of 10 nM testosterone (Testo), 0.5 mM ﬂutamide
lized to the internal galactosidase control. Data were normalized to vehicle control
ed in triplicates. (B) Displacement of radiolabeled [3H]-testosterone from the AR by
re incubated with 10 nM [3H]-testosterone and various concentrations of unlabeled
ed to the maximal binding at 10 nM [3H]-testosterone and represent the AR bound
92
K.R. Beck et al. / Toxicology 370 (2016) 70–77 75concentrations below 1 mM inhibits PDR5, and a hypothesis to be
tested in future experiments includes the induction of the
expression of PDR5 or another transport protein that catalyzes
the efﬂux of glucocorticoids from the yeast cytosolic compartment.
Transport was found to be at least partly responsible for the
distinct GR-ligand response in yeast (Kralli et al., 1995). Another
important factor impacting on steroid hormone receptor activity is
the availability of chaperones and co-activator/co-repressor
proteins. Although yeast does not have steroid receptors, it
expresses two heat shock proteins (HSP82 and HSC82) that might
fulﬁll at least in part the function of HSP90 in controlling the
folding of human steroid hormone receptors (Chang and Lindquist,
1994). Nevertheless, the limitations of the low sensitivity of the
yeast receptor assays have been addressed by introducing the co-
chaperones FKBP52 and HIP, resulting in enhanced GR reporter
gene activation (Nelson et al., 2004; Riggs et al., 2003).
Rather than directly modulating GR function it is more likely
that TBBPA might act on pathways downstream of GR. Several
studies suggested that TBBPA interacts with mitogen-activated
protein kinase (MAPK) pathways. Exposure of natural killer (NK)
cells to TBBPA led to the activation of the MAPKs ERK1/2 and P38 as
well as their upstream activator MAPK kinases (Cato et al., 2014).
This appeared to be involved in the TBBPA-mediated reduction of
the lytic function of NK cells (Kibakaya et al., 2009). Additionally, a
study in murine RAW 264.7 macrophage showed that TBBPA
induced COX2, TNFa, IL-1b and IL-6 expression through enhanced
phosphorylation of Akt, the MAPKs p38, ERK1/2 and JNK, as well as
transcriptional activation of NF-kB and AP-1 (Han et al., 2009).
Furthermore, TBBPA was reported to induce reactive oxygen
species formation by an ERK1/2-dependent pathway (Reistad et al.,
2005; Reistad et al., 2007).
A majority of in vitro studies on TBBPA-mediated effects used
concentrations in the lower micromolar range. Thus, evaluation of
relevant concentrations observed in the human body is crucial for
its risk assessment. TBBPA blood serum concentrations in the
general population were assessed in different studies worldwide
including two large Canadian biomonitoring surveys (Canada,
2012). One study evaluated 50,599 serum samples of which all
analyzed samples displayed TBBPA concentrations below the limit
of detection (LOD) of 0.03 ng/l serum. The second study deter-
mined TBBPA concentrations in plasma samples of 771 Inuit
participants. In 5% of the measured subjects, TBBPA was found at
concentrations ranging from 10 to 480 ng/l (0.08–3.5 nM). A
Belgian study involving 515 participants detected maximal TBBPA
serum levels of 0.186 ng/l (Kicinski et al., 2012). Measurements in
human milk displayed average TBBPA levels of 0.06–4.11 ng/g fat
(EFSA, 2011). Limited data are available for personnel with
occupational exposure to TBBPA. Two studies examining the
TBBPA serum levels of computer technicians and workers at
electronic dismantling plants revealed serum concentrations up to
7.4 pmol/g fat (EFSA 2011; Jakobsson et al., 2002). The low systemic
bioavailability of TBBPA after oral exposure can be explained by the
extensive ﬁrst-pass metabolism by conjugation with glucuronic
acid or sulfate (Kuester et al., 2007; Schauer et al., 2006). The
TBBPA conjugates are preferentially translocated into the bile and
excreted by the feces (Colnot et al., 2014). Therefore, TBBPA does
not bioaccumulate and the concentrations measured in the general
population are several orders of magnitude lower than the
concentrations causing the reported biochemical effects in the
in vitro experiments.
However, the International Agency for Research on Cancer
(IARC) recently classiﬁed TBBPA as probably carcinogenic to
humans (group 2A) (Grosse et al., 2016), based on rodent
carcinogenicity studies by the U.S. National Toxicology Program
(NTP). A signiﬁcantly increased incidence of uterine adenocarci-
nomas, adenomas and malignant mixed Müllerian tumors wasfound in female Wistar Han rats receiving 500 or 1000 mg TBBPA/
kg body weight (bw)/day in a two-year gavage study (Dunnick
et al., 2015; NTP 2013). At such high concentrations, the enzymes
for sulfation and glucuronidation may become saturated and
conjugation of TBBPA likely competes with that of endogenous
mediators such as estrogens, resulting in a higher concentration of
free estrogens which stimulate cell proliferation and promote
tumor growth (Lai et al., 2015; Wikoff et al., 2016). In support of
this, several in vitro and computational studies provided evidence
that TBBPA inhibits estrogen sulfotransferases (Gosavi et al., 2013;
Hamers et al., 2006; Kester et al., 2002). However, the TBBPA serum
concentrations measured in humans differ by several orders of
magnitude from the plasma concentrations that compromised
sulfation of TBBPA in rats. Thus, at the exposure levels seen in
humans TBBPA is expected to be conjugated and excreted before it
can cause adverse effects. Moreover, TBBPA toxicity studies in rats
addressing non-cancer endpoints indicated no considerable effects
on histopathology, organ and body weights, reproductive and
developmental parameters, behavior and neuropathology, clinical
signs, serum chemistry or mortality rate (reviewed by (Colnot
et al., 2014; Lai et al., 2015; EPA, 2015)). The only treatment-related
alteration in rats was limited to decreased circulating thyroxine
(T4) serum levels, the inactive form of thyroid hormones. However,
no concomitant changes of active triiodothyronine (T3) and
compensatory increase of thyroid stimulating hormone (TSH)
were noted, as well as any evidence of histopathological changes of
the thyroid tissue. As this observation was only found in rats, it is
suggested to be species-speciﬁc and related to hepatic induction of
T4-uridine diphosphate glucuronyl transferase (UDP-GT) enzymes
which increase T4metabolism in the liver. Due the non-biologically
relevant doses of TBBPA applied in these studies and the absence of
other thyroid-related effects, this effect is not considered to be of
relevance for human health (Canada, 2012; ECB, 2006). Therefore,
to our knowledge, so far no effects of concern for human health
have been reported for TBBPA.
5. Conclusion
In vitro and in vivo risk assessment studies of potential EDCs
should include a careful consideration of human exposure and
toxicokinetic parameters for the determination of systemically
relevant compound concentrations. To avoid biased results in
mode-of-action studies, the limitations and applicability of the in
vitro testing systems need to be considered. Yeast GR screens are
highly limited because of their low sensitivity towards glucocorti-
coids, probably due to efﬂux transport proteins. This may lead to
false negative or false positive results, as exempliﬁed in the current
study for TBBPA. Using cell-free receptor binding and human cell-
based transactivation assays, the results of the current study show
no direct effect of TBBPA on GR function and very weak
antagonistic effects on AR. Considering its rapid metabolism and
low concentrations found in humans, TBBPA is unlikely to cause
adverse effects by acting through GR or AR. The current study
emphasizes the combined use of cell-based and cell-free assays for
the assessment of chemical effects on steroid hormone receptors.
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Studying potential endocrine disrupting chemicals:
comparison of yeast and human cell-based in vitro assays
The production of chemicals for agricultural and industrial use, cosmetics or food additives is
steadily increasing. To protect the environment and human health against the potential risks arising
from these man-made chemicals, the authorities introduced several programs to promote adequate
substance-based hazard and risk characterizations. Such chemicals may cause harmful effects by
disturbing the hormonal system. These so-called endocrine disrupting chemicals (EDCs) can mimic
or block the action of endogenous hormones on their corresponding receptors, disrupt their
synthesis, metabolism, transport or underlying signaling pathways. Sex steroid hormones
(androgens, estrogens) orchestrate in particular developmental and reproductive functions,
whereas glucocorticoids (especially cortisol) essentially regulate the immune system, blood
pressure, energy metabolism and developmental aspects. Disruption of the endocrine system has
been associated with developmental and reproductive malfunctions, allergies, diabetes,
cardiovascular diseases, and cancer.
Fig. 1. Schematic representation of a yeast and a human reporter gene cell and the purified
receptor in a test tube. Due to a transporter X on the yeast cell membrane, the yeast cell is able to
export glucocorticoids, thereby limiting the ligand accessibility to the GR. This alters the assay
sensitivity and could lead to false positive or false negative results. In comparison, the human cell
is lacking this transporter X. However, the only test system with free ligand accessibility represents
the purified receptor in a test tube. Therefore, an adequate evaluation of chemicals acting on
steroid hormone receptors should include a combination of cell-based and cell-free assays.
In vitro testing systems play a crucial role during the safety assessment of EDCs and gained even
more importance since chemicals used in body care products can no longer be tested in animals.
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These in vitro studies are conducted with microorganisms or cellular components in an artificial
system separated from their natural environment. Human cell-based assays are widely used to
study EDC action on hormone receptors, whereby receptor-mediated reporter genes are used as
receptor activation read-out. A cost-effective alternative are yeast reporter cell assays. However,
each in vitro testing system has its limitations, which needs to be considered for data analysis.
Yeast androgen (YAS) and estrogen screen (YES) show limited uptake of certain compounds
through the yeast cell membrane and may not sufficiently allow discriminating between compounds
activating or suppressing the receptor activity.
The extensively applied flame retardant tetrabromobisphenol A (TBBPA) was previously reported
to strongly inhibit the activity of the glucocorticoid receptor (GR) and to a lesser extent the
androgen receptor (AR) in yeast reporter gene assays. Regarding the limitations of these systems,
the current study evaluated this observation in a human cell-based assay. TBBPA did not stimulate
nor suppress GR activity. To exclude limitations due to different cellular uptake of TBBPA by yeast
and human cells, receptor binding assays were conducted under cell-free conditions with direct
access of the compound to the receptor. Nevertheless, this experiment allows only conclusions on
the affinity of a substance to bind to a receptor but not its ability to activate or inhibit. In this regard,
TBBPA did not affect the ligand binding to the GR. Computer simulations with TBBPA and GR
supported this finding. Thus, TBBPA does no directly disturb GR function. However, inhibition of
the AR could be confirmed in the human cell-based and cell-free systems, although the effect was
much less pronounced.
The discrepancy to the earlier report may be due to limitations of the yeast assay. GR yeast assays
are known for their low sensitivity, probably due to a yeast specific transporter exporting
glucocorticoids from the cell. By upregulating the expression of this transporter TBBPA might
indirectly affect the glucocorticoid concentration in the yeast cell and therefore lead to false positive
results. Thus, it is highly important to be aware of the limitations of each in vitro testing system to
avoid false positive or false negative results. Many studies applied TBBPA concentrations far
above those found in the human body. However, appropriate risk assessment should always
include the evaluation of the substance at the concentration found in human. TBBPA is rapidly
degraded and only detected at very low concentrations in human. Thus, TBBPA unlikely causes
adverse effects by disrupting GR or AR action. The current study highlights the use of a
combination of cell-based and cell-free assays for the evaluation of chemicals on steroid hormone
receptors.
Katharina R. Beck, Alex Odermatt
 Swiss Center of Applied Human Toxicology and Division of Molecular and Systems Toxicology,
 Department of Pharmaceutical Sciences, University of Basel, Switzerland
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3.2.2. Discussion 
 
The re-evaluation of TBBPA on GR function revealed neither agonistic nor antagonistic effects in the 
GR transactivation assay in HEK-293 cells. To exclude limitations due to different cellular uptake of 
TBBPA by yeast and human cells, receptor binding assays were performed under a cell-free 
environment in order to achieve direct access of the compound to the receptor. Nevertheless, this 
experiment allows only conclusions on the affinity of a substance to bind to a receptor, respectively its 
ability to displace an already bound ligand from the binding site but does not allow conclusions about 
its potential to activate or suppress a receptor’s function. In the cell-free GR binding assay TBBPA was 
not able to displace the radiolabeled ligand dexamethasone from the GR ligand binding pocket. 
Docking calculations were performed to computationally elucidate the obtained results and to assess 
the interactions formed between the GR ligand binding pocket and TBBPA. Particular attention was 
paid on potential interactions with the helix 12, as a relocation of this helix can reshape the coactivator 
binding site into the corepressor binding site and thereby lead to repression of GR gene transcription 
mediated by the binding of nuclear receptor corepressors [65]. Although no exclusion of TBBPA from 
the GR binding pocket was found due to steric hindrance, key stabilizing interactions detected with 
dexamethasone or the GR antagonist RU486 (mifepristone) were absent in the case of TBBPA. 
Especially the side pocket important for helix 12 interactions was not covered by TBBPA as compared 
to RU486. Thus, no direct interactions of TBBPA with GR could be identified.  
Nevertheless, the antiandrogenic activity of TBBPA could be confirmed in HEK-293 cells, although an 
order of magnitude less pronounced than that observed in the yeast screen. The discrepancy between 
these observations and the earlier report seem to be due to the limitations of the yeast assay. The low 
sensitivity of GR yeast assays has already been observed earlier and is probably a result of limited 
intracellular concentrations of dexamethasone modulated by the yeast-specific ATP-binding cassette 
transporter PDR5 [66-68]. Mutant yeast strains lacking PDR5 showed increased glucocorticoid 
sensitivity and higher intracellular dexamethasone concentrations. PDR5, a functional homolog of the 
human P-gp, was further reported to be inhibited by TBBPA, albeit only at high concentrations of 
TBBPA (IC50 ~25 µM) [69]. However, taking the potent antiglucocorticoid effect of TBBPA in the yeast 
screen into consideration, inhibition of PDR5 at TBBPA concentration below 1 µM is unlikely. 
Moreover, reduced PDR5 activity would rather lead to increased dexamethasone concentrations in the 
cytosolic compartment and thereby counteract the antagonistic activity. Instead, a hypothesis to be 
tested would include the transcriptional induction of PDR5 or genes encoding for other transport 
proteins inducing the efflux of glucocorticoids from the yeast cytosol. Interestingly, a study involving a 
P-gp homologue from scallop showed around 1.5 fold upregulation of the corresponding mRNA 
compared to control levels upon exposure to 9 nM TBBPA [70]. Nevertheless, an altered transport 
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mechanism may not be the only factor contributing to distinct GR-ligand response in yeast [68]. 
Introduction of co-chaperons for example was able to enhance GR reporter activity in yeast cells [71, 
72]. To sum up, GR yeast screens display considerable limitations due to their low sensitivity towards 
glucocorticoids, being highly susceptible to biased results in mode-of-action studies.  
EDC safety evaluations present a major challenge concerning assay sensitivity. Highly sophisticated 
analytical techniques such as Liquid or Gas Chromatography–Tandem Mass Spectrometry 
Measurements (LC-MS/GC-MS) allow the detection and quantification of almost all analytes of 
interest. However, an important aspect of hormone action is that it occurs at extremely low 
concentrations. Alternatively, effect-based methods quantifying the activation of a receptor, including 
reporter-gene assays, often achieve higher sensitivity in substance screenings. The limit of 
quantification (LOQ) for the active estrogen estradiol in chemical analytical methods is ~100 pg/L 
whereas the effect-based ER-Calux assay shows a LOQ of ~17 pg/L [73]. In contrast, the inactive estrone 
can be analytically quantified with a LOQ of ~10 pg/L, but in the effect-based system only with a LOQ 
of ~850 pg/L [73]. Regarding estrone, a modified ER-Calux expressing the estrone to estradiol 
converting enzyme 17β-HSD1 would be an interesting option to achieve also high sensitivity to detect 
estrone. Furthermore, effect-based methods are currently the only available methods to detect 
specific endocrine effects of environmental samples with an unknown composition of different 
substances. On the other hand, these in vitro tests already assume knowledge or hypotheses of the 
mode of action of an EDC. 
An EDC might exert its mode of action not exclusively through one but through multiple mechanisms, 
and as a part of compound mixtures occurring in the environment a certain compound may react even 
different. The absence of one mechanism is not automatically the evidence that this compound may 
not act through another mechanism. Regarding TBBPA, several studies suggested an interference with 
a pathway further downstream of GR, the mitogen-activated protein kinase (MAPK) pathways 
(described in our published article [58]). However, the majority of these in vitro studies used TBBPA 
concentrations in the lower micromolar range. Against this background, Knudsen et al stated that ‘the 
relative specificity of assays/targets/chemicals have revealed the general concept of an ‘assay burst’ 
of promiscuity at high chemical concentrations […]’ [74]. Therefore, the relevant concentrations 
observed in the human body are crucial to elucidate for an appropriate risk assessment. TBBPA was 
only found at extremely low concentrations in the human body and the concentrations reported to 
cause biochemical effects in in vitro experiments were several orders of magnitude higher. Its rapid 
first pass metabolism by conjugation with glucuronic acid or sulfate may explain the low bioavailability 
after oral exposure. A more comprehensive report is found in the published article ‘Evaluation of 
tetrabromobisphenol A effects on human glucocorticoid and androgen receptors: a comparison of 
results from human- with yeast-based in vitro assays’ in the section above [58]. Hence, at the exposure 
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levels observed in humans, TBBPA can be considered to be metabolized and excreted before it causes 
harmful effects.  
Concerns about the environmental risk of such industrial chemicals led to the development of a market 
for novel replacement alternatives. Several TBBPA derivatives belong to this group such as 
tetrabromobisphenol A-bis(2,3-dibromopropylether) (TBBPA-DBPE), Tetrabromobisphenol A 
dihydroxyethyl ether (TBBPA-DHEE) or Tetrabromobisphenol A bis(allyl) ether (TBBPA-BAE) [75]. Still, 
the introduction of new or modified chemicals always implies a lack of sufficient information on 
environmental and human exposure as well as possible health aspects, a gap that may be filled years 
after the market launch and with an uncertain outcome. Thus, might there be a solution to avoid the 
design of hazardous chemicals as early as possible? As already discussed in the published review article 
‘Virtual screening applications in short-chain dehydrogenase/reductase research’, in silico applications 
display valuable tools to evaluate potential EDCs at an early stage and thereby may aid to prioritize the 
chemicals for further in vitro assessments [9]. Computational analysis can include the assessment of 
potential biologically actives respectively anti-target screenings (by molecular docking, quantitative 
structure activity relationships (QSAR) models or computational systems biology applications) or the 
prediction of physico-chemical properties [76-78]. However, computational tools should always be 
considered as complementary techniques to in vitro testing systems. The prioritizing of chemicals can 
facilitate the selection of effect-based methods as, discussed in the section above, this requires 
previous knowledge of a potential mode of action. On the other hand, high-throughput in vitro screens 
offer a solution for this issue as well, albeit the selection of the most predictive assays seems to be a 
major challenge. Unfortunately, receptor activities are often determined with partial constructs 
including only the ligand binding domain, which can lead to biased results. To meet the requirements 
of the complex biology behind the endocrine system, further intact as well as secondary mechanistic 
assays and finally in vivo studies would be crucial to fully elucidate the safety of a chemical. Figure 2 
displays a potential strategy for the evaluation of potential EDCs, adapted from the screening strategy 
for biological validation published in our review article and with reference to the Tiered Protocol for 
Endocrine Disruptors [9, 76]. Nevertheless, it is essential to always consider the limitations of each 
testing system including the distinct sensitivities and specificities as well as observational human data 
if available.  
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 Figure 2. Potential EDC screening strategy.   
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4. Substrate identification 
 
SDRs metabolize a remarkably broad range of substrates including steroid hormones, oxysterols, bile 
acids, fatty acids, prostaglandins, retinoids and various xenobiotics [4, 79]. Despite the considerable 
structural similarity between the different members of the SDR superfamily, their primary sequence 
similarities are rather low and the substrate specificities and the physiological functions of a large 
percentage of the SDRs remain poorly investigated. Therefore, to improve the understanding of the 
physiological roles of so-called orphan SDRs and by that potentially identifying novel drug or anti-drug 
targets, SDR deorphanization strategies are of great importance.  
However, SDRs do not have a common activity element that could be used as suitable assay read-out 
to assess potential substrates, compared to other protein families. This impedes the effort and the 
progression of SDR deorphanization. G protein-coupled receptors (GPCR), for instance, exert specific 
changes upon activation that can be detected by monitoring well-described steps including the 
accumulation of second messengers [80]. Furthermore, the wide spectrum of metabolic reactions 
catalyzed by SDRs and the lack of structural information for many SDR, additionally hamper the 
attempt to deorphanize SDRs. In this regard, only a small number of studies applied structural 
modeling approaches for SDR substrate identification. Examples for members of the SDR family, but 
also for non-SDR enzymes, can be found in the published review ‘Virtual screening applications in 
short-chain dehydrogenase/reductase research’, therein under chapter 2.2.3. ‘Application of 
structural modeling for substrate identification’ [9].  
The application of the VS approach used for the identification of enzyme inhibitors, as it was described 
in the sections above, is extended in following parts including investigations of novel substrate 
specificities for three different SDR members: the two multi-functional enzymes, 11β-HSD1 and 
carbonyl reductase (CBR) 1 as well as the orphan enzyme DHRS7.  
 
4.1. 11β-hydroxysteroid dehydrogenase type 1 
 
By catalyzing the local conversion of inactive to active glucocorticoids, 11β-HSD1 plays an important 
role in the regulation of metabolic functions. In most tissues it is co-expressed with the enzyme hexose-
6-phosphate-dehydrogenase (H6PDH) [81], both facing the endoplasmic reticulum (ER) lumen [82-84]. 
H6PDH functions as supplier of the cofactor NADPH for 11β-HSD1 and determines thereby the reaction 
direction towards an oxoreductase, representing the predominant activity in vivo [85]. Additionally, a 
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physical interaction between 11β-HSD1 and H6PDH as well as the need of a high NADPH/NADP+ ratio 
for maintaining the 11β-HSD1 oxoreductase activity was reported [86, 87].  
Elevated 11β-HSD1 activity has been associated with insulin-resistant diabetes, hyperlipidemia, 
hypertension, and visceral obesity [88, 89]. Several studies addressed drug development efforts and 
pharmacological inhibition of 11β-HSD1 as a therapeutic option to treat metabolic diseases as 
described in more detail in the sections ‘11β-hydroxysteroid dehydrogenase type 1’ in both published 
review articles [9, 10].  
Several of the steroid metabolizing enzymes are highly promiscuous in their ligand binding specificity 
due to the fact that the steroid backbone has several symmetry planes  [90]. The position 11 of the 
steroid molecule is rotationally symmetric to position 7 and position 3 is symmetric to positions 17 and 
20 (see Figure 6) [90-92]. This property is nicely reflected by the substrate specificity of 11β-HSD1, 
metabolizing in addition to glucocorticoids also other 11- and 7-oxygenated steroids and cholesterol 
derivatives such as 11-oxoandrogens, 11-oxogestagens, 7-oxo bile acids or 7-ketocholesterol 
(reviewed in [93]). The physiological impact of several of these metabolites is mostly unexplored. The 
multi-functionality of 11β-HSD1 is further emphasized by is function as a carbonyl reductase towards 
a variety of non-steroidal xenobiotics in phase I biotransformation reactions (reviewed in [93, 94]). The 
reduction of reactive carbonyl compounds displays an important detoxification reaction involving 
different enzymes, mainly from the SDR family (including CBR1, which is discussed in more detail in 
the following chapter) and AKRs, which show conserved Tyr and Lys residues in similar positions as 
described in the introduction of this thesis.  
Evidence for glucocorticoid-independent effects and therefore the presence of so far unexplored 
endogenous substrates of 11β-HSD1 is provided by earlier studies; 11β-HSD1 is known to catalyze the 
conversion of the secondary bile acid 7-oxolithocholic acid (7oxoLCA) mainly into chenodeoxycholic 
acid (CDCA) [95]. Whereas 11β-HSD1 deficiency increased the circulating levels of unconjugated bile 
acids, probably due to a reduced expression of FATP5, an enzyme involved in bile acid conjugation, the 
expression of glucocorticoid target genes was unaltered [96]. However, liver-specific GR knockdown, 
although affecting glucocorticoid target gene expression, did not alter FATP5 expression.  
Additionally, depending on the duration of an inflammatory condition, 11β-HSD1 deficiency/inhibition 
can either lead to a more severe outcome, as found during acute inflammation, or it may be beneficial, 
as seen in chronic inflammatory situations such as in atherosclerosis (reviewed in [97]). This may also 
indicate a yet unknown contribution of 11β-HSD1 to other, glucocorticoid-independent metabolic 
pathways. 
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The following sections cover investigations into involvement of 11β-HSD1 in the generation of 
dihydroxylated oxysterols and an attempt to apply a VS strategy for the characterization and 
deorphanization of SDRs, using 11β-HSD1 as a model enzyme.   
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4.1.1. Oxysterol metabolism 
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Abstract 
Oxysterols are metabolites from cholesterol derived either through autoxidation or enzymatic 
processes. They consist of a large family of bioactive lipids involved in lipid and carbohydrate 
homeostasis, neuronal development and immune system regulation, and they have been associated 
with the progression of multiple pathologies. A role for 11β-hydroxysteroid dehydrogenase type 1 
(11β-HSD1) in oxysterol metabolism by metabolizing 7ketocholesterol (7kC) has been demonstrated. 
However, no endogenous receptor has been identified so far for 7kC or its metabolite 7β-
hydroxycholesterol, in contrast to the known receptors for 7α,25-dihydroxycholesterol (7α25OHC), i.e. 
Epstein-Barr virus-induced gene 2 (EBI2), or 7β,27-dihydroxycholesterol (7β27OHC), i.e. retinoic acid 
related orphan receptor (ROR)γ. In order to unravel the underlying biosynthetic pathways of such 
dihydroxylated oxysterols, this work investigated the role of 11β-HSD1 in the generation of 
dihydroxylated oxysterols. For the first time, the stereospecific and seemingly irreversible 
oxoreduction of 7-keto,25-hydroxycholesterol (7k25OHC) and 7-keto,27-hydroxycholesterol 
(7k27OHC) to their corresponding 7β-hydroxylated metabolites 7β25OHC and 7β27OHC by 
recombinant human 11β-HSD1 could be demonstrated in vitro in intact transfected HEK-293 cells. 
Furthermore, 7k25OHC and 7k27OHC potently inhibited the 11β-HSD1-dependent oxoreduction of 
cortisone to cortisol. Binding of 7k25OHC and 7k27OHC to 11β-HSD1 was investigated by molecular 
modeling calculations, suggesting competition with cortisone at the substrate binding pocket. A 
contribution of the 11β-HSD1-dependent metabolism of these oxysterols to the pathogenesis of 
hepatic steatosis by regulation of ROR or to the migration of immune cells by EBI2 activation might be 
potential target mechanisms that need to be explored.  
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1. Introduction 
Oxysterols are oxidized metabolites derived from cholesterol or cholesterol precursors either through 
radical processes or enzymatic reactions, bearing additional oxygen functionalities at the side chains 
and/or in the ring system of cholesterol [1]. In the past, oxysterols have been mainly considered as 
intermediates of bile acid and steroid hormone biosynthetic pathways; however, research in the last 
years emphasized their role as bioactive lipids involved in cholesterol, lipid and carbohydrate 
homeostasis, neuronal development and immune system regulation but also implicated a contribution 
to the progression of multiple pathologies such as atherosclerosis, multiple sclerosis, Alzheimer’s 
disease, retinopathies and nonalcoholic fatty liver disease (NAFLD) (reviewed in [2-5]). In order to 
unravel (patho-)physiological mechanisms involving oxysterols, it is crucial to elucidate the underlying 
formation and degradation of oxysterols and to uncover their intracellular and tissue-specific site of 
generation/metabolism.  
7-ketocholesterol (7kC) is one of the most extensively studied oxysterols and particularly known for its 
pro-inflammatory and cytotoxic properties (reviewed in [1, 6, 7]). It still remains unclear, however, 
whether the biological effects are caused by 7kC or by its metabolites. In situ, 7kC is mainly generated 
by autoxidation of cholesterol during conditions of oxidative stress. In contrast to the low abundance 
of oxysterols in the circulation, compared to cholesterol, 7kC levels of up to 10 µM have been 
measured in macrophage-derived foam cells in atherosclerotic lesions and in lenses of patients with 
cataract [8-10]. In macrophages as well as in the retinal pigment epithelium, conversion of 7kC into 7-
keto,27-hydroxycholesterol (7k27OHC) by sterol 27-hydroxylase (CYP27A1) was reported [11, 12]. This 
metabolic step is ablated in macrophages derived from patients suffering from cerebrotendinous 
xantheomatosis, bearing a defect in the gene encoding for CYP27A1 [11]. These patients have normal 
circulating cholesterol, but increased 7kC levels and are prone for the development of premature 
atherosclerosis [13].  
As the mitochondrial CYP27A1 is the first enzyme involved in the alternative biosynthesis pathway of 
bile acids in the liver, hepatic conversion of dietary 7kC to 7k27OHC is evident [14, 15]. However, a 
study with mice having a homozygous null mutation in the Cyp27 gene showed rapid and extensive 
metabolism of 7kC in the liver, indicating the involvement of another enzyme for the hepatic 7kC 
metabolism [16]. This enzyme was proposed to be 11β-hydroxysteroid dehydrogenase type 1 (11β-
HSD1), stereo-specifically converting 7kC into 7β-hydroxycholesterol (7βOHC) in humans, rats and 
mice [17-19]. These results were further supported by data from transgenic 11β-Hsd1-deficient mice 
exhibiting an increased 7kC to 7βOHC ratio in liver tissue samples [20].  
The role of 11β-HSD1, well-known for the local conversion of inactive into active glucocorticoids, in 
oxysterol metabolism and atherosclerotic plaque progression has been addressed in several studies 
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(reviewed in [21]). Interestingly, no direct accumulation of 7kC could be detected in the arterial wall 
of Hsd11b1-/- mice [22], and a disturbed 11β-HSD1 function was rather associated with an 
atheroprotective and beneficial metabolic profile [23-25]. Whether the observed favorable effects 
upon 11β-HSD1 inhibition were due to decreased intracellular levels of active glucocorticoids or 
whether these effects were glucocorticoid-independent remains unclear and requires further 
research.  
Evidence for metabolic effects of 11β-HSD1 modulation that are independent of glucocorticoid 
metabolism was provided by an analysis of its impact on bile acid homeostasis [26]. 11β-HSD1 catalyzes 
the conversion of the secondary bile acid 7-oxolithocholic acid (7oxoLCA) mainly into 
chenodeoxycholic acid (CDCA) and to a lesser extent into ursodeoxycholic acid (UDCA) [27]. Disruption 
of the 11β-HSD1 function was found to increase circulating levels of unconjugated bile acids, possibly 
due to a decreased expression of an enzyme involved in bile acid conjugation, FATP5 [26]. Interestingly, 
no change in FATP5 expression was detected in liver-specific glucocorticoid receptor (GR) knockdown 
mice, suggesting that the altered FATP5 expression was glucocorticoid-independent.  
Despite the extensive research focusing on the effects of 7kC and 7βOHC, no cognate endogenous 
receptors have been identified for them so far, whereas a variety of targets are known for side-chain 
oxidized oxysterols (e.g. 25-hydroxycholesterol (25OHC) or 27-hydroxycholesterol (27OHC)), 
dihydroxylated oxysterols such as 7β,27-dihydroxycholesterol (7β27OHC) or 7α,25-
dihydroxycholesterol (7α25OHC) or the related bile acids (as reviewed in [2, 28, 29]). Members of the 
nuclear hormone receptor family belong to most extensively studied targets of oxysterol function, with 
a primary focus on the Liver X receptors (LXR), playing an important role in lipid homeostasis. Another 
nuclear hormone receptor, the retinoic acid related orphan receptor gamma (RORγ) and its splice 
variant RORγt, which is required for the generation of IL-17-producing Th17 T cells in immune host 
defense, was recently discovered to be activated by 7β27OHC [30]. Whilst formation of 7α,25OHC and 
7α,27OHC from 25OHC and 27OHC is controlled by CYP7B1 [28, 31], the origin of the 7β-hydroxy forms 
remained unknown. However, since the conversion of 7kC into 7k27OHC by CYP27A1 has been 
detected in different tissues, it remained to be investigated whether 7β27OHC can be formed 
enzymatically from 7k27OHC by 11β-HSD1 and whether 11β-HSD1 could control the regulation of 
nuclear receptors other than GR. A further receptor involved in immune response mechanisms 
targeted by dihydroxylated oxysterols is the G-protein-coupled receptor (GPCR) Epstein-Barr virus-
induced gene 2 (EBI2) [32, 33]. 7α25OHC, 7α27OHC and to a lesser extent their corresponding β-
isomers were found to act as endogenous chemoattractants for immune cells expressing EBI2, thereby 
regulating immune cell migration. The hydroxylation of 7kC through cholesterol 25-hydroxylase 
(Ch25H) to 7k25OHC, although, not yet experimentally determined, has been proposed [34]. 
Considering the stereo-specific conversion of 7kC to 7βOHC by human 11β-HSD1, a careful assessment 
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whether 11β-HSD1 can metabolize 7k25OHC and 7k27OHC and whether it exclusively forms the 7β-
hydroxy forms or also the 7α-hydroxy metabolites is necessary.  
Thus, the present study aimed to investigate whether 11β-HSD1 is involved in the generation of 
dihydroxylated oxysterols. Recombinant human and mouse 11β-HSD1 were expressed in HEK-293 
cells, followed by incubation with the respective oxysterol and assessment of enzyme activity using 
ultra-high pressure liquid chromatography tandem mass spectrometry (UHPLC-MS/MS). Additionally, 
the oxysterol-dependent inhibition of cortisone oxoreduction by human and murine 11β-HSD1 was 
assessed, and binding to 11β-HSD1 was investigated by molecular modeling. 
 
2. Materials and Methods 
2.1. Chemicals and reagents 
[1,2-3H]-cortisone was purchased from American Radiolabeled Chemicals (St.Louis, MO), 7k,25OHC, 
7β,25OHC, 7α,25OHC, 7k,27OHC, 7β,27OHC, 7α,27OHC, 7α,25OHC-d6 and 7β,27OHC-d6 from Avanti 
Polar Lipids, Inc. (Alabaster, AL) and all other chemicals from Sigma Aldrich (Buchs, Switzerland) of the 
highest grade available. Cell culture media were obtained from Sigma Aldrich. UHPLC-grade purity 
methanol, acetonitrile and formic acid were obtained from Biosolve (Dieuze, France). T0504 (5H-1,2,4-
triazolo(4,3-a)azepine,6,7,8,9-tetrahydro-3-tricyclo(3-3-1-13-7)dec-1-yl was purchased from Enamine 
(Kiev, Ukraine). 
 
2.2. Cell culture 
Human Embryonic Kidney-293 cells (HEK-293) cells were obtained from ATCC (Manassas, VA, USA) and 
were cultured in Dulbecco’s modified Eagle medium (DMEM) supplemented with 10% fetal bovine 
serum, 4.5 g/L glucose, 100 U/mL penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES, pH 7.4, 
and 10% MEM non-essential amino acid solution.  
 
2.3. Inhibition of human and mouse 11β-HSD1 cortisone oxoreduction activity by oxysterols determined 
in cell lysates 
Enzyme activities were determined as described earlier using lysates of HEK-293 cells stably expressing 
human 11β-HSD1 and hexose-6-phosphate dehydrogenase (H6PDH; HHH7 clone) [35] or HEK-293 cells 
transiently expressing mouse 11β-Hsd1. 11β-HSD1 reductase activity was measured by incubating the 
lysates for 10 min at 37°C with 200 nM radiolabeled cortisone, 500 μM NADPH and test substance or 
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vehicle. The reaction was stopped by adding an excess amount of unlabeled cortisone and cortisol (1:1, 
2 mM each, in methanol). Steroids were separated by thin layer chromatography (TLC) using 
chloroform and methanol (9:1). Conversion of radiolabeled substrate was measured by scintillation 
counting. The substrate conversion was determined and compared to the enzyme activity in the 
control sample. Data (mean ± SD) were normalized to vehicle control (DMSO) and obtained from at 
least three independent experiments. 
 
2.4. Determination of the 11β-HSD1-dependent metabolism of oxysterols in intact cells  
HEK-293 cells stably expressing human 11β-HSD1 and H6PDH (50’000 per well) were seeded in poly-L-
lysine coated 96-well plates and cultivated for 24 h. The cells were washed with steroid-free DMEM 
(cDMEM) and incubated for 2 h at 37°C. The medium was then replaced by 50 µL cDMEM containing 
either 1 µM of the respective oxysterol (7k25OHC, 7k27OHC, 7β25OHC, 7β27OHC, 7α25OHC or 
7α27OHC) or 1 µM cortisone in the presence or absence of 1 µM 11β-HSD1 inhibitor (T0504), followed 
by incubation for 1 h. For quantification of oxysterol and cortisone/cortisol levels by UHPLC-MS/MS, 
liquid-liquid extraction of cell culture supernatants was performed. Cell supernatants (45 µL) were 
mixed with 100 µL ice-cold acetonitrile:isopropanol (7:3) containing 100 nM deuterium-labeled 
7α25OHC, 7β27OHC or corticosterone as internal standards and 1 µL/20 µL sample of a standard 
solution of the antioxidants butylhydroxytoluol (BHT) and triphenylphosphine (TPP) (standard solution 
of 10 mg BHT and 25 mg TPP in 10 mL ethanol) to avoid autoxidation. After incubating the samples in 
a shaker for 30 min at 4°C and 300 rotations/min, the samples were evaporated to dryness under 
nitrogen to minimize oxidation from atmospheric oxygen and reconstituted in 25 µL methanol:ultra 
pure water (1:1). The samples were then centrifuged at 4°C, 3220 × g for 10 min and the supernatant 
stored at -20°C until further analysis. 
 
2.5. Ultra-high pressure liquid chromatography–tandem mass spectrometry measurements 
Oxysteroles were simultaneously analyzed by UPLC-MS/MS using an Agilent 1290 Infinity UPLC binary 
solvent delivery system equipped with a column oven and a temperature controlled auto sampler 
(maintained at 4°C), coupled to an Agilent 6490 triple quadrupole mass spectrometer with a jet stream 
electrospray ionization interface (AJS-ESI) (Agilent Technologies, California, USA). Fragmentation for 
multiple reaction monitoring (MRM) and source conditions within the positive ion mode were 
automated defined by use of the integrated compound- and source- optimizer software modules 
(Agilent Technologies, B.07.01). Measured MRM transitions for analytes were automated defined as 
following: 7k25OHC (m/z 417.34  m/z 399.3 and m/z 191.4; RT = 3.68 min), 7k27OHC (m/z 417.34 
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 m/z 417.3; RT = 3.55 min), 7β25OHC (m/z 383.3  m/z 365.3 and m/z 95; RT = 3.45 min), 7β27OHC 
(m/z 383.3  m/z 159.0; RT = 3.38 min), 7α25OHC (m/z 383.3  m/z 365.3 and m/z 147.3; RT = 3.63 
min), 7α27OHC (m/z 383.3  m/z 383.3 and m/z 159.0; RT = 3.51 min), 7α25OHC-d6 (m/z 389.38  
m/z 371.5 and m/z 95.1; RT = 3.33 min), 7β27OHC-d6 (m/z 407.38  m/z 389.1 and m/z 159.1; RT = 
3.32 min), cortisol (m/z 363.22  m/z 121.1 and m/z 90.9; RT = 1.01 min), cortisone (m/z 361.2  
m/z 163.0 and m/z 121.1; RT = 1.09 min) or corticosterone-d8 (m/z 355.2  m/z 337.0 and m/z 125.1; 
RT = 1.43 min). The general source parameters were set as following: Gas temperature 290°C, gas flow 
14 L/min, sheath gas temperature 300°C, sheath gas flow 11 L/min, nozzle voltage 1500 V, Capillary 
voltage 3000 V, cell accelerator voltage 4 V, fragmentation voltage 380 V and Nebulizer 20 psi. Analyte 
separation was achieved using a reversed-phase column (ACQUITY UPLC BEH C18, 1.7 μm, 2.1 × 150 
mm, Waters, Wexford, Ireland), heated to 65 ± 0.8°C. The mobile phase consisted of water acetonitrile 
formic acid (A) (95/5/0.1; v/v/v) and (B) (5/95/0.1; v/v/v). The eluent gradient was set from 45 - 97% 
of B within 0- 4 min using a constant flow-rate from 0.5 mL/min, followed by a washout (80% of B, 4.5-
7 min) and column re-equilibration (45% B, 2 min). The injection volume was 2 μL per sample. 
Methanol in water (75/25 v/v) was used as needle and needle-seat flushing solvent for 10 s after 
sample aspiration. Samples were stored until analysis in the auto sampler (maintained at 4°C). Data 
acquisition and analysis was performed using Mass Hunter Workstation Acquisition Software Version 
07.01 SP1 and MassHunter Workstation Software Quantitative Analysis Version B.07.00 /Build 
7.0457.0, respectively (Agilent Technologies). 
 
2.6. Docking of oxysterols into the ligand binding pocket of 11β-HSD1 
Docking was performed using the GOLD version 5.2 software (Cambridge Crystallographic Data Centre, 
Cambridge, UK) [36]. This program applies a genetic algorithm for the identification of accurate docking 
poses for small molecules into the binding pocket of a protein. The crystal structure with the Protein 
Data Bank (PDB) entry 2BEL [DOI: http://dx.doi.org/10.2210/pdb2bel/pdb] was chosen for the human 
11β-HSD1 protein and PDB entry 1Y5R [DOI: http://10.2210/pdb1y5r/pdb] for the mouse enzyme. 
First, the co-crystallized ligands (carbenoxolone for 2BEL and corticosterone for 1Y5R) were deleted 
from the binding site and re-docked into the ligand binding site to investigate whether GOLD could 
restore the original binding orientation and therefore validate the docking settings (RMSD value of 
0.563 for carbenoxolone and 0.683 for corticosterone). The binding site was centered on the hydroxyl 
group of Tyr183 in 2BEL (x 3.08; y 19.19; z 13.65) as well as in 1Y5R (x 76.88; y 49.68; z 38.08) and 
surrounded by a 9 Å and a 10 Å sphere, respectively. CHEMPLP was selected as scoring function in both 
docking settings. Interactions found by the docking solutions between the ligand and the 11β-HSD1 
binding pockets were evaluated using LigandScout 3.12 (inte:ligand GmbH, Vienna, Austria). This 
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program automatically analyzes the observed interaction pattern between the docked ligand and the 
protein, based on the chemical functionalities, the geometric distances and the angles between 
neighboring structures [37]. 
 
3. Results 
3.1. Oxoreduction of 7k25OHC and 7k27OHC by 11β-HSD1 in intact cells 
In a first step, the oxoreduction of 7k25OHC and 7k27OHC in intact HEK293 cells stably expressing 
human 11β-HSD1 and H6PDH was investigated. Both 7k25OHC and 7k27OHC were stereo-specifically 
metabolized by 11β-HSD1 to 7β25OHC and 7β27OHC. No formation of 7α25OHC and 7α27OHC could 
be detected. Incubation of stably transfected HEK293 cells with 1 µM 7k25OHC, 7k27OHC or cortisone 
revealed apparent enzyme velocity values of 0.37 ± 0.12 nmol/h/mg total protein for 7k25OHC, 0.52 ± 
0.10 nmol/h/mg total protein for 7k27OHC and 1.59 ± 0.25 nmol/h/mg total protein for cortisone. No 
dehydrogenase activity could be detected when incubating the stably transfected cells with 7α25OHC 
or 7β25OHC or the respective 27-hydroxylated oxysterols. Also, no isomerase activity could be 
observed between the 7α- and 7β-hydroxylated oxysterols. In order to evaluate the mouse as potential 
animal model for further studies, the metabolism of 7k25OHC and 7k27OHC by the murine 11β-Hsd1 
was determined. Preliminary results for the mouse orthologue indicated, similar to the human enzyme, 
the exclusive conversion of 7k25OHC and 7k27OHC to 7β25OHC and 7β27OHC, without the formation 
of 7α-hydroxy metabolites, as well as absence of the reverse reaction or isomerization (data not 
shown).  
 
3.2. Inhibition of 11β-HSD1-dependent oxoreduction of cortisone by oxysterols 
To assess the potential of 7-oxygenated 25OHC and 27OHC oxysterols to interfere with the conversion 
of inactive to active glucocorticoids, the oxysterol-dependent inhibition of 11β-Hsd1 enzyme activity 
was measured in HEK293 cell lysates expressing the human and mouse enzyme, respectively. 7k25OHC 
and 7k27OHC inhibited the oxoreduction of cortisone to cortisol by the recombinant human 11β-HSD1 
with IC50 values of 400 ± 150 nM and 359 ± 44 nM, respectively (Figure 1A and B), and that by the 
mouse orthologue with IC50 values of 53 ± 16 nM and 36 ± 7 nM, respectively (Figure 1C and D).  
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Figure 1. Inhibition of cortisone oxoreduction by human 11β-HSD1 (A and B) and murine 11β-Hsd1 
(C and D) by 7k25OHC and 7k27OHC determined in HEK-293 cell lysates. Lysates of HEK-293 cells 
expressing recombinant human 11β-HSD1 and H6PDH or murine 11β-hsd1 were incubated for 10 min 
at 37°C with 200 nM radiolabeled cortisone, 500 µM NADPH and increasing concentrations of 7k25OHC 
(A and C), and 7k27OHC (B and D). The substrate conversion was determined and compared to the 
enzyme activity in the control samples (0.1% DMSO). Data represent mean ± SD from three 
independent experiments. 
 
For their corresponding 7β-reduced forms IC50 values of >3µM were obtained for the human enzyme 
with 7β25OHC and 7β27OHC (not shown) and of 119 ± 24 nM and 66 ± 30 nM, respectively (Figure 2A 
and B), for the mouse enzyme. The 7α-hydroxy metabolites inhibited human and mouse 11β-HSD1 
cortisone oxoreduction to a much lesser extent than the 7β-hydroxy metabolites, albeit the 7α-
hydroxy metabolites inhibited the murine enzyme more potently then the human orthologue (data 
not shown).  
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Figure 2. Inhibition of cortisone oxoreduction by murine 11β-Hsd1 by 7β25OHC (A) and 7β27OHC (B) 
determined in HEK-293 cell lysates. Lysates of HEK-293 cells expressing murine 11β-hsd1 were 
incubated for 10 min at 37°C with 200 nM radiolabeled cortisone, 500 µM NADPH and increasing 
concentrations of 7β25OHC and 7β27OHC. The substrate conversion was determined and compared 
to the enzyme activity in the control samples (0.1% DMSO). Data represent mean ± SD from three 
independent experiments. 
 
3.3. In silico analysis of oxysterol binding to the ligand binding pocket of 11β-HSD1 
In order to predict the binding orientation of 7-oxygenated 25OHC and 27OHC oxysterols in the 
substrate binding pocket of human and mouse 11β-Hsd1 and attempting to provide an explanation for 
the results obtained from the enzyme activity measurements, molecular docking calculations were 
performed. 7k25OHC and 7k27OHC fitted into the human 11β-HSD1 binding pocket within a 
comparable distance to the two key residues of the catalytic site, Ser170 and Tyr183, as observed for 
the substrate cortisone. Whereas both 7β25OHC and 7β27OHC are orientated to the catalytic site and 
the nicotinamide ring of the cofactor at a distance similar to that of cortisone, 7k25OHC and 7k27OHC 
(Figure 3A and 4A), the 7α-reduced oxysterols displayed a slightly turned upwards position and an 
enlarged distance to Ser170, Tyr183 and especially to the cofactor of 3-5Å (Figure 3B and 4B).  
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 Figure 3. Predicted binding of cortisone and 25-hydroxylated oxysterols to human 11β-HSD1. (A) 
Representative binding poses of cortisone (turquoise), 7k25OHC (orange) and 7β25OHC (grey). 
Important interactions for protein-ligand binding and the cofactor are shown in stick style and 
corresponding distances in Å are indicated as dashed lines (same color code as docked ligands). (B) 
Binding mode of 7β25OHC (grey) and 7α25OHC (blue). 
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 Figure 4. Predicted binding of cortisone and 27-hydroxylated oxysterols to human 11β-HSD1. (A) 
Representative binding poses of cortisone (turquoise), 7k27OHC (green) and 7β27OHC (purple). 
Important interactions for protein-ligand binding and the cofactor are shown in stick style and 
corresponding distances in Å are indicated as dashed lines (same color code as docked ligands). (B) 
Binding mode of 7β27OHC (green) and 7α27OHC (salmon pink). 
 
An analogous binding mode of 7k25OHC, 7k27OHC, their reduced 7β-hydroxy metabolites and 11-
dehydrocorticosterone was also observed in the in silico analyses of the murine 11β-Hsd1 (Figure 5A). 
However, compared to the position of 7α25OHC and 7α27OHC adopted in the human enzyme, these 
molecules align well in the murine 11β-Hsd1 binding pocket with the known substrates and within a 
distance of ~3.5Å (Figure 5B and C). 
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 Figure 5. Predicted binding of 11-dehydrocorticosterone (11DHC), 25-hydroxylated and 27-
hydroxylated oxysterols to murine 11β-HSD1. (A) Representative binding poses of 11DHC (bright 
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turquoise), 7k25OHC (orange) and 7k27OHC (green). Important interactions for protein-ligand binding 
and the cofactor are shown in stick style and corresponding distances in Å are indicated as dashed lines 
(same color code as docked ligands). (B) Binding mode of 7k25OHC (orange), 7β25OHC (grey) and 
7α25OHC (blue). (C) Binding mode of 7k27OHC (green), 7β27OHC (purple) and 7α27OHC (salmon pink). 
 
4. Discussion 
The investigation of oxysterols is highly complex and challenging, arising not only from the large 
number of molecules in this family, but also due to their low abundance in biological systems compared 
to cholesterol and their susceptibility for autoxidation, forming the same metabolites ex vivo as 
present in vivo [1]. Moreover, a given oxysterol can be derived from different substrates or may be 
formed non-enzymatically by autoxidation. Additionally, different enzymes can catalyze the 
conversion of one particular oxysterol. For example, 7β27OHC may be formed either by oxoreduction 
of 7kC through 11β-HSD1 to 7βOHC and then further by hydroxylation to 7β27OHC through CYP27A1 
or via direct hydroxylation of autoxidation-derived 7βOHC by CYP27A1.  
The current study proposes a new alternative biosynthetic pathway for the generation of 7β27OHC by 
11β-HSD1-dependent oxoreduction of 7k27OHC. Furthermore, for the first time the enzymatic 
formation of 7β25OHC could be demonstrated in vitro. So far, the metabolic pathway leading to 
7β25OHC has only been postulated as oxoreduction of 7kC through 11β-HSD1 to 7βOHC and then 
further by hydroxylation to 7β25OHC by CH25H or CYP27A1 [28], although experimental evidence is 
still lacking. Similarly, experimental evidence is missing for the hypothesized hydroxylation of 7kC to 
7k25OHC by CH25H. Thus, further investigations are required to uncover the biosynthetic pathways of 
oxysterol metabolism.  
Due to the stereospecific and seemingly irreversible action of the human 11β-HSD1, forming 
exclusively 7β-hydroxylated oxysterols, the potent EBI2 ligand 7α25OHC could neither be formed nor 
degraded by 11β-HSD1. Nevertheless, although the 7α-hydroxy group was shown to be preferred over 
the 7β-hydroxy group for EBI2 activation, 7β25OHC was still able to trigger an EBI2 response, with EC50 
values in the lower nanomolar range [32]. Therefore, in situations of oxidative stress, with excessive 
accumulation of 7kC and in the presence of CH25H expression, substantial amounts of 7k25OHC may 
be generated, followed by 11β-HSD1-dependent formation of 7β25OHC, which in turn could then act 
as a danger signal to initiate EBI2 response. 7kC serving as a first line danger signal might be supported 
by mRNA expression studies showing a very dynamic regulation of the enzymes necessary for oxysterol 
synthesis [38]. Primary human monocytes and macrophages were reported to express high levels of 
CYP27A1, lower levels of CH25H and even more limited CYP7B1, which is required for 7α-hydroxylation 
of 25OHC. Upon an immune challenge, immediate strong up-regulation of CH25H and CYP27A1 mRNA 
levels were observed compared to a delayed rise of CYP7B1 in M0 macrophage. Hence, 7β25OHC may 
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control EBI2-mediated immune cell migration under oxidative stress in a first step, followed by an 
adaptive response through signaling via the more potent 7α25OHC.  
Interestingly, bone marrow-derived macrophage from mice carrying a natural occurring mutation in 
the gene of Rorα1, so called staggerer (sg/sg) mice, showed decreased mRNA expression levels of 
Ch25h before and after an immune challenge with lipopolysaccharide (LPS) and are characterized by 
impaired innate immunity and a higher susceptibility to atherosclerosis [39]. Against this background, 
7αOHC was reported in vitro as an inverse agonist for RORα, although submicromolar concentrations 
were needed to affect receptor activity [40]. Whether 7-hydroxylated 25OHC or 27OHC oxysterols 
interfere with RORα activity or its role in CH25H regulation and immune cell migration has not been 
elucidated so far. However, the closely related nuclear receptors RORγ and RORγt are known to be 
activated by 7β27OHC and 7α27OHC, but not by 7α25OHC and most importantly not by 7k27OHC 
when full length receptor constructs were used [30]. The reduction of 7k27OHC to 7β27OHC by 11β-
HSD1 observed in the current study may therefore represent a mechanism of pre-receptor control of 
receptors other than GR such as ROR and/or EBI2. RORs as well as 11β-HSD1 have both been implicated 
in different aspects of the metabolic syndrome. 11β-Hsd1 knockout mice displayed improved insulin 
sensitivity and plasma lipid profile, whereas transgenic mice overexpressing 11β-Hsd1 in the adipose 
tissue developed pronounced visceral obesity [41-43]. Rorα-deficient mice are protected against 
insulin resistance, hepatosteatosis or diet-induced obesity and also Rorγ -/- mice showed an improved 
insulin sensitivity (reviewed in [44]). All these characteristics of the metabolic syndrome are strongly 
associated with NAFLD [45]. As the liver is a major site of oxysterol metabolism and oxidative stress 
represents a central contributor to non-alcoholic steatohepatitis (NASH), the involvement of oxysterols 
in NASH progression seems to be evident. However, to date the role of oxysterols in NASH is only 
poorly explored [46]. Supporting data for an implication of RORγ and RORγt in the pathogenesis of 
NASH come from preclinical and clinical studies. Liver tissue samples of patients and mouse models 
with NASH displayed an increased infiltration of Th17 cells and elevated expression levels of RORγ and 
IL-17 mRNA [47, 48]. RORγ protein levels were further upregulated in patients with liver cirrhosis and 
suggested to regulate epithelial-mesenchymal transition in hepatocytes during fibrosis [49]. Moreover, 
IL17 was reported to induce liver fibrosis in mice by different pathways [50]. Whether 11β-HSD1-
dependent oxysterol metabolism, in particular of 7k27OHC and thereby regulating RORγ(t), plays a role 
in the pathogenesis of NASH warrants further investigations.  
The present study showed for the first time the stereospecific oxoreduction of 7k25OHC and 7k27OHC 
to their corresponding 7β-hydroxylated metabolites by 11β-HSD1. A contribution of these oxysterols 
to the pathogenesis of NASH by regulation of RORγ or to the migration of immune cells by EBI2 
activation represent potential target mechanisms; however, thorough analysis of the involved 
pathways is needed.   
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4.1.2. Human metabolome and lipid maps structure database screening 
 
The present project is an attempt towards applying pharmacophore-based modeling and compound 
library screening for the characterization and deorphanization of SDRs in order to explore novel 
physiological functions and to identify potential drug targets. To test this strategy, the extensively 
studied 11β-HSD1 was selected as a ‘model enzyme’ and structure-based pharmacophore models 
were generated and employed for filtering of the human metabolome database (HMDB) and the lipid 
maps structure database (LMSD) to identify potential novel substrates of this multifunctional enzyme. 
A similar approach was recently reported by Zemanová et al. for the closely related orphan SDR family 
member DHRS7 based on homology modeling and structure-based VS of the HMDB (described in more 
detail in the following section) [98].  
 
Methods 
Data sets 
A test set of 18 structurally diverse and experimentally confirmed 11β-HSD1 substrates [93, 99] as well 
as a set of 20 inactive compounds [100] was collected and used for structure-based pharmacophore 
modeling (see Appendix Figure A1 and A2). The 2D-structures of these molecules were drawn with 
ChemBioDraw Ultra 12.0 and for each compound a maximum of 500 different conformations was 
created using OMEGA-best settings [101-103] implemented in LigandScout 3.12 (inte:ligand GmbH, 
Vienna, Austria) [104]. For the VS, the HMDB [105-107] version 2.5 and the LMSD [108, 109] (version 
November 2014), containing 41182 and 35624 structures, respectively, were downloaded as sdf files 
from their corresponding websites (http://www.hmdb.ca/downloads; 
http://www.lipidmaps.org/resources/downloads/index.html) and transformed into 3D-
multiconformational databases by creating 500 conformations with OMEGA-best settings using 
LigandScout 3.12.  
 
Pharmacophore modeling and virtual screening 
Structure-based pharmacophore modeling can be implemented if an X-ray crystal structure of the 
required molecular target containing a bound ligand is available. The interactions found between the 
protein and the ligand can then directly be integrated into a pharmacophore model. In the current 
project structure-based pharmacophore models were generated using the LigandScout 3.12 software. 
Due to the lack of a human 11β-HSD1 crystal structure in complex with a substrate, cortisone and 7kC 
were docked into the binding pocket of human 11β-HSD1 (PDB entry 2BEL [DOI: 
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http://dx.doi.org/10.2210/pdb2bel/pdb]) using GOLD software version 5.2 (Cambridge 
Crystallographic Data Centre, Cambridge, UK) [110] and according to the method described in the 
manuscript ‘The Oxysterols 7β,25-dihydroxycholesterol and 7β,27-dihydroxycholesterol are 
Enzymatically Formed by 11β-Hydroxysteroid Dehydrogenase Type 1’ - chapter 3.3. ‘In silico analysis 
of oxysterol binding to the ligand binding pocket of 11β-HSD1’. Interactions detected by the docking 
calculations between the ligand and the 11β-HSD1 binding pocket were evaluated and translated into 
common pharmacophore features by using LigandScout. In addition, a structure-based 
pharmacophore was generated of the interactions observed in the crystal structure of the murine 11β-
HSD1 complexed with corticosterone (PDB entry 1Y5R [DOI: http://10.2210/pdb1y5r/pdb]). Both 
models were manually refined and then merged by using the alignment tool of the LigandScout 
software. The generated model (model_1) was further evaluated and refined (setting features 
optional, removing features, adding exclusion volumes; for a general model refinement workflow 
consider the following reference [100]) in order to train the model to retrieve as many active 
compounds (substrates) as possible and to omit the inactive compounds from the fitting with the data 
set described above. In addition, further pharmacophore models were constructed to cover all the 
structurally different active training compounds (11β-HSD1 substrates). Therefore, model_1 was 
merged with newly two generated ligand-based pharmacophore models either on the basis of all active 
compounds containing a steroid backbone (model_2 and model_3) or on metyrapone and 
triadimefone (model_4). The ligand-based pharmacophore models were constructed according to an 
earlier described workflow [111]. The quality of the pharmacophore models was quantitatively 
assessed by calculation of the selectivity and the specificity of a model (see Appendix Table A1). The 
VS of the HMDB and the LMSD with the generated pharmacophore models representing 11β-HSD1 
substrates was conducted by using LigandScout 3.12. In addition, pharmacophore models for 11β-
HSD1 inhibitors described earlier were also implemented for VS and subsequent comparison of the 
virtual hits list for consensus hits [100].  
 
Results and Discussion 
The VS yielded several hundred virtual hits among which known substrates were successfully found 
such as endogenous 11-ketoglucocorticoids, synthetic glucocorticoids (such as prednisone), 7kC, and 
several bile acids known to inhibit the enzyme. The hit list comprised also different constituents of the 
root of licorice (Glycyrrhiza spp) and (processed) coffee, both products with known 11β-HSD1 
inhibitory activity [112, 113]. Furthermore, the hit list contained several different eicosanoids including 
prostaglandins, leukotrienes, cyclopentenone isoprostanes, levuglandins or hydroxyeicosatetraenoic 
acids (HETEs). A selection thereof can be found in the appendix (Figure A3). Regarding the pivotal roles 
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of 11β-HSD1 and eicosanoids during inflammation, potential 11β-HSD1 substrates may be found 
among those compounds. However, their highly flexible molecule structures can easily adopt plausible 
binding poses in the pharmacophore model and then can then be filtered as hits during the VS. 
Evidently, this is further supported by the hydrophobic nature of the binding pocket of 11β-HSD1. 
Docking of a few hits (Prostaglandin E3, 12-Keto-leukotriene B4, 15-oxo-ETE and 12-oxo-ETE), selected 
on the basis of consensually retrieved hits between the different models respectively their closest 
related carbonyl-forms (leukotriene B4 12-Keto-leukotriene B4, 15(S)-HETE 15-oxo-ETE and 12-
HETE 12-oxo-ETE), into the binding pocket of 11β-HSD1 predicted different binding conformations 
for all the selected hits compared to the known substrates cortisone and 7kC, which are found in one 
major pose (data not shown). Whether this observation is due to the great flexibility of the selected 
compounds, the rigid docking settings applied, or because they are inert towards the catalytic activity 
of 11β-HSD1, needs to be determined in biological assays. Interestingly, a similar observation was 
reported in molecular modeling experiments of 4-oxonon-2-enal (4ONE) into the active site of CBR1 
[114]. The highly reactive and genotoxic lipid aldehyde 4ONE was described in the same study to be 
converted by CBR1 into less reactive metabolites; however, 4ONE was also found to have a high degree 
of freedom in the active site of CBR1 and to adopt several active conformations. Moreover, the authors 
reported no specific contacts (e.g. hydrogen bonds) between the substrate and the enzyme in their 
calculated models.  
Due to the evidence for CBR1 to be involved in oxidative stress response (described in more detail in 
our published review article ‘Virtual screening applications in SDR research, chapter 2.2.3. ‘Application 
of structural modeling for substrate identification’), Oppermann et al. suggested the compound class 
of reactive isoprostanes, which was also retrieved by our 11β-HSD1 screening, as particularly 
interesting for further investigations into this research field [115]. As already mentioned, CBR1 and 
11β-HSD1 are both involved in detoxification reactions of xenobiotics and even share a certain 
substrate specificity (e. g. the tobacco-derived carcinogen 4-(methylnitrosoamino)-1-(3-pyridyl)-1-
butanone (NKK)). A superimposition of 11β-HSD1 and CBR1 illustrates the essential SDR-folding 
pattern for both enzymes; however, CBR1 displays a rather wide pocket opening, whereas the binding 
pocket of 11β-HSD1 is more elongated (Figure 3).  
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 Figure 3. Superimposition of 11β-HSD1 (yellow; PDB entry 2BEL) and CBR1 (blue; PDB entry 2PFG). 
NADPH and catalytic residues are depicted as sticks. 11β-HSD1 shows a more elongated binding pocket 
compared to the rather wide binding pocket entry of CBR1. 
 
In contrast to the cytoplasmic orientation of CBR1, the active site of 11β-HSD1 faces the ER lumen. 
Regarding the metabolism of xenobiotics, the relevance of the luminal orientation of 11β-HSD1 is not 
fully understood. Hydroxylation might facilitate conjugation reactions and thereby protect the 
cytoplasm from reactive ER luminal metabolites [93, 116]. Therefore, whether the suggestion to 
investigate isoprostanes as substrates for CBR1 should be extended to 11β-HSD1 requires further in 
vitro mechanistic analyses exploring the role of 11β-HSD1 in the metabolism of the different 
eicosanoids.  
Another interesting class of compounds filtered by the pharmacophore models belong to the 
kynurenine pathway (Figure 4).  
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 Figure 4. Tryptophan metabolism including the kynurenine pathway with virtual hits circled in red. 
(Adapted from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [117-120].) 
 
Kynurenine derivatives are the main products from the enzymatic catabolism of tryptophan, besides 
serotonin and melatonin, and have been implicated in distinct inflammatory diseases, the regulation 
of the immune response and the de novo synthesis of nicotinamide adenine dinucleotide (NAD+) 
(reviewed in [121, 122]). The virtual hit list primarily included products downstream of the first rate-
limiting steps of the kynurenine pathway: N-Formyl-kynurenine, 3-Hydroxy-L-kynurenine (3-HK), 3-
Hydroxy-anthranilate (3-HAA), 4-(2-Amino-3-hydrpxyphenyl)-2,4-dioxobutanoate, quinolinic and 
picolinic acid (Figure 5). Importantly, the latter compounds do not have a reactive carbonyl group 
required for metabolism by 11β-HSD1.  
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 Figure 5. 2D and 3D representation of virtual hits in the 11β-HSD1 pharmacophore model. (A) 
Cortisone (bright blue), 11-dehydrocorticosterone (11-DHC) (turquoise) and 3-HK (magenta) in an 11β-
HSD1 pharmacophore model. Yellow spheres display hydrophobic features (H), red hydrogen bond 
acceptors (HBA) and green hydrogen bond donors (HBD). Dotted spheres are optional features. The 
2D representations show the matched pharmacophore features of 3-HK (B), 11-DHC (C) and cortisone 
(D). The color code corresponds to part A.  
 
Nevertheless, docking into the binding pocket of 11β-HSD1 revealed one major binding conformation 
for picolinic acid, 3-HAA and 3-HK (data not shown). 3-HK acts as a substrate concurrently for two 
metabolic routes, the conversion via 3-HAA and quinolinic acid to the nicotinamide metabolic pathway 
or to the formation of xanthurenic acid (XA). Vitamin B6 deficiency was shown to shift the metabolism 
of 3-HK from the formation of NAD+ towards increased levels of XA and kynurenine, due to its function 
as cofactor for the enzymatic step from 3-HK to 3-HAA [123]. However, elevated levels of XA, 3-HK or 
kynurenine have been associated with a rather proatherogenic phenotype, showing increased 
occurrence in patients suffering from type 2 diabetes, induced experimental diabetes in rats and 
correlated with triglyceride or low-density lipoprotein (LDL) levels (reviewed in [124-126]). On the 
other hand, administration of 3-HAA to LDL receptor deficient mice led to significantly decreased total 
plasma cholesterol and triglyceride levels, reduced atherosclerotic lesion size and modulated local and 
systemic inflammatory responses [127]. In this regard, it becomes evident that the fine tuning of this 
systems is highly complex and may also involve other yet unexplored interaction partners. Therefore, 
it can be hypothesized that 11β-HSD1 potentially stabilizes 3-HK and thus may support the 
proatherogenic profile, and that inhibition of the enzyme may have glucocorticoid- and oxysterol-
independent beneficial effects in atherosclerosis by interfering with the kynurenine pathway. This is 
highly speculative at the moment, and further biological validation is of utmost necessity to test this 
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hypothesis based on in silico data and also to confirm the substrate identification strategy in order to 
extend it to orphan SDRs to uncover their physiological roles. A first attempt to implement this 
approach for an orphan member of the SDR enzyme family, DHRS7, is described in the following 
section.    
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4.2. DHRS7 
 
The closest relative of the orphan SDR family member DHRS7 (SDR34C1) is 11β-HSD1 [128]. Although 
the physiological role of DHRS7 has not yet been elucidated, DHRS7 knock-down experiments in human 
LNCaP prostate cancer cells showed increased cell proliferation, migration and reduced cell adhesion 
[129]. Moreover, reduced DHRS7 expression has been detected with increased prostate cancer 
progression, suggesting a function as tumor suppressor [129, 130]. The close evolutionary proximity 
between 11β-HSD1 and DHRS7, may represent a valuable starting point for the identification of novel 
substrates for this orphan enzyme. In this regard, Wsol and coworkers proposed several endogenous 
and exogenous compounds known as 11β-HSD1 substrates, such as cortisone, NKK or metyrapone, as 
potential substrates of DHRS7 and they provided evidence that purified recombinant human DHRS7 
indeed catalyzes the carbonyl reduction of several compounds [131-133]; however, the physiological 
relevance of their metabolism by DHRS7 was not further assessed. Regarding cancer progression, 
cortisone to cortisol conversion would support the decreased anti-proliferative and pro-apoptotic 
effects found with enhance prostate cancer progression and reduced DHRS7 expression. Araya et al. 
investigated the role of DHRS7 in the interconversion of cortisone/cortisol and the modulation of AR 
activity by interconversion of androstenedione/testosterone and 5α-dihydrotestosterone 
(5αDHT)/3α-androstandediol (3αAdiol) [92]. Cortisone was found to be reduced by DHRS7, however 
not at 11 position of the steroid backbone, but at position 20 to 20β-dihydrocortisone. 
Androstenedione was excluded as relevant substrate; nevertheless, 5αDHT was converted by DHRS7 
to the inactive metabolite 3αAdiol thereby showing a suppressive effect on AR activity, although at 
high concentrations that may not be of physiological relevance. In this regard, DHRS7 nicely exhibits 
catalytic activity on rotational symmetric sites of the steroid backbone, at positions 3 and 20, compared 
to positions 7 and 11 as seen with 11β-HSD1 (Figure 6). Nevertheless, the physiological roles remain 
uncertain and further investigations are needed.  
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 Figure 6. Rotational symmetry of the steroid backbone exemplified on the two DHRS7 substrates 
5αDHT (blue) and cortisone (green). (Figure adapted from Araya et al. [92]) Cortisone 180°rotated and 
overlaid with 5αDHT shows the close proximity of the 3-oxo and the 20-oxo groups. 
 
Thus, the existence of other yet unexplored substrates of DHRS7 can be assumed and we intended to 
employ homology modeling including a structure-based VS approach to identify potential novel 
substrates. Since DHRS7 has an ER transmembrane anchor, the three-dimensional protein structure 
resolution has not been accomplished so far. Therefore, 11β-HSD1 was utilized as structural template 
due to the highest structural sequence identity. Three DHRS7 homology models were generated using 
Swiss-Model (https://swissmodel.expasy.org/interactive) [134-137] based on the 11β-HSD1 X-ray 
structures with the PDB entry 2BEL [DOI: http://dx.doi.org/10.2210/pdb2bel/pdb], 1XSE [DOI: 
http://dx.doi.org/10.2210/pdb1xse/pdb] and 1XU9 [DOI: http://dx.doi.org/10.2210/pdb1xu9/pdb]. 
Subsequently, the cofactor NADPH from the template was fitted into the models and subjected to 
energy minimization within a sphere of 9 Å implemented in the program package Molecular Operating 
Environment (MOE, Chemical Computing Group, (http://www.chemcomp.com) [138]. 3D structural 
alignment of all three homology models revealed a highly variable region comprising a part of the 
ligand binding site but especially the entry of the binding pocket (Figure 7A). This limits the predictivity 
of the models if applied for further structure-based VS approaches. Nevertheless, the models generally 
displayed a cone-shaped binding site (Figure 7B) with a rather hydrophobic core. The flexible loops 
surrounding the binding pocket suggest the induction of an induced fit upon ligand binding. Although 
rigid docking calculations of cortisone into the homology model of DHRS7 showed the major 
conformation of cortisone pointing with its carbonyl group at the position 20 towards the catalytic 
center, the distances to the catalytic residues were >5Å (Figure 7C).  
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 Figure 7. DHRS7 homology models. (A) Structural alignment of the three DHRS7 homology models 
(dark blue: PDB: 2BEL as template; bright blue: PDB: 1XU9 and orange: PDB 1XSE). The highly variable 
regions comprising a part the entry of the binding pockets is depicted in the frame. (B) Cone-shaped 
binding pocket of the DHRS7 homology model (based on 2BEL) with NAPDH. (C) Rigid docking 
calculation of cortisone (orange) into the binding pocket of DHRS7 (model based on 2BEL) with the 
carbonyl group at position 20 pointing towards the catalytic center.  
 
Thus, structural optimization of the homology models and especially of the poorer resolved binding 
entry site is required before considering VS for potential substrates.  
However, Zemanová et al. recently described a substrate identification approach for DHRS7 based on 
a combination of homology modeling, structure-based docking calculations and experimental 
evaluations [98] – the initial intention of the current project. By screening of an in-house database and 
a part of the HMDB, they confirmed 5αDHT as substrate for DHRS7 and reported two novel substrates 
benzil and 4,4’-dimetylbenzil, albeit the observed kinetic activity was very low. This supports further 
investigations regarding the identification of other physiologically relevant substrates for DHRS7. The 
elongated cone-shaped binding pocket of DHRS7 may suggest larger metabolites to be converted as 
for instance different eicosanoids or other lipid mediators that represent interesting compound classes 
for following analyses.  
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4.3. Carbonyl reductase 1 
 
The cytosolic enzyme CBR1 is particularly known for its role in phase I metabolism of a variety of 
carbonyl containing xenobiotic compounds including the detoxification of polycyclic aromatic 
hydrocarbons, p-quinons, but also the conversion of the anthracycline cytostatic agent doxorubicin 
into a cardiotoxic anthracycline alcohol metabolite, which further contributes to the development of 
a chemotherapy resistance [139, 140]. Endogenous substrates of CBR1 have been reported and 
comprise steroids, prostaglandins, S-nitrosoglutathione and lipid aldehydes (see also chapter 4.1.2 
HMDB and LMSD screening) [94, 114, 115, 140-143]. However, the physiological relevance of the 
endogenous substrates proposed to be metabolized by CBR1 remains unclear, since the kinetic 
properties for the majority of them, are much lower than for several xenobiotic compounds.  
Substantial interindividual differences in the expression and activity of CBR1 have been reported, 
which could lead to unpredictable pharmacokinetics and pharmacodynamics of drugs metabolized by 
CBR1 (reviewed in [140, 144]). Genetic polymorphisms may contribute to the observed variable CBR1 
activities. Their functional impact, however, has not been fully understood yet. Furthermore, CBR1 
homozygous null mice showed an embryonic lethal phenotype, indicating an essential role during fetal 
development [139]. 
To further explore the physiological roles of CBR1, the following section describes the identification of 
a novel function for CBR1 in the metabolism glucocorticoids. 
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Carbonyl reductase 1 catalyzes 
20β-reduction of glucocorticoids, 
modulating receptor activation and 
metabolic complications of obesity
Ruth A. Morgan1,2, Katharina R. Beck3, Mark Nixon  1, Natalie Z. M. Homer  4, Andrew A. 
Crawford1,5, Diana Melchers6, René Houtman6, Onno C. Meijer7, Andreas Stomby8, Anna 
J. Anderson1, Rita Upreti1, Roland H. Stimson1, Tommy Olsson8, Tom Michoel  9, Ariella 
Cohain10, Arno Ruusalepp11,12,13, Eric E. Schadt  10, Johan L. M. Björkegren10,11,12,13,14, Ruth 
Andrew  1,4, Christopher J. Kenyon1, Patrick W. F. Hadoke1, Alex Odermatt  3, John A. Keen2 
& Brian R. Walker1,4
Carbonyl Reductase 1 (CBR1) is a ubiquitously expressed cytosolic enzyme important in exogenous 
drug metabolism but the physiological function of which is unknown. Here, we describe a role for 
CBR1 in metabolism of glucocorticoids. CBR1 catalyzes the NADPH- dependent production of 
20β-dihydrocortisol (20β-DHF) from cortisol. CBR1 provides the major route of cortisol metabolism 
in horses and is up-regulated in adipose tissue in obesity in horses, humans and mice. We 
demonstrate that 20β-DHF is a weak endogenous agonist of the human glucocorticoid receptor (GR). 
Pharmacological inhibition of CBR1 in diet-induced obesity in mice results in more marked glucose 
intolerance with evidence for enhanced hepatic GR signaling. These findings suggest that CBR1 
generating 20β-dihydrocortisol is a novel pathway modulating GR activation and providing enzymatic 
protection against excessive GR activation in obesity.
Carbonyl reductase 1 is a member of the short chain dehydrogenase/reductase family and is most commonly 
studied for its role in exogenous drug metabolism, particularly the conversion of chemotherapeutic drug doxo-
rubicin to cardiotoxic danurubicin1, 2. Significant effort has gone into developing inhibitors of this enzyme which 
could be administered as an adjunct to doxorubicin therapy and thus reduce cardiac side effects3–5. There is also 
marked biological variation in expression of the CBR1 protein between ethnicities6 and following exposure to 
environmental agents such as cigarette smoke7 and flavonoids8. However the physiological role of this enzyme is 
unknown. Here we describe a novel role for CBR1 in glucocorticoid metabolism.
Glucocorticoids act through ubiquitous glucocorticoid receptors (GR) and cell-specific mineralocorticoid 
receptors (MR) to modulate, for example, fuel metabolism, inflammation and salt and water balance. Plasma 
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glucocorticoid concentrations are controlled by the hypothalamic-pituitary-adrenal axis, which balances adrenal 
secretion of glucocorticoids against their clearance from the circulation by intracellular enzymes, predominantly 
active in the liver and kidney. These enzymes also modulate intracellular glucocorticoid concentrations inde-
pendently of plasma concentrations, thereby conferring tissue-specific control of GR and MR activation. For 
example, in mineralocorticoid-responsive tissues such as the kidney and colon, MR are protected from exposure 
to the high-affinity ligand cortisol by 11β-hydroxysteroid dehydrogenase type 2 (11β-HSD2)9, which converts cor-
tisol to inert cortisone; inhibition of 11β-HSD2 results in cortisol-dependent excessive MR activation and hyper-
tension. In contrast, in glucocorticoid-responsive tissues such as liver and adipose, cortisol is regenerated from 
cortisone by 11β-HSD type 1 (11β-HSD1) thereby amplifying GR activation10; inhibition of 11β-HSD1 improves 
glucose tolerance in patients with type 2 diabetes11. Further modulation of receptor activation may be conferred 
by generation of glucocorticoid metabolites which retain activity at corticosteroid receptors. For example, hepatic 
5α-reduction is the predominant clearance pathway for cortisol in humans but the product of this pathway, 
5α-tetrahydrocortisol (5α-THF), is a selective GR modulator which may contribute to anti-inflammatory sig-
naling12; inhibition of 5α-reductase type 1 results in glucose intolerance and liver fat accumulation, likely due 
to increased cortisol action in liver or skeletal muscle13. In humans and in rodent models, obesity is associated 
with tissue-specific dysregulation of cortisol metabolism, for example increased 5α-reductase activity and altered 
11β-HSD1 activity14.
We embarked on an investigation of cortisol metabolism in domesticated horses, for whom obesity is a grow-
ing problem15 and discovered that the predominant metabolite of cortisol (F) in this species is 20β-dihydrocortisol 
(20β-DHF), which is increased in obesity. 20β-DHF has previously been identified in equine16 and human17 
urine. Increased urinary excretion of 20β-DHF has been associated with Cushing’s disease18 and hypertension19 in 
humans. In this study we: dissected pathway producing 20β-DHF in horses, humans and mice; documented the 
enzyme responsible as carbonyl reductase 1 (CBR1); discovered that 20β-DHF modulates GR; and demonstrated 
the metabolic consequences of inhibiting CBR1.
Results
20β-Dihydrocortisol is a metabolite of cortisol in horses and humans and its urinary excretion is 
increased in obesity. Urine, blood and tissue were collected from healthy (n = 14) and obese (n = 14) horses 
at post-mortem (see Supplementary Table S1 for clinical characteristics). Glucocorticoids were extracted and 
quantified using GC-MS/MS (urine) or LC-MS/MS (tissue and plasma). 20β-DHF accounted for approximately 
60% of total glucocorticoid metabolite urinary excretion in healthy horses, and was increased in obese horses 
(Fig. 1A). Plasma 20β-DHF, but not cortisol, concentrations were also increased in obese horses (Fig. 1B). In 
Figure 1. 20β-Dihydrocortisol (20β-DHF) is an abundant cortisol metabolite which is increased in plasma and 
urine of obese horses. (A) Obese horses excreted significantly more urinary β-cortol, β-cortolone and 20β-DHF 
than lean horses as measured by GC-MS/MS. (B) Plasma 20β-DHF concentrations were significantly higher in 
obese horses compared to lean horses. (C) Hepatic 20β-DHF concentrations did not differ between lean and 
obese horses. (D) Visceral adipose 20β-DHF concentrations did not differ between lean and obese horses. Data 
are mean ± SEM, n = 14/group, *P < 0/05.
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visceral adipose tissue and liver, cortisol and 20β-DHF concentrations were measurable but not different between 
lean and obese horses (Fig. 1C–D).
Twenty-four hour urine samples were collected from healthy lean men (mean age 37.7 ± 15.9 years), and from 
obese men with and without type 2 diabetes (mean age 51.1 ± 14.9 years). As previously reported, the human 
urinary cortisol metabolite profile was dominated by products of 5α- and 5β- reduction, β-cortol in particular17, 
and total metabolite excretion was increased in obesity20 (Supplementary Fig. S1). 20β-DHF was observed in 
human urine, accounting for approximately 3% of total urinary cortisol metabolites (Supplementary Fig. S1), 
and 20β-DHF excretion was increased in obesity (Fig. 2A), independently of the presence of diabetes, but was 
not disproportionately increased compared with other measured cortisol metabolites (see Supplementary Fig. S1 
for metabolite pathways). 20β-DHF was also readily detected in plasma from healthy lean men at similar levels to 
corticosterone (Fig. 2B), but was not altered in obesity.
Carbonyl reductase 1 converts cortisol to 20β-dihydrocortisol and is increased in equine, 
murine and human obesity. The enzyme responsible for 20β-DHF production was previously unknown. 
Carbonyl reductase 1 (CBR1) is a ubiquitously expressed short-chain dehydrogenase known for its role in xeno-
biotic metabolism21. Cortisol is reported as a substrate of CBR1 but its product has not been identified21. We 
found that recombinant human CBR1 converted cortisol to 20β-DHF in the presence of NADPH at a rate of 
1.2 ± 0.4 ng/mg CBR1 protein per minute (1 μM cortisol substrate). Moreover, CBR1 accounts for equine pro-
duction of 20β-DHF, which was the predominant metabolite in equine liver homogenate incubated with cortisol 
(Supplementary Fig. S2A), since this reaction was blocked by co-incubation with the CBR1 inhibitor quercetin in 
equine liver cytosol (Supplementary Fig. S2B). 20β-DHF was not produced by incubation of equine liver micro-
somes with cortisol.
CBR1 is highly expressed in gut, liver, adipose and renal tissue of mice and humans (http://www.proteinatlas.
org/ENSG00000159228-CBR1/tissue), the expression profile of horses has not been reported. We chose to exam-
ine the effect of obesity on expression of CBR1 in liver and adipose tissue. Hepatic CBR1 mRNA was not altered 
in obesity in horses or mice but CBR1 mRNA was increased in adipose tissue of obese horses (Fig. 3A). CBR1 
mRNA was also higher in high-fat fed mice (Fig. 3B) and in visceral adipose tissue from obese compared with 
lean men (n = 8/group, Fig. 3C).
Common functional genetic variants in the CBR1 locus predict metabolic disturbances in 
obesity. We used an expression quantitative trait loci (eQTL) approach in the STARNET dataset22 to test 
whether any SNPs in the CBR1 locus had a functional effect on hepatic or visceral adipose CBR1 expression, 
and then tested their association with phenotypic traits in publicly accessible datasets using MR-Base23. There 
were no eQTLs which influenced visceral adipose expression of CBR1 but eQTLs were identified in liver. Further 
analyses suggested that SNPs associated with higher CBR1 expression in the liver were causally associated with 
higher fasting glucose (beta 0.01, se <0.01, p = 0.02), higher glycated haemoglobin (beta 0.01, se <0.01, p = 0.01) 
(Supplementary Table S5). There was no evidence that CBR1 expression was causally associated with fasting 
insulin, HOMA-B or HOMA-IR (p > 0.2), although there was suggestive evidence that higher CBR1 expression 
causes lower body fat (beta −0.01, se 0.01, p-0.06). In addition to these observations in population based cohorts, 
eQTLs of CBR1 in liver were associated with BMI in the STARNET study participants (rs2835288, p = 5.7E-4). 
The eQTL rs2835288 had a negative effect on BMI (r = −0.13) but a positive effect on CBR1 liver expression 
(r = 0.43); accordingly CBR1 liver expression and BMI were negatively correlated (r = −0.093, p = 0.03). Using a 
conservative causal inference test24 there was suggestive evidence (p = 0.07) that expression of CBR1 in liver was 
causal for variation in BMI.
Figure 2. Urinary 20β-DHF is detectable in human urine and increased in obesity. (A) Obese (BMI >25, 
n = 37) humans excrete 20β-DHF at higher levels than lean (BMI <25, n = 15) humans. (B) 20β-DHF is readily 
detectable in human plasma but concentrations are not altered in obesity (n = 10/group). Plasma cortisol and 
corticosterone were not different between the groups. Data are mean ± SEM, *P < 0/05.
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20β-DHF activates glucocorticoid receptors. Given apparently contradictory associations of genetically 
high CBR1 activity with metabolic dysfunction but not obesity in humans, and the association of CBR1 expres-
sion and activity with obesity in multiple species, we investigated the interaction of 20β-DHF with GR in order to 
predict consequences of elevated CBR1 for GR activation.
Computational evaluation of the interactions formed by 20β-DHF with the GR ligand binding site using 
docking calculations revealed a similar binding pose compared to cortisol (Fig. 4A). Both ligands formed 
hydrogen-bonds (H-bonds) similar in length with the same amino acid residues (Arg611, Gln570, Asn564 and 
Thr739). The only difference observed was the hydroxyl group of 20β-DHF at position 20 representing a hydrogen 
bond donor instead of the carbonyl group of cortisol at the same position serving as hydrogen bond acceptor. 
Human epithelial A549 cells expressing endogenous GR and SF9 and HEK293 cells transfected with human 
GR were used to investigate 20β-DHF as an endogenous ligand of GR. In binding studies, unlabeled 20β-DHF 
displaced dexamethasone from GR in SF9 cell lysate preparations but only at 1000-fold higher concentration 
than cortisol (Fig. 4B). Nonetheless, transfection of HEK293 cells with GFP-GR showed that 20β-DHF induced 
nuclear translocation of GR within 30 minutes (Fig. 4C).
In functional studies, 20β-DHF was a weak agonist of GR. In A549 cells MMTV promoter-induced lucif-
erase activity, indicative of GR activation, was only partially induced by 20β-DHF at high concentration (2.5 μM; 
Fig. 4D). However, endogenous GR-responsive genes glucocorticoid-induced leucine zipper (GILZ), insulin-like 
growth factor binding protein 1 (IGFBP1), dual specificity phosphatase 1 (DUSP1) and FK506-binding protein 
51 (FKBP51) were all up-regulated by 20β-DHF in a concentration-dependent manner (Fig. 4E) and to a similar 
maximum as cortisol, albeit at substantially higher concentrations than cortisol. Similar dose-response relation-
ships were seen comparing the effects of cortisol and 20β-DHF in preventing IL-1β induction by TNFα in A549 
cells (Fig. 4F).
Co-regulator recruitment by GR on binding 20β-DHF was assessed by microarray assay for real-time 
co-regulator-nuclear receptor interaction (MARCoNI) with the GR agonist dexamethasone used as a positive 
control25. Under these conditions, 20β-DHF-activated GR recruited approximately 36% of the co-regulators 
recruited by dexamethasone (Fig. 5 and supplementary Excel file).
Pharmacological inhibition of Cbr1 in mice results in increased hepatic GR activation and 
worsens the metabolic effects of high-fat feeding. Knowing that both cortisol and 20β-DHF might 
amplify GR activation, we sought to test the effects of Cbr1 inhibition in mice to determine whether increas-
ing the substrate/product balance would increase or decrease GR activation. Unlike horses and humans, mice 
produce corticosterone (B) rather than cortisol as their major glucocorticoid. To validate the use of murine 
models to study the CBR1/20β-dihydroglucocorticoid pathway, preparatory work included demonstration that 
20β-dihydrocorticosterone (20β-DHB), the murine equivalent of 20β-DHF, induced MMTV-luciferase activity 
in HEK293 cells transfected with murine GR (Supplementary Fig. S3) and is present in murine plasma and tissue 
(Supplementary Fig. S4), and that Cbr1 mRNA was higher in adipose of C57BL/6 J adult male mice fed on a high 
fat diet for 6 weeks than controls on a normal chow diet (n = 6/group) (Fig. 3B). Murine diet-induced obesity 
was therefore used as a model in which to investigate the functional role of CBR1 and 20β-dihydro metabolites. 
Groups of adult male C57BL/6 J mice (n = 12/group) maintained on a high fat diet were randomly assigned to 
groups receiving vehicle (ethanol) or Cbr1 inhibitor (quercetin, 50 μg/mouse/day, administered in drinking water 
for 6 weeks).
Quercetin lowered hepatic 20β-DHB (Fig. 6A) and increased the ratio of Cbr1 substrate (corticosterone) to 
product (20β-DHB) in liver (vehicle B: 20β-DHB ratio 0.5 ± 0.2 versus quercetin B: 20β-DHB ratio 1.6 ± 0.4, 
P = 0.01). Quercetin did not alter 20β-DHB levels in subcutaneous adipose tissue (Fig. 6B) or plasma (Fig. 6C). 
Quercetin also raised peak plasma corticosterone concentrations (Fig. 6D) but did not affect food or water intake 
or bodyweight over the course of the experiment (Fig. 6E). However, quercetin raised fasting plasma insulin 
concentrations and blood glucose during glucose tolerance tests (Fig. 6F,G). Quercetin also increased hepatic 
expression of the GR-responsive gene Period 1 (Per1), but did not alter the mineralocorticoid-responsive gene 
serum glucocorticoid kinase 1 (Sgk1) or key gluconeogenic enzyme phosphoenolpyruvate carboxykinase (Pepck) 
Figure 3. Carbonyl reductase 1 expression is increased in adipose tissue in obese horses, humans and mice. 
(A) CBR1 mRNA transcript levels are increased in visceral adipose of obese horses (n = 14/group), (B) Visceral 
adipose Cbr1 transcript levels were increased in mice on a high-fat diet for 6 weeks (n = 6/group). (C) Visceral 
adipose CBR1 transcript levels were increased in obese humans (n = 8/group). Data are mean ± SEM, *P < 0.05.
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Figure 4. 20β-Dihydrocortisol binds, translocates and activates glucocorticoid receptor inducing gene 
transcription and suppressing inflammatory gene transcription. (A) Docking of cortisol and 20β-DHF into the 
ligand binding site of GR. The automatically created pharmacophore indicates the essential structural features 
for ligand binding (red and green arrows with spheres display hydrogen-bond (H-bond) interactions and 
yellow spheres hydrophobic interactions). Amino acid residues crucial for ligand binding are shown as sticks. 
Compared to the binding interactions of cortisol 20β-DHF differs only in the hydroxyl group at the position 
20, representing a H-bond donor instead of the carbonyl group of cortisol serving as H-bond acceptor. (B) 
Unlabelled 20β-DHF displaced 3[H]-dexamethasone from GR in the lysate of SF9 cells expressing GR. (C) 1uM 
20β-DHF induced translocation of cytoplasmic GR to the nucleus of HEK293 cells within 30 minutes visualised 
by fluroescence imaging at 20x magnification. (D) 2.5uM 20β-DHF induced luciferase activation in A549 cells 
transfected with glucocorticoid responsive plasmid MMTV-luc. (E) 20β-DHF induced transcription of GR-
responsive genes IGFBP1 (EC50 0.51 µM), DUSP1 (EC50 0.32 µM), FKBP51 (EC50 0.44 µM) and GILZ (EC50 
1.25 µM) in A549 cells. (F) TNFα induced transcription of IL-1β in A549 cells, this was inhibited by cortisol and 
by 20β-DHF at 0.15 µM. Transcription was not reduced by co-incubation of cortisol or 20β-DHF with the GR 
antagonist RU486. Experiments were performed in triplicate on three occasions. Data are mean ± SEM (N = 3). 
Data were compared by two-way ANOVA and Bonferroni correction test: *P < 0.05, **P < 0.01 compared to 
vehicle.
Figure 5. 20β-Dihydrocortisol induces similar co-regulator interactions with GR as dexamethasone MARCoNI 
analysis of co-activator recruitment showed that on binding 20β-DHF, GR recruited 36% of the co-regulators 
recruited by dexamethasone. The colour of the bar represents the modulation index i.e. compound induced 
log-fold change of binding, red a positive fold change and blue a negative fold change. *P < 0.05, **P < 0.01, 
***P < 0.001 compared to the unbound receptor.
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in the liver (Fig. 6H). Transcript levels of Per1, adiponectin and lipoprotein lipase were not altered by quercetin 
in subcutaneous adipose tissue (Fig. 6I).
Discussion
We describe a novel pathway of glucocorticoid metabolism, whereby cortisol is converted to 20β-dihydrocortisol 
by the cytosolic enzyme CBR1, producing a metabolite which is a weak activator of GR. This pathway is 
up-regulated in adipose-tissue of obese horses, humans and mice; genetic variation in the liver predicts glucose 
dysregulation and its pharmacological inhibition alters the hypothalamic-pituitary-adrenal axis and tissue steroid 
levels in mice, with associated changes in GR-dependent gene expression and in metabolic homeostasis. This 
provides important new insights into the control of tissue glucocorticoid action and its contribution to cardio-
metabolic disease.
The glucocorticoid metabolite profile of horses, a cortisol-dominant species26, has not previously been 
described, although inter-species variation in hepatic cortisol metabolism has been reported27. 20β-DHF has 
been measured in horse urine16 and purported to be a sensitive indicator of cortisol administration, but ours are 
the first data showing 20β-DHF relative to other metabolites, and the first demonstrating 20β-DHF in plasma, 
adipose tissue and liver of horses. Predominance of 20β-DHF production occurs in other large herbivores, includ-
ing sheep28, 29. The human cortisol metabolome is more thoroughly described17, 30, and is dominated by products 
of 5α- and 5β-reduction. However, 20β-DHF has previously been identified in human urine17, 18 at levels similar 
to that of 5α-tetrahydrocortisol (5α-THF). Occasional case reports indicate urinary excretion of 20β-DHF is 
increased in human Cushing’s syndrome18, collagen disease31, rheumatoid arthritis32, hypertension19 and liver 
cirrhosis33, 34. In our study 20β-DHF was readily detectable in the plasma of healthy humans at levels equal or 
higher to that of corticosterone, but 20β-DHF represented a much smaller proportion of cortisol metabolism 
than in horses.
Figure 6. Inhibition of CBR1 in a murine model of diet-induced obesity results in increased GR activation 
and metabolic dysfunction. (A) Hepatic 20β-DHB levels were significantly lower in quercetin treated mice, 
(B) 20β-DHFB levels were not altered in subcutaneous adipose tissue, (C) plasma 20β-DHB levels were not 
altered by quercetin treatment (D) quercetin treatment resulted in increased peak plasma corticosterone 
levels. (E) Bodyweight was not different between mice in the vehicle treated group and mice treated with 
quercetin. (F,G) Quercetin-treated mice were significantly more insulin resistant and had higher fasted plasma 
insulin concentrations. (H) mRNA transcript levels of hepatic Per1 were increased in quercetin treated mice, 
(I) Adipose mRNA expression of Per1, Adiponectin (Adipq) and lipoprotein lipase (Lpl) were not altered by 
quercetin treatment. Data are mean ± SEM, n = 12/group, *P < 0.05.
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There are reports of reduction of cortisol to 20β-DHF in various human cell/tissue types including kidney and 
prostate35, gingiva36, fibroblasts37 and thrombocytes38. We found that CBR1, a ubiquitously expressed member of 
the short-chain dehydrogenase/reductase (SDR) superfamily1 catalyzes the conversion of cortisol to 20β-DHF. 
CBR1 expression is highest in tissues involved in detoxification or clearance, e.g. liver, colon, renal tubules and 
placenta39 and has been studied for its role in drug metabolism3 and as an antioxidant40. Its expression is associ-
ated with cancer, particularly lung cancer7, and reported to protect against pancreatic islet cell death41. Inhibitors 
of CBR1 have been proposed for use with chemotherapeutic agents to reduce the cardiotoxic side-effects of drugs 
such as doxorubicin4. Although glucocorticoids are known to be substrates of CBR1, the products have not been 
identified previously40. We attribute 20β-dihydro glucocorticoid generation to CBR1 since isolated CBR1 converts 
cortisol to 20β-DHF and not to other metabolites, hepatic microsomal preparations are devoid of such activity, 
and inhibition of CBR1 is sufficient to prevent 20β-DHF generation in equine liver cytosol and to lower tissue 
20β-DHB in mouse liver in vivo.
The majority of cortisol metabolites are thought to be inert and are produced to facilitate steroid excretion. 
Some metabolites, however, such as 5α-tetrahydrocorticosterone (5α-THB) bind and activate GR12. Given that 
20β-DHF was found in plasma and tissues of humans at similar levels to the endogenous glucocorticoid corti-
costerone, and is thus potentially of physiological significance, we investigated the action 20β-DHF on GR. We 
found that 20β-DHF bound GR with a lower affinity than that of cortisol but induced nuclear translocation of the 
receptor within 30 minutes, a time period comparable with cortisol. 20β-DHF induced transrepressive and trans-
activation effects after binding to GR albeit at higher concentrations than cortisol. The consequences of variation 
in CBR1 activity for GR activation are therefore hard to predict.
In human obesity, increased total cortisol production42 without consistently elevated plasma cortisol concen-
trations has been attributed to enhanced clearance of cortisol20, and in turn to increased 5α- and 5β-reductase 
and reduced 11β-HSD1 activities20. In humans, horses and mice obesity was associated with increased CBR1/
Cbr1 expression in adipose tissue, in horses with increased 20β-DHF in plasma, and in humans and horses 
with increased 20β-DHF in urine. Although 20β-DHF was not disproportionately raised in urine, total cortisol 
metabolite excretion was increased so these data are consistent with the CBR1/20β-DHF pathway contributing to 
increased cortisol clearance in obesity. Up-regulation of the CBR1 pathway in obesity was evident in adipose but 
not liver in horses and mice. In addition we did not identify any eQTL for CBR1 expression in adipose suggesting 
that this up-regulation is a functional response to obesity. This is consistent with intra-adipose inflammation and 
hypoxia in obesity, since CBR1 expression is up-regulated in response to hypoxia and inflammation via transcrip-
tion factors including Nrf2, AhR and HIF-1α43, 44. In contrast our data suggest that there are genetic influences 
on hepatic CBR1 expression in humans and that higher expression is associated with higher leptin, higher fasting 
glucose and higher HbA1c. Tissue-specific regulation of CBR1 is reported43, 45, 46 so the eQTLs we identified may, 
for example, exert their influence through liver-specific promoter(s).
To further explore the contribution of CBR1 dysregulation in obesity, we administered the Cbr1 inhibitor 
quercetin to mice with diet-induced obesity. Pharmacodynamic data suggest that quercetin inhibited corticoster-
one conversion to 20β-DHB in liver, but not in adipose tissue; this may indicate that adipose 20β-DHB is mainly 
derived from plasma rather than from local generation, or that the drug was unable to penetrate adequately into 
adipose tissue. Although an eQTL predicting higher hepatic CBR1 was associated with adverse metabolic indices, 
a paradoxical deterioration in glucose metabolism was observed when we inhibited the enzyme. This was accom-
panied by altered GR-regulated genes in liver which may be explained by the effect of substrate (corticosterone) 
accumulation or by secondary activation of the HPA axis with elevated peak plasma corticosterone resulting from 
impaired clearance. A similar phenotype and liver transcript profile occurs in mice with genetic deletion of the 
glucocorticoid-inactivating enzyme 5α-reductase type 147. Alternatively we could infer that there is a non-linear 
relationship between Cbr1 expression and effect and that an optimal cortisol/20β-DHF balance may be required 
for normal liver GR activation, such that dysregulation of Cbr1 in either direction leads to GR excess.
These findings are important since there are wide variations in CBR1 activity between individuals, in dis-
ease and after consumption of a number of naturally occurring CBR1 inhibitors: human tissue CBR1 expression 
and activity varies significantly between ethnic groups6; CBR1 expression and activity is increased in Down’s 
syndrome due to the location of the CBR1 gene on chromosome 2148; CBR1 inhibitors such as flavonoids and 
polyphenols are present in many foods and supplements49 and reported enhancers of CBR1 activity include com-
ponents of cigarette smoke7. Our data suggest the resulting variation of CBR1/20β-DHF has important conse-
quences for glucocorticoid metabolism and GR activation in health and disease.
Materials and Methods
Study design. We conducted case-control, cross-sectional or intervention studies in horses, humans, cells 
and mice. Sample sizes were chosen for 80% power to detect magnitudes of difference inferred from pilot data 
with the number of subjects and outcomes defined below or in figure legends. In vitro experiments were per-
formed in triplicate with the number of experiments and outcomes defined below and in figure legends. Details 
on inclusion and exclusion criteria for horse and human subjects are detailed below. There were no dropouts and 
no outliers were excluded.
Cortisol metabolism in horses. The first aim of the study was to characterize cortisol metabolism in lean 
and obese horses. We addressed this aim using an observational case-control study recruiting lean horses and 
obese horses that were destined for euthanasia at the Royal (Dick) School of Veterinary Studies, University of 
Edinburgh. Studies in horses were approved by the Royal (Dick) School of Veterinary Studies Ethics and Research 
committee (VERC 7014). The study was performed according to the approved ethical guidelines. The sample 
size (n = 14/group) was determined by interim analysis using total glucocorticoid metabolite excretion as the 
end-point (80% power to detect a 20% difference in groups, p < 0.05). Lean (body condition score, measure of 
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obesity ≤3/550) and obese (body condition score ≥4/5) castrated male and female horses destined for euthanasia, 
were recruited from clinics at the Royal (Dick) School of Veterinary Studies. Horses were excluded if they were 
less than 1 year old, suffering from any concurrent systemic illness or had received glucocorticoid treatment in the 
3 months prior to commencement of the study. Blood was obtained after overnight fasting, between 0900 h and 
1100 h, via an intravenous cannula inserted in the jugular vein for the purpose of euthanasia.
Horses were humanely euthanased (0900 h to 1100 h) with quinalbarbitone sodium and cinchocaine 
hydrochloride (1 mL/10Kg bodyweight; Somulose, Dechra Veterinary Products, Shrewsbury, UK). Samples of 
peri-renal adipose, liver and urine were snap frozen and stored at −80 °C.
Glucocorticoids were extracted from plasma, adipose and liver and quantified by LC-MS/MS (see supple-
mentary methods). Urinary glucocorticoids were derivatized and quantified by GC-MS/MS (supplementary 
methods). Urinary creatinine was measured by the modified Jaffe’s reaction (IL650 analyzer, Instrumentation 
Laboratories). Glucocorticoid concentrations were expressed as μg/mmol creatinine. RNA was extracted from 
adipose and liver samples for quantification of CBR1 mRNA relative to housekeeping genes SDHA and 18 s (see 
supplementary methods and supplementary Table S7).
20β-DHF in humans. In order to determine the relevance of 20β-DHF to human health and disease sam-
ples were collected from male participants at the University of Edinburgh with approval from the University 
of Edinburgh Research Ethics Committee, National Health Service Lothian Research and Development Office, 
and at Umea University with approval from the Umea Regional Ethical Review Board. The study was performed 
according to the approved ethical guidelines. Participants were required to give written informed consent prior 
to recruitment to the study. Lean individuals were defined as having a BMI <25 kg/m2 and obese individuals as 
having a BMI >25 kg/m2. Clinical details are given in supplementary Tables 2–4.
Twenty-four hour urine samples were obtained from healthy lean (n = 15) and obese (n = 18) men recruited 
as part of a separate study13. In addition, urine was collected from obese men (n = 19) with Type 2 diabetes (with 
no insulin treatment) (Supplementary Table S2). Morning fasted plasma samples were collected from healthy 
lean (n = 10) and obese (n = 10) men (Supplementary Table S3). Adipose biopsy samples for RNA extraction 
were collected from lean (n = 8) and obese (n = 8) individuals undergoing surgery (Supplementary Table S4). 
Glucocorticoids were extracted and quantified from plasma and urine as detailed in supplementary methods.
CBR1 activity in vitro. In order to determine if CBR1 could convert cortisol to 20β-DHF recombinant 
human CBR1 (Source Bioscience, Nottingham, UK) was incubated with cortisol (1 mM) and NADPH (2 mM) 
for a time course (5, 10, 20, 30, 60 and 120 minutes) at 37 °C. The reaction was stopped with the addition of ace-
tonitrile (500 µL). Deuterated cortisol (9, 11, 12, 12-[2H]4-cortisol) was added as an internal standard for quanti-
fication of cortisol and 20β-DHF. Following centrifugation (5 minutes) the supernatant was removed, dried down 
and re-suspended in mobile phase (60 µL 50:50 Methanol: water) for analysis by LC-MS/MS (Supplementary 
methods).
Interrogation of genetic data for CBR1 expression and phenotypic associations. No genetic 
variants have been robustly associated with CBR1 enzyme activity. Therefore, genetic variants that are associated 
with CBR1 transcript levels in liver were used as a surrogate for CBR1 enzymatic activity. Expression quantitative 
trait loci (eQTLs) located near to the CBR1 gene and associated with CBR1 expression in the liver were identified 
from the Stockholm-Tartu Atherosclerosis Network Engineering Task (STARNET) study. STARNET comprises 
data on 600 cases of cardiovascular disease undergoing surgical intervention with collection of multiple tissue 
types including the liver. Genome wide genotyping and tissue expression analyses including RNAseq have been 
performed22.
A two-sample Mendelian randomization approach was used to estimate the effect of CBR1 expression in the 
liver on outcomes of body mass index (BMI), body fat, and glucose and insulin sensitivity. The outcome data were 
extracted from publicly available datasets, including from GIANT and MAGIC consortia, using MR-Base23. In 
cases where outcome data were available from more than one study, the study containing all the relevant informa-
tion with the largest sample size was selected. The causal effect of CBR1 expression on the relevant outcomes was 
estimated using the Wald (or ratio) method. This method divides the coefficient from regression of the outcome 
on the genetic variant by the coefficient from regression of the exposure on the variant51; the former was derived 
from publicly available data and the latter from STARNET. This approach makes the assumption that all instru-
mental variables are valid and not subject to horizontal pleiotropy where a genetic variant affects the outcome via 
more than one biological pathway. Study overlap is a concern when undertaking two sample Mendelian random-
ization analyses. The STARNET study has not provided data to the GIANT or MAGIC consortia.
20β-DHF interaction with glucocorticoid receptor. Docking of 20β-DHF with GR. Docking studies 
were performed using the GOLD software version 5.2 (Cambridge Crystallographic Data Centre, Cambridge, 
UK)52. This software allows the identification of precise docking poses for small molecules in the binding pocket 
of a protein applying a genetic algorithm. The crystal structures with the Protein Data Bank (PDB) entry 4P6X 
[DOI:10.2210/pdb4p6x/pdb] was selected for GR. First the respective co-crystallized ligand, cortisol for GR, was 
removed from the binding pocket and re-docked into the binding site to examine whether GOLD could restore 
the original binding pose and therefore to validate the docking settings (RMSD value of 0.409 for GR). The GR 
binding sites were defined by the ligand surrounded by a 6 Å region lining the active site. GoldScore was used as 
scoring function.
Protein ligand interactions determined by the docking software were further assessed using LigandScout 3.12 
(inte:ligand GmbH, Vienna, Austria). Based on chemical functionalities, geometric distances and angles between 
146
www.nature.com/scientificreports/
9SCIENTIFIC REPORTS | 7: 10633  | DOI:10.1038/s41598-017-10410-1
adjacent structures, this software automatically evaluates the observed binding pattern between the protein and 
the docked ligand53.
Glucocorticoid binding in SF9 cell lysates. Competitive GR binding experiments were conducted as described 
previously54. Briefly, recombinant human GRα baculovirus stock was produced using the Bac-to-Bac expression 
system and subsequently expressed in Sf9 cells according to the instructions by the manufacturer (Invitrogen, 
Carlsbad, CA). Sf9 cell lysates expressing recombinant human GR were then incubated in the presence of 
10 nM [1,2,4,6,7–3 H]-dexamethasone and unlabelled competitor (either 10 μM or 100 nM cortisol or 10 μM 
20β-DHF) for 4 h at 16 °C. Unbound ligand was separated by adding 5% dextran coated charcoal, followed by 
incubation at 4 °C for 10 min and centrifugation for 10 min at 3200 × g and 4 °C. The GR bound fraction of 
[1,2,4,6,7–3H]-dexamethasone in supernatants was measured by scintillation counting.
Experiments in cell culture. Human alveolar carcinoma cell line, A549, the human embryonic kidney cell 
line, HEK293 and the clonal line of Spodoptera frugiperda, SF9 were obtained from the European Collection of 
Cell cultures (ECACC; distributor Sigma-Aldrich Co.). Cells were grown and maintained in Dulbecco’s mod-
ified Eagle’s medium (DMEM, Lonza Group Ltd., Basel, Switzerland) supplemented with glucose (4.5 g/L), 
heat-inactivated fetal bovine serum (HI-FBS) (10% v/v), penicillin (100 IU/mL), streptomycin (100 µg/mL) and 
L-glutamine (2 mM). Cells were maintained and grown in a humidified atmosphere (95% air, 5% CO2, 37 °C). 
Unless otherwise stated cells were seeded at 2 × 105 per 35-mm well. Cells were cultured in steroid-free medium 
for 24 h prior to experimentation. Plasmids were a kind gift from K.E.Chapman, Centre for Cardiovascular 
Science, University of Edinburgh.
To study GR translocation, HEK293 cells were transfected with GR labelled with Green Fluorescent Protein 
(GFP-GR). After seeding and overnight incubation in steroid free medium, the medium was replaced with phe-
nol red free Opti-MEM (Lonza Group Ltd., Basel, Switzerland), and cells transfected using Lipofectamine 2000 
(Invitrogen, Thermo Fisher Scientific Co., Waltham, MA, USA) with 1 μg of GFP-GR plasmid. Cells were then 
treated with vehicle, cortisol (1 μM) or 20β-DHF (1 μM) and imaged using fluorescence microscopy (Nikon 
Eclipse TS100) prior to treatment and at 30, 60, 120 minutes and 4 hours.
GR activation by 20β-DHF was tested in A549 cells transiently transfected with MMTV-luciferase plasmid. 
Cells were transfected with 1 μg of pMMTV LTR–luciferase12 and 1 μg of pKC275 (encoding β-galactosidase 
as internal control) and treated with vehicle, cortisol (0.3 μM-5 μM) or 20β-DHF (0.3 μM-5 μM) for 4 hours. 
Cells were lysed and luciferase and β-galactosidase activities measured as described previously55. Galactosidase 
activity was assayed using a Tropix Kit (Applied Biosystems, Foster City, CA, USA). The mean ratio of lucif-
erase/b-galactosidase activities was calculated.
To determine effects of 20β-DHF on endogenous glucocorticoid-induced transcripts, A549 cells were incu-
bated in the presence of increasing concentrations of either cortisol, 20β-DHF (0.15 μM-5 μM) or vehicle (etha-
nol) for 4 hours. RNA was extracted and RT-qPCR used to quantify DUSP1 (dual specificity phosphatase 1), GILZ 
(glucocorticoid-induced leucine zipper), IGFBP1 (insulin-like growth factor binding protein 1) and of FKBP51 
(FK506-binding protein 51) relative to 18 S (see supplementary Table S6 for primer design and supplementary 
methods). To determine the effects of 20β-DHF on inflammatory transcripts cells were pre-incubated with vehi-
cle or TNFα (10 ng/mL) for 1 hour before a further 4 hours in the presence of vehicle, cortisol or 20β-DHF 
(0.15 μM–5 µM). RNA was extracted and IL-1β (interleukin 1β) mRNA quantified relative to 18S.
MARCoNI analysis of 20β-DHF binding to GR. A microarray Assay for Real-time Co-regulator-Nuclear 
Receptor Interaction (MARCoNI) was used to compare the quantitative and qualitative co-regulator recruitment 
induced when 20β-DHF (1 μM) binds with GR with that of recruitment in response to dexamethasone (1 μM) 
using a previously described method22, 56.
Pharmacological inhibition of CBR1 in vivo. For in vivo studies in mice, experiments were approved 
by the University of Edinburgh ethical committee and performed under the Provisions of the Animals Scientific 
Procedures Act (1986) of the UK Home Office, in accordance with EU Directive 2010/63. Male C57BL/6 J mice 
aged 8 weeks were purchased from Harlan laboratories and used to conduct a randomized vehicle controlled 
experiment. Mice were randomly assigned to the vehicle (n = 12) or quercetin-treatment group (n = 12). All 
the mice were fed ad-lib high-fat diet (D12331, Research Diets inc., New Jersey, USA) for 6 weeks. Quercetin 
treatment was administered in drinking water (50 μg/mouse/day57). Bodyweight, food and water intake were 
monitored weekly. At week 6 blood collected from tail nick at 0800 h and at 2000h for analysis of plasma basal cor-
ticosterone by Enzo Corticosterone EIA Kit (Enzo Life Sciences, Exeter, UK). Mice were fasted for 6 h (0800–1400 
h) in clean cages before undergoing a glucoses tolerance test (GTT). Glucose (2 mg/g body weight, 40% w/v in 
saline) was administered via intraperitoneal injection. Blood was collected from tail nick immediately prior to 
injection, 15, 30, 60, and 90 minutes after injection. Glucose was measured immediately using a point-of-care 
glucometer. Plasma insulin was measured using the Ultra-Sensitive Mouse Insulin ELISA kit (Crystal Chem, Inc., 
IL, USA). Seven days after the GTT animals were culled by decapitation. Plasma was extracted from trunk blood 
and stored at −20 °C. Tissue was extracted and stored at −80 °C. mRNA and glucocorticoid extraction and quan-
tification are described in supplementary methods (see Supplementary Table S8 for murine primer sequences).
Statistical analysis. For horse, human and mouse studies data were tested for normality by 
Kolmogorov-Smirnov test and subsequent comparisons (lean v obese) performed using unpaired Student’s t-tests 
or Mann-Whitney U test. For cell-based studies with changing steroid concentrations comparisons (20β-DHF v 
cortisol) were performed using two-way ANOVA with Bonferroni post-hoc tests. Statistical significance was set 
at P < 0.05.
147
www.nature.com/scientificreports/
1 0SCIENTIFIC REPORTS | 7: 10633  | DOI:10.1038/s41598-017-10410-1
References
 1. Malátková, P., Maser, E. & Wsól, V. Human carbonyl reductases. Curr. Drug Metab. 11, 639–658, doi:10.2174/138920010794233530 
(2010).
 2. Oppermann, U. In Annual Review of Pharmacology and Toxicology Vol. 47 (ed A. K. Cho) 293–322 (2007).
 3. Olson, L. E. et al. Protection from Doxorubicin-Induced Cardiac Toxicity in Mice with a Null Allele of Carbonyl Reductase. Cancer 
Research 63, 6602–6606 (2003).
 4. Tanaka, M. et al. An unbiased cell morphology-based screen for new, biologically active small molecules. PloS Biol. 3, 0764–0776, 
doi:10.1371/journal.pbio.0030128 (2005).
 5. Jo, A. et al. Inhibition of Carbonyl Reductase 1 Safely Improves the Efficacy of Doxorubicin in Breast Cancer Treatment. Antioxidants 
and Redox Signaling 26, 70–83, doi:10.1089/ars.2015.6457 (2017).
 6. Covarrubias, V. G., Lakhman, S. S., Forrest, A., Relling, M. V. & Blanco, J. G. Higher activity of polymorphic NAD(P)H:quinone 
oxidoreductase in liver cytosols from blacks compared to whites. Toxicol. Lett. 164, 249–258, doi:10.1016/j.toxlet.2006.01.004 (2006).
 7. Kalabus, J. L., Cheng, Q., Jamil, R. G., Schuetz, E. G. & Blanco, J. G. Induction of carbonyl reductase 1 (CBR1) expression in human 
lung tissues and lung cancer cells by the cigarette smoke constituent benzo[a]pyrene. Toxicology Letters 211, 266–273, doi:10.1016/j.
toxlet.2012.04.006 (2012).
 8. Carlquist, M., Frejd, T. & Gorwa-Grauslund, M. F. Flavonoids as inhibitors of human carbonyl reductase 1. Chemico-Biological 
Interactions 174, 98–108, doi:10.1016/j.cbi.2008.05.021 (2008).
 9. Edwards, C. R. W. et al. Localisation of 11β-hydroxysteroid dehydrogenase-tissue specific protector of the mineralocorticoid 
receptor. The Lancet 332, 986–989, doi:10.1016/S0140-6736(88)90742-8 (1988).
 10. Seckl, J. R. & Walker, B. R. Minireview: 11 beta-hydroxysteroid dehydrogenase type 1 - A tissue-specific amplifier of glucocorticoid 
action. Endocrinology 142, 1371–1376 (2001).
 11. Hughes, K. A., Webster, S. P. & Walker, B. R. 11-Beta-hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) inhibitors in Type 2 
diabetes mellitus and obesity. Expert Opinion on Investigational Drugs 17, 481–496, doi:10.1517/13543784.17.4.481 (2008).
 12. McInnes, K. J. et al. 5α-reduced glucocorticoids, novel endogenous activators of the glucocorticoid receptor. Journal of Biological 
Chemistry 279, 22908–22912, doi:Export Date 9 July 2014 (2004).
 13. Upreti, R. et al. 5α-Reductase Type 1 Modulates Insulin Sensitivity in Men. Journal of Clinical Endocrinology and Metabolism 99, 
E1397–E1406, doi:10.1210/jc.2014-1395 (2014).
 14. Wake, D. J. & Walker, B. R. 11 beta-Hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Molecular and 
Cellular Endocrinology 215, 45–54, doi:10.1016/j.mce.2003.11.015 (2004).
 15. Wyse, C. A., McNie, K. A., Tannahil, V. J., Murray, J. K. & Love, S. Prevalence of obesity in riding horses in Scotland. Veterinary 
Record 162, 590–591 (2008).
 16. Popot, M. A. et al. New approaches to detect cortisol administration in the horse. Equine Veterinary Journal 31, 278–284 (1999).
 17. Shackleton, C. H. L. Profiling steroid hormones and urinary steroids. J. Chromatogr. B Biomed. Sci. Appl. 379, 91–156, doi:10.1016/
S0378-4347(00)80683-0 (1986).
 18. Schoneshofer, M., Weber, B. & Nigam, S. Increased urinary excretion of free 20α- and 20β-dihydrocortisol in a hypercortisolemic 
but hypocortisoluric patient with Cushing’s disease. CLIN. CHEM. 29, 385–389 (1983).
 19. Kornel, L., Miyabo, S., Saito, Z., Cha, R. W. & Wu, F. T. Corticosteroids in human blood. VIII. Cortisol metabolites in plasma of 
normotensive subjects and patients with essential hypertension. Journal of Clinical Endocrinology and Metabolism 40, 949–958 
(1975).
 20. Andrew, R., Phillips, D. I. W. & Walker, B. R. Obesity and gender influence cortisol secretion and metabolism in man. Journal of 
Clinical Endocrinology and Metabolism 83, 1806–1809 (1998).
 21. Wermuth, B. Purification and properties of an NADPH-dependent carbonyl reductase from human brain. Relationship to 
prostaglandin 9-ketoreductase and xenobiotic ketone reductase. Journal of Biological Chemistry 256, 1206–1213 (1981).
 22. Franzén, O. et al. Cardiometabolic risk loci share downstream cis- and trans-gene regulation across tissues and diseases. Science 353, 
827–830, doi:10.1126/science.aad6970 (2016).
 23. Hemani, G. et al. MR-Base: a platform for systematic causal inference across the phenome using billions of genetic associations. 
bioRxiv. doi:10.1101/078972 (2016).
 24. Millstein, J., Zhang, B., Zhu, J. & Schadt, E. E. Disentangling molecular relationships with a causal inference test. BMC Genet. 10, 
doi:10.1186/1471-2156-10-23 (2009).
 25. Desmet, S. J. et al. Cofactor profiling of the glucocorticoid receptor from a cellular environment. Methods Mol. Biol. 1204, 83–94, 
doi:10.1007/978-1-4939-1346-6_8 (2014).
 26. Irvine, C. H. G. & Alexander, S. L. Factors affecting the circadian rhythm in plasma cortisol concentrations in the horse. Domestic 
Animal Endocrinology 11, 227–238 (1994).
 27. Abel, S. M., Back, D. J., Maggs, J. L. & Park, B. K. Cortisol metabolism in vitro - II. Species difference. Journal of Steroid Biochemistry 
and Molecular Biology 45, 445–453 (1993).
 28. Picard-Hagen, N. et al. Discriminant value of blood and urinary corticoids for the diagnosis of scrapie in live sheep. Veterinary 
Record 150, 680–684 (2002).
 29. Schelcher, F. et al. Corticoid concentrations are increased in the plasma and urine of ewes with naturally occurring scrapie. 
Endocrinology 140, 2422–2425 (1999).
 30. Abel, S. M., Maggs, J. L., Back, D. J. & Park, B. K. Cortisol metabolism by human liver in vitro. I. Metabolite identification and inter-
individual variability. Journal of Steroid Biochemistry and Molecular Biology 43, 713–719 (1992).
 31. Ichikawa, Y. Metabolism of cortisol-4-C14 in patients with infectious and collagen diseases. Metabolism 15, 613–625 (1966).
 32. Kemény, V., Farkas, K. & Gömör, B. Production of unconjugated 20-DHF (11 beta, 17 alpha, 20 beta, 21-tetrahydroxy-pregn-4-en-
3-one) in active rheumatoid arthritis. Acta Med Acad Sci Hung 27, 381–387 (1970).
 33. Bradlow, H. L., Fukushima, D. K., Zumoff, B., Hellman, L. & Gallagher, T. F. Metabolism of Reichstein’s substance E in man. The 
Journal of clinical endocrinology and metabolism 22, 748–753 (1962).
 34. Bradlow, H. L., Zumoff, B., Fukushima, D. K., Hellman, L. & Gallagher, T. F. Biotransformations of the C-20-dihydro metabolites of 
cortisol in man. Journal of Clinical Endocrinology and Metabolism 34, 997–1002, doi:10.1210/jcem-34-6-997 (1972).
 35. Jenkins, J. S. The metabolism of cortisol by human extra-hepatic tissues. Journal of Endocrinology 34, 51–56 (1966).
 36. El Attar, T. M. A. In vitro metabolism studies of [1,2,6,7-3H]-cortisol in human gingiva in health and disease. Steroids 25, 355–364, 
doi:10.1016/0039-128X(75)90092-6 (1975).
 37. Sweat, M. L. et al. The metabolism of cortisol and progesterone by cultured uterine fibroblasts, strain U12-705. BBA - Biochimica et 
Biophysica Acta 28, 591–596 (1958).
 38. Arie, R., Hoogervorst-Spalter, H., Kaufmann, H., Joshua, H. & Klein, A. Metabolism of cortisol by human thrombocytes. Metabolism 
28, 67–69, doi:10.1016/0026-0495(79)90170-7 (1979).
 39. Wirth, H. & Wermuth, B. Immunohistochemical localization of carbonyl reductase in human tissues. J. HISTOCHEM. 
CYTOCHEM. 40, 1857–1863 (1992).
 40. Forrest, G. L. & Gonzalez, B. Carbonyl reductase. Chemico-Biological Interactions 129, 21–40, doi:10.1016/S0009-2797(00)00196-4 
(2000).
 41. Rashid, M. A. et al. Carbonyl reductase 1 protects pancreatic β-cells against oxidative stress-induced apoptosis in glucotoxicity and 
glucolipotoxicity. Free Radic. Biol. Med. 49, 1522–1533, doi:10.1016/j.freeradbiomed.2010.08.015 (2010).
148
www.nature.com/scientificreports/
1 1SCIENTIFIC REPORTS | 7: 10633  | DOI:10.1038/s41598-017-10410-1
 42. Strain, G. W. et al. Sex difference in the influence of obesity on the 24 hr mean plasma concentration of cortisol. Metabolism 31, 
209–212, doi:10.1016/0026-0495(82)90054-3 (1982).
 43. Ebert, B., Kisiela, M. & Maser, E. Transcriptional regulation of human and murine short-chain dehydrogenase/reductases (SDRs) 
– an in silico approach. Drug Metab. Rev. 48, 183–217, doi:10.3109/03602532.2016.1167902 (2016).
 44. Miura, T., Taketomi, A., Nishinaka, T. & Terada, T. Regulation of human carbonyl reductase 1 (CBR1, SDR21C1) gene by 
transcription factor Nrf2. Chemico-Biological Interactions 202, 126–135, doi:10.1016/j.cbi.2012.11.023 (2013).
 45. Guo, C., Wang, W., Liu, C., Myatt, L. & Sun, K. Induction of PGF2α synthesis by cortisol through GR dependent induction of CBR1 
in human amnion fibroblasts. Endocrinology 155, 3017–3024, doi:10.1210/en.2013-1848 (2014).
 46. Lakhman, S. S., Chen, X., Gonzalez-Covarrubias, V., Schuetz, E. G. & Blanco, J. G. Functional characterization of the promoter of 
human carbonyl reductase 1 (CBR1). Role of XRE elements in mediating the induction of CBR1 by ligands of the aryl hydrocarbon 
receptor. Mol. Pharmacol. 72, 734–743, doi:10.1124/mol.107.035550 (2007).
 47. Dowman, J. K. et al. Loss of 5α-Reductase Type 1 accelerates the development of hepatic steatosis but protects against hepatocellular 
carcinoma in male mice. Endocrinology 154, 4536–4547, doi:10.1210/en.2013-1592 (2013).
 48. Quiñones-Lombraña, A. et al. Interindividual variability in the cardiac expression of anthracycline reductases in donors with and 
without Down syndrome. Pharmaceutical Research 31, 1644–1655, doi:10.1007/s11095-013-1267-1 (2014).
 49. Boušová, I., Skálová, L., Souček, P. & Matoušková, P. The modulation of carbonyl reductase 1 by polyphenols. Drug Metab. Rev. 47, 
520–533, doi:10.3109/03602532.2015.1089885 (2015).
 50. Carroll, C. L. & Huntington, P. J. Body condition scoring and weight estimation of horses. Equine Veterinary Journal 20, 41–45 
(1988).
 51. Didelez, V. & Sheehan, N. Mendelian randomization as an instrumental variable approach to causal inference. Stat. Methods Med. 
Res. 16, 309–330, doi:10.1177/0962280206077743 (2007).
 52. Jones, G., Willett, P., Glen, R. C., Leach, A. R. & Taylor, R. Development and validation of a genetic algorithm for flexible docking. J. 
MOL. BIOL. 267, 727–748, doi:10.1006/jmbi.1996.0897 (1997).
 53. Wolber, G. & Langer, T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening 
filters. J. Chem. Inf. Model. 45, 160–169, doi:10.1021/ci049885e (2005).
 54. Beck, K. R., Sommer, T. J., Schuster, D. & Odermatt, A. Evaluation of tetrabromobisphenol A effects on human glucocorticoid and 
androgen receptors: A comparison of results from human- with yeast-based in vitro assays. Toxicology 370, 70–77, doi:10.1016/j.
tox.2016.09.014 (2016).
 55. Voice, M. W., Seckl, J. R. & Chapman, K. E. The sequence of 5’ flanking DNA from the mouse 11β-hydroxysteroid dehydrogenase type 
1 gene and analysis of putative transcription factor binding sites. GENE 181, 233–235, doi:10.1016/S0378-1119(96)00490-8 (1996).
 56. Atucha, E. et al. A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain. 
Endocrinology 156, 4105–4114, doi:10.1210/en.2015-1390 (2015).
 57. Hayek, T. et al. Reduced progression of atherosclerosis in apolipoprotein E-deficient mice following consumption of red wine, or its 
polyphenols quercetin or catechin, is associated with reduced susceptibility of LDL to oxidation and aggregation. Arteriosclerosis, 
Thrombosis, and Vascular Biology 17, 2744–2752 (1997).
Acknowledgements
We are grateful to S. Kothiya, L. Ramage and A. Rutter for analytical support, the staff of the Edinburgh Clinical 
Research Facility and its Mass Spectrometry Core Laboratory, K Chapman for the gift of the plasmids, Prof 
Thierry Langer, University of Vienna and Inte:Ligand GmbH for providing LigandScout software and Pro, Daniela 
Schuster, University of Innsbruck for support with docking, and the staff of the Royal (Dick) School of Veterinary 
Studies Equine Hospital for their help with sample collection. We would like to thank the owners whose horses 
were included in the study. The laboratory is supported by a British Heart Foundation Centre of Excellence 
Award. RM was supported by the Biological and Biotechnological Sciences Research Council and Zoetis Animal 
Health (Grant No R42126 and R82976) with additional funding from the University of Edinburgh Wellcome 
Trust Institutional Strategic Support Fund. AO was supported by the Swiss National Science Foundation (Grant 
No. 31001–159454). BW was supported by a British Heart Foundation Programme Grant and Wellcome Trust 
Investigator Award.
Author Contributions
R.M., K.B., M.N., A.C., D.M., R.H., A.S., A.A., R.U., P.H., T.M., C.K., J.K. and A.O. designed and/or conducted the 
experiments and/or analysed the data. N.H. and R.A. developed and supervised the mass spectrometry measurements. 
R.S., T.O., O.M., and R.A. contributed to the design and execution of the clinical studies. A.C., A.R., E.S. and J.B. 
contributed data for GWAS analysis. R.M. and B.W. conceived the studies and supervised the experimental design, 
execution, and analysis. R.M. and B.W. wrote the manuscript, which was reviewed by all authors.
Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-10410-1
Competing Interests: The authors declare that they have no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2017
149
Carbonyl reductase 1 catalyzes 20β-reduction of glucocorticoids, 1 
modulating receptor activation and metabolic complications of obesity 2 
 3 
Authors: Ruth A Morgan1,2, Katharina R Beck3, Mark Nixon1, Natalie ZM Homer4, Andrew 4 
A Crawford1,5, Diana Melchers6, René Houtman6, Onno C Meijer7, Andreas Stomby8, Anna J 5 
Anderson1, Rita Upreti1, Roland H Stimson1, Tommy Olsson8, Tom Michoel9, Ariella 6 
Cohain10, Arno Ruusalepp11,12,13, Eric E. Schadt10, Johan L. M. Björkegren10,11,12,13,14, Ruth 7 
Andrew1,4, Christopher J Kenyon1, Patrick WF Hadoke1, Alex Odermatt3, John A Keen2, and 8 
Brian R Walker1,4,* 9 
 10 
Affiliations:  11 
1 University/BHF Centre for Cardiovascular Science, The Queen’s Medical Research 12 
Institute, University of Edinburgh, UK 13 
2 Royal (Dick) School of Veterinary Studies, University of Edinburgh, UK 14 
3 Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, 15 
University of Basel, Switzerland 16 
4 Mass Spectrometry Core Laboratory, Wellcome Trust Clinical Research Facility, The 17 
Queen’s Medical Research Institute, University of Edinburgh, UK 18 
5School of Social and Community Medicine, University of Bristol, UK  19 
6 PamGene International, Den Bosch, The Netherlands 20 
7Department of Internal Medicine, Division Endocrinology, Leiden University Medical 21 
Center, Leiden, The Netherlands 22 
8Department of Public Health and Clinical Medicine, Umeå University 901 87 Umeå, 23 
Sweden 24 
9The Roslin Institute, University of Edinburgh, Easter Bush Campus, UK 25 
150
10Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale 26 
Biology, Icahn School of Medicine at Mount Sinai, New York, USA  27 
11Department of Physiology, Institute of Biomedicine and Translation Medicine, University of 28 
Tartu, Estonia  29 
12Clinical Gene Networks AB, Stockholm, Sweden  30 
13Department of Cardiac Surgery, Tartu University Hospital, Tartu, Estonia 31 
14Integrated Cardio Metabolic Centre, Department of Medicine, Karolinska Institute, Sweden 32 
 33 
*Author to whom correspondence should be addressed:  34 
Professor Brian Walker, Email: b.walker@ed.ac.uk, University/BHF Centre for 35 
Cardiovascular Science, The Queen's Medical Research Institute, University of Edinburgh, 36 
47 Little France Crescent, Edinburgh EH16 4TJ 37 
  38 
151
Supplementary Materials: 39 
SM1 Quantification of urinary glucocorticoid metabolites 40 
Glucocorticoids were extracted from equine urine (20mL) by solid phase extraction on Bond 41 
Elut Nexus mixed mode Large Reservoir Capacity, 60 mg columns (Agilent Technologies, 42 
Santa Clara, CA, USA). Glucocorticoids were extracted from human urine (10mL) by solid 43 
phase extraction on Sep-Pak columns (Waters, Milford, MA, USA).  44 
Steroid conjugates were hydrolysed using β-glucuronidase followed by re-extraction. The 45 
steroids obtained were derivatized to form methoxime-trimethylsilyl (MO-TMS) derivatives. 46 
Steroidal derivatives were separated by gas chromatography using the TRACE GC Ultra Gas 47 
Chromatograph (Thermo Fisher Scientific). Analysis was performed on a TSQ Quantum Triple 48 
Quadrupole GC-tandem mass spectrometer (Thermo Fisher Scientific) using a 35HT 49 
Phenonemex column (30m, 0.25mm, 0.25µm, Agilent Technologies) as previously described 50 
(45, 46). Epi-cortisol and epi-tetrahydrocortisol were used as internal standards (Steraloids, 51 
Newport, RI, USA). The steroids analyzed were cortisol (F), cortisone (E), 5β-52 
tetrahydrocortisol (5β-THF), 5β-tetrahydrocortisone (5β-THE), 5α-tetrahydrocortisol (5α-53 
THF) (45, 46) with the inclusion of the following transitions (collision energy)  α-cortol 54 
(535→355, 20V) and β-cortol (535→455, 10V), α- and β-cortolone (449→269, 10V), 6β-55 
hydroxycortisol (693→513, 10V), 20α- dihydrocortisol (578→488, 10V) and 20β-56 
dihydrocortisol (681→578, 10V). 57 
 58 
Steroid quantities in equine urine were expressed as a ratio to creatinine, which was measured 59 
using a colorimetric method based on the modified Jaffe’s reaction (IL650 analyser, 60 
Instrumentation Laboratories, Barcelona, Spain). 61 
SM2 Quantification of glucocorticoids in plasma 62 
152
Plasma samples (1 mL Equine, 200 μL Human) enriched with internal standard (D4-F, D4-E 63 
and D8-B; 250 ng of each) were extracted by liquid-liquid extraction. Chloroform (10 volumes) 64 
was added to each sample, mixed and the organic layer was dried under nitrogen (60 °C). The 65 
extracts were re-suspended in mobile phase (60 µL, water: methanol 70:30 v/v) for 66 
quantification of steroids by LC-MS/MS. The injection volume was 30 µL.  67 
SM3 Quantification of glucocorticoids in adipose tissue 68 
Adipose samples (100mg) were homogenized in ethyl acetate (1 mL) and enriched with internal 69 
standard (D4-F, D8-E, D8-B; 250ng of each). The homogenate was slowly dripped onto chilled 70 
ethanol: glacial acetic acid: water (95:3:2 v/v, 10 mL) and frozen at -80 °C overnight. Samples 71 
were thawed (4 °C) prior to sonication (8 x 15 second bursts) and centrifugation (3000 x g, 30 72 
mins, 4 °C). The supernatant was dried under nitrogen (60 °C), re-suspended in methanol (10 73 
mL) and frozen at -80 °C overnight. Samples were thawed (RT) and hexane (10 mL) added 74 
and mixed. The hexane layer was removed, the remaining methanol dried down under nitrogen 75 
(60 °C) and re-suspended in water (400 µL) and ethyl acetate (4 mL). The organic layer was 76 
removed, dried under nitrogen (60 °C) and re-suspended in 30 % methanol (5 mL). C18 Bond 77 
Elut columns (Agilent Technologies, Santa Clara, CA, USA) were conditioned (methanol 5 78 
mL) and equilibrated (water 5 mL), samples were loaded and steroids eluted with methanol (2 79 
mL). Eluates were dried down under nitrogen (60 °C) and re-suspended in 60 µL mobile phase 80 
(water: methanol, 70:30 v/v) for quantification of steroids by LC-MS/MS. Injection volume 81 
was 30 µL.  82 
SM4 Quantification of mRNA by RT-qPCR 83 
Total RNA was extracted from adipose and liver using the RNAeasy Mini Kit (Qiagen Inc, 84 
Valencia, CA, USA). The tissue was mechanically disrupted in either QIAzol (Qiagen) for 85 
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adipose tissue or RLT buffer (Qiagen) for liver tissue. Total RNA was extracted from cells in 86 
QIAzol lysis reagent using an RNeasy Mini Kit according to the manufacturer’s instructions. 87 
Quantitative real-time polymerase chain reaction was performed using a Light-cycler 480 88 
(Roche Applied Science, Indianapolis, IN, USA). Primers were designed using sequences from 89 
the National Centre of Biotechnological Information and the Roche Universal Probe Library 90 
(see Table S7-9) for details of primers for genes of interest and housekeeping genes). Samples 91 
were analysed in triplicate and amplification curves plotted (y axis fluorescence, x axis cycle 92 
number). Triplicates were deemed acceptable if the standard deviation of the crossing point 93 
was < 0.5 cycles. A standard curve (y axis crossing point, x axis log concentration) for each 94 
gene was generated by serial dilution of cDNA pooled from different samples and fitted with 95 
a straight line and deemed acceptable if reaction efficiency was between 1.7 and 2.1. 96 
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 Supplementary Tables and Figures 
Table S 1 Characteristics of equine study subjects  
 Lean (n=14) Obese (n=14) 
Age (years) 
 
15.6 ± 5.6 13.8 ± 7.8 
Sex 4 Females 
10 Castrated males 
8 Female 
5 Castrated males 
Breeds 11 Thoroughbred  
2 Native pony 
1 Percheron 
2 Thoroughbred 
3 Cob 
7 Native ponies 
1 Arab pony 
1 Clydesdale 
Body condition score 
(/5)  
 
2.3 ±  0.3 3.8 ± 0.7* 
Data are expressed as mean ± SEM. Student’s t-test or Mann-Whitney U test: *p<0.05 
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 Table S 2 Characteristics of obese human participants with type 2 diabetes providing 24 hour 
urine samples 
 
n 19 
Age (years) 58.9 ± 1.5 
Body Mass Index 
(kg/m2) 
32.60 ± 1.2 
Concurrent 
medications 
4 no medication 
15 metformin 
All participants were male and diagnosed with diabetes. Participants provided 24 hour urine 
samples. The additional lean and obese participants providing urine were recruited as part of 
a different study (Upreti et al 2014). Data are expressed as mean ± SEM. 
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Table S 3 Characteristics of lean and obese study participants providing plasma samples 
 Lean (n=10) Obese (n=10) 
Age (years) 50.5 ± 10.4 50.0 ± 11.8 
Body Mass Index 
(kg/m2) 
23.8 ± 1.2 32.9 ± 2.7 
Concurrent 
mediciations 
 6 No medication 
 1 perindopril, 
nifedipine, 
 1 citalopram, 
simvastatin, 
clopidogrel, ranitidine 
 1 clomipramine 
 1 ranitidine 
 8 No medication 
 1 tamsulosin, lansoprazole 
 1 pantoprazole 
Plasma was collected (between 8 and 9am) from lean and obese but otherwise healthy men. 
Participants with diabetes or prior corticosteroid treatment were excluded prior to 
recruitment. Data are expressed as mean ± SEM. 
 
Table S 4 Characteristics of lean and obese men providing adipose biopsy samples during 
surgery. 
 Lean (n=8) Obese (n=8) 
Age (years) 55.7 ± 12.7 52.8 ± 13.7 
Body Mass Index 
(kg/m2) 
23.0 ± 1.7 38.8 ± 6.7 
Surgery  Cholecystectomy 
 Laparoscopic 
cholecystectomy 
 Removal of gastric 
band 
 Hernia repair 
 Open cholecystectomy 
 3 Abdominal hernia 
repairs 
 Gastric bypass 
 Laparoscopic sleeve 
gastrectomy 
 Laparoscopic cholecystectomy 
 Cholecystectomy 
 2 Laparoscopic fundoplications 
 Laparoscopic cholecystectomy 
 Laparoscopic removal of 
gastric band and gastric bypass 
All the participants were male. Samples were obtained at the time of surgery. Data are 
expressed as mean ± SEM.
157
Table S 5 Estimates of the phenotypic associations with CBR1 expression in the liver 
based on Mendelian Randomisation 
 
Outcome Beta Se P value N Sample 
BMI -0.01 0.01 0.25 339224 (55) 
Body Fat -0.01 0.01 0.06 100716 (56) 
2hr glucose 
adjusted for BMI 
<0.01 0.03 0.89 15234 (57) 
Fasting glucose 0.01 <0.01 0.02 58074 (58) 
Fasting insulin <0.01 <0.01 0.45 51750 (58) 
HOMA-B <0.01 <0.01 0.59 46186 (59) 
HOMA-IR 0.01 0.01 0.27 46186 (59) 
HbA1c 0.01 <0.01 0.01 46368 (60) 
These analyses used rs1005696 as the instrument for CBR1 expression in liver and 
associations were analysed using MR-base. See supplementary references for further 
details of studies used.  
 
 
158
Table S 6 Human primer sequences for PCR 
 
 
Table S 7 Equine primer sequences for PCR 
Gene Symbol, 
full name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s  
(ribosomal RNA 
18s) 
CTTCCACAGGAGGCCTACA
C 
CGCAAAATATGCTGGAACT
TT 
DUSP1 (dual 
specificity 
phosphatase 1) 
TTCAAGAGGCCATTGACTT CCTGGCAGTGGACAAACA
C 
GILZ 
(glucocorticoid- 
induced leucine 
zipper) 
CCGTTAAGCTGGACAACAG
TG 
ATGGCCTGTTCGATCTTGT
T 
FKBP51 
(FK506-binding 
protein 51) 
GGATATACGCCAACATGTT
CAA 
CCATTGCTTTATTGGCCTCT 
IGFBP1 
(insulin-like 
growth factor 
binding protein 
1) 
GCCTTGGCTAAACTCTCTA
CGA 
CCATGTCACCAACATCAAA
AA 
IL-1β 
(Interleukin 1β) 
TGTAATGAAAGACGGCACA
CC 
TCTTCTTTGGGTATTGCTTG
G 
CBR1 
(Carbonyl 
Reductase 1) 
TCCCTCTAATAAAACCCCA
AGG 
GGTCTCACTGCGGAACTTC
T 
Gene Symbol, 
full name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s 
(ribosomal RNA 
18s) 
TGACCCAAGGCTAGTAGCT
GA 
TTCAACACATCACCCACCA
T 
SDHA 
(Succinate 
CTACGGAGACCTTAAGCAT
CTGA 
GGGTCTCCACCAGGTCAGT
A 
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Table S 8 Murine primer sequences for PCR 
dehydrogenase 
complex) 
Equine CBR1 
(Carbonyl 
Reductase 1) 
ACCCAGCCATGTCTTACAC
C 
CAGGATAGTGAAGCCGAT
GC 
Gene Symbol, full 
name 
Forward Primer (3’→ 5’) Reverse Primer (5’→ 3’) 
RNA18s (ribosomal 
RNA 18s)   
CTCAACACGGGAAACCT
CAC 
CGCTCCACCAACTAAGA
ACG 
Tbp (TATA-binding 
protein)  
  
GGGAGAATCATGGACCA
GAA 
GATGGGAATTCCAGGAG
TCA 
Per1 (Period 1) GCTTCGTGGACTTGACAC
CT  
 
TGCTTTAGATCGGCAGT
GGT  
 
Pepck  
(phosphoenolpyruvate 
carboxykinase) 
GAGGCACAGGTCCTTTTC
AG 
GTTCCTGGGCCTTTGTG
AC 
Adipq (Adiponectin) GGTGAGAAGGGTGAGAA
AGGA 
TTTCACCGATGTCTCCCT
TAG 
Lpl (Lipoprotein 
lipase) 
CTCGCTCTCAGATGCCCT
AC  
 
GGTTGTGTTGCTTGCCAT
T  
 
Sgk1 (serum 
glucocorticoid kinase 
1) 
TTTCCAAAGGGGGATGC
T 
TGTTGGCATGATTACAT
TGTTCT 
ENaC1 (Epithelial 
sodium channel 1) 
AGCACAGAGAACACCCC
TGT 
TGGCTCTTCCTACCCTCT
CTC 
Cbr1 
(Carbonyl Reductase 
1) 
AGGTGACAATGAAAACG
AACTTT 
GGACACATTCACCACTC
TGC 
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Figure S 1 The human urinary glucocorticoid metabolite profile in lean and obese individuals 
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Urinary glucocorticoids of lean and obese participants were extracted, derivitized and 
quantified by GC-MS/MS. Urinary excretion of 20β-dihydrcortisol was higher in the obese 
group. 
 
Figure S 2 Equine liver cytosol metabolises cortisol to 20β-dihydrocortisol and this 
production is inhibited by quercetin 
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[A] In the presence of NADPH equine liver cytosol produced 20β-DHF as the predominant 
metabolite. (THF = tetrahydrocortisol, THE = tetrahydrocortisone). [B] CBR1 inhibitor 
quercetin prevented production of 20β-DHF by equine liver cytosol. Data are mean ± SEM. 
 
Figure S 3 20β-Dihydrocorticosterone is present in murine tissues 
 
 
 
 
20β-Dihydrocortisone (the murine equivalent of 20β-dihydrocortisol) was measured by LC-
MS/MS in murine [A] plasma and [B] liver. Data are mean ± SEM. 
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Figure S 4 20β-Dihydrocorticosterone induces murine glucocorticoid receptor activation  
 
HEK293 cells transfected with murine GR-MMTV-Luc were incubated with increasing 
concentrations of 20β-dihydrocorticosterone (20β-DHB) the murine equivalent of 20β-
dihydrocortisol. Data are mean ± SEM, *P<0.05 compared to vehicle. 
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4.4. Discussion 
 
In silico approaches represent valuable tools for the identification of drug-like compounds to a cognate 
protein. The present thesis extended this concept to toxicologically relevant compounds and further 
to aid the prediction of potentially novel substrates for already characterized enzymes; however with 
the ultimate goal to support enzyme deorphanization. Three different members of the SDR superfamily 
were investigated for novel substrate specificities during this thesis: the two multi-functional enzymes 
11β-HSD1 and CBR1 as well as the orphan enzyme DHRS7.  
The dihydroxylated oxysterols 7β,25OHC and 7β,27OHC were found to be generated by 11β-HSD1 
from their corresponding 7-keto oxidized forms. Their close structural relationship to the known 11β-
HSD1 substrate 7kC, led to the analysis of 7k25OHC and 7k27OHC. The subsequently performed VS of 
the HMDB with the 11β-HSD1 substrate pharmacophore models, implemented to further explore 11β-
HSD1 function, did not retrieve these oxysterols as hits. However, this could be especially attributed 
to the fact that neither the 7keto- nor the 7β-dihydroxylated forms were contained in the screening 
library. This represents a major limitation of the VS assessment. Obviously, only compounds present 
in the chemical database can be potentially filtered during the screening process. Thus, one needs to 
be aware that these databases used for VS are not fully representative. Moreover, particularly enzyme-
substrate recognition purposes are influenced by this factor, since many databases contain small-drug 
like compounds. In this regard, the HMDB is a highly useful database even though many metabolites 
that are difficult to detect or that exist at very low concentrations are not contained in the library.  
On the other hand, pharmacophore-based VS only retrieves molecules that exactly match the 
individual features of the model; an advantage during the drug development process, but not 
necessarily for the identification of endogenous substrates of a certain enzyme, as for example a 
ligand-induced fit cannot be simulated with this method. Therefore, the 11β-HSD1 substrates models, 
generated in this thesis, allowed some degree of freedom for instance with the use of optional features 
or by employing considerably different pharmacophore models to cover all the structurally distinct 
training compounds.  
Additionally, it becomes evident that also the predictive power of a model is determined by the 
underlying data. In this regard, the limitations of the DHRS7 homology models have already been 
addressed in the corresponding part in this thesis. The quality of a homology model varies depending 
on the sequence alignment with the template used for model construction. A sequence identity of 
>40% is regarded as ideal and <25% as a poor basis [145]. The template results for the DHRS7 homology 
model construction, however, showed for all templates a sequence identity of ≤32%. The generally 
found low sequence identity among SDRs certainly represents another key challenge in the 
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deorphanization process of SDR members. To improve the poorly resolved regions at the binding site 
entry, detected in the DHRS7 homology models, a potential solution might be the identification of 
homologous protein sequences particularly for this region, which could then be used to complete the 
model. Although the physiological value of the recently detected DHRS7 substrates remains unclear, 
they can be used in further studies for the generation of a ligand-based pharmacophore model. 
Importantly, the compounds with no observed catalytic activity are as well highly useful as inactive 
training compounds to improve the model quality. Nevertheless, to receive a more complete recovery 
of active hits, a combination of different computational programs may be suitable, since they can 
generate distinct virtual hit lists, even when the same protein structure and the same screening library 
was used [146-148].  
Importantly, to verify the results obtained from the in silico screenings, appropriate in vitro assays are 
essential. As already described, SDRs do not have a common activity element that could be used as 
suitable assay read-out, to assess potential substrates. Individual solutions for each enzyme need to 
be established. Therefore, large in vitro HTS applications for SDR deorphanization are practically not 
feasible, but pharmacophore-based VS approaches represent promising alternatives to enable a 
preselection of potential novel substrate candidates based on structural features of the substrate 
binding pocket and/or on already known ligands, which then can be tested in vitro with, for instance, 
LC-MS based bioassays.  
Catalytic in vitro activity does not automatically imply an in vivo function. Especially for orphan 
enzymes, when their physiological role is completely unexplored, the prediction and the assessment 
of potential substrates is highly challenging. An interesting approach addressing this issue, includes 
expanded metabolite docking to entire pathways (reviewed in [145]). Docking or filtering of a 
metabolite against multiple models for proteins participating or hypothesized to participate in a given 
pathway may enhance the predictive in silico reliability. With this in mind, the assessment of a potential 
involvement of 11β-HSD1 in the kynurenine pathway becomes particularly interesting, because several 
consecutively generated metabolites were filtered through the VS.  
Instead of directly studying an orphan enzyme, one could also assess metabolites of ‘orphan enzymatic 
reactions’, for instance by docking or fitting them into the substrate binding site of proteins with 
unknown and/or known functions. 20β-DHF was discovered in the accepted research article ‘Carbonyl 
reductase 1 catalyses 20β-reduction of glucocorticoids, modulating corticosteroid receptor activation 
and metabolic complications of obesity’ as the predominant metabolite of cortisol in domestic horses, 
which is increased in obesity. However, the responsible enzyme for its generation was previously 
unexplored. Docking calculations confirmed cortisol in a single position fitting into the binding pocket 
of CBR1 (unpublished data, see Appendix Figure A4) and additionally revealed similar binding poses in 
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the binding pocket of GR for 20β-DHF and cortisol. 20β-DHF was further demonstrated as weak 
endogenous agonist of the GR, suggesting a novel pathway to modulate GR activation by CBR1-
depenent protection against excessive GR activation in obesity. Nevertheless, further research is 
required to explore the contribution of CBR1 dysregulation in obesity and the consequence of the wide 
interindividual variability of CBR1 expression. Unfortunately, to date no specific CBR1 inhibitors are 
available [144]. In order to study enzyme functions and to avoid biased results due to unspecific 
inhibitor activity, specific enzyme inhibitors represent valuable and important tools, also with regard 
to the deorphanization of enzymes. Although knockdown by siRNA can solve part of the specificity 
problem, this technique has the disadvantage of the long time needed until a given enzyme is silenced, 
and therefore cannot replace the use of specific inhibitors but rather should be used in combination. 
An example of remarkably high sequence identity (72%) among SDR members can be found for CBR1 
and CBR3 [149]. However, a comparison of the substrate profiles of CBR1 and CBR3 showed a much 
narrower substrate spectrum for CBR3 and most of the known CBR1 substrates were either inactive or 
had lower catalytic activity compared to CBR1 [150]. Moreover, to date no validated endogenous 
substrate for CBR3 is known. Although CBR1 and CBR3 share a considerable sequence similarity, the 
resolution of the CBR3 crystal structure showed differences in their active sites considering size, shape, 
critical residues for substrate recognition and surface properties (Appendix Figure A5 and described in 
more detail in our published review [9]). Hence, the orphan CBR3 shows most probably a distinct 
substrate spectrum from that of CBR1 and represents an interesting target to be further explored by 
the proposed in silico approach, particularly since the protein structure has already been solved. In this 
regard, solely sequence similarities do not guarantee a simplified identification of (endogenous) 
substrates for orphan enzymes, an important point to take into account during substrate identification. 
In contrast, Koch et al. proposed structural organization of the binding sites rather than sequence 
similarity as criterion whether a certain substance may affect the activity of enzymes [151]. To identify 
drug-like proteins, they proposed structure similarity clustering of the ligand-sensing cores of protein 
domains in combination with a compound library development guided by natural products. This may 
as well represent a strategy that could be employed for the identification of substrates for orphan 
enzymes; however, a reliable resolution of the binding sites of all enzymes would be crucial for this 
approach. Nevertheless, by screening of known substrates from structurally related enzymes and 
scaffold hopping to related derivatives, novel substrate specificities might be identified.  
To sum up, successful applications of pharmacophore-based in silico tools for the identification of 
inhibitors for a broad spectrum of SDR members led us to the implementation of these tools for 
substrate identification purposes in the domain of multifunctional SDRs, and particularly with the 
indent to extend this approach as deorphanization strategy for unexplored SDR members. First 
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attempts revealed promising results, however, careful consideration of the individual limitations is 
crucial.  
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5. Appendix 
 
.  
Figure A1. 2D-structures of the active test set compounds [93, 116]. 
169
 Figure A2. 2D-structures of the inactive test set compounds [100]. 
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Table A1. Calculation of descriptive model parameters. The model performance was analyzed by 
counting the number of fitting active test compounds (true positives), fitting inactive test compounds 
(false positives), discarded actives (false negatives) and discarded inactives (true negatives). These 
numbers were further used to calculate the following parameters: yield of actives (YA) (Equation 1), 
enrichment factor (EF) (Equation 2), sensitivity (Equation 3) and specificity (Equation 4). 
Model YA (1) EF (2) Sensitivity (3) Specificity (4) 
model_1 1.0 2.11 0.22 1.0 
model_2 1.0 2.11 0.39 1.0 
model_3 1.0 2.11 0.50 1.0 
model_4 1.0 2.11 0.22 1.0 
 
(1)   𝑌𝐴 =
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 ℎ𝑖𝑡𝑠
 
(2)   𝐸𝐹 =
𝑌𝐴
(𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎𝑏𝑠𝑒)/(𝑑𝑎𝑡𝑎𝑏𝑎𝑠𝑒 𝑠𝑖𝑧𝑒)
 
(3)   𝑠𝑒𝑛𝑠𝑖𝑡𝑖𝑣𝑖𝑡𝑦 =
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠
𝑡𝑟𝑢𝑒 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎𝑏𝑠𝑒
 
(4)   𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐𝑖𝑡𝑦 =
𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠
𝑡𝑟𝑢𝑒 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒𝑠 𝑖𝑛 𝑡ℎ𝑒 𝑑𝑎𝑡𝑎𝑏𝑠𝑒
 
 
 
 
 
Figure A3. Arachidonic acid metabolism with virtual hits retrieved from the VS with the 11β-HSD1 
substrate models (circled in red), the 11β-HSD1 inhibitor models (blue) and consensus hits (green). 
(Adapted from the Kyoto Encyclopedia of Genes and Genomes (KEGG) database [117-119, 152].) 
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 Figure A4. Docking of cortisol into the binding pocket of CBR1 (PDB code 2PFG). (A) The automatically 
generated pharmacophore maps important structural details of the ligand for binding (yellow spheres 
illustrate hydrophobic interactions, red/green arrows are hydrogen bond interactions; amino acid 
residues of the catalytic center and the cofactor are depicted as sticks). (B) Two-dimensional 
representation of the binding interactions of cortisol. Distance of hydrogen bonds are shown in 
angstrom (Å). 
 
 
 
Figure A5. Superimposition of CBR1 (blue; PDB entry 2PFG) and CBR3 (orange; PDB entry 2HRB). 
CBR1 forms a barrier with a short segment of the substrate binding loop whereas CBR3 shows a rather 
open binding pocket. NADPH is depicted as sticks.  
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